Multiparameter flow cytometry as a tool to study psoriasis by Glade, C.P.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/146389
 
 
 
Please be advised that this information was generated on 2017-12-05 and may be subject to
change.
Multiparameter flow cytometry 
as a tool to study psoriasis 
-yp 
HfcP ΨΜ 
/ 
\ 
& 
v_-^  
Conrad P. Glade 

MULTIPARAMETER FLOW CYTOMETRY 
AS A TOOL TO STUDY PSORIASIS 


MULTIPARAMETER FLOW CYTOMETRY 
AS A TOOL TO STUDY PSORIASIS 
Een wetenschappelijke proeve op het gebied 
van de Medische wetenschappen 
Proefschrift ter verkrijging van de graad van doctor 
aan de Katholieke Universiteit Nijmegen, 
volgens besluit van het College van Decanen 
in het openbaar te verdedigen op 
maandag 9 juni 1997 
des namiddags te 3.30 uur precies 
door 
Conrad Peter Giade 
geboren op 17 november 1963 te Heidelberg 
Promotor: Prof. Dr. Dr. P.C.M, van de Kerkhof 
Co-promotores: Dr. P.E.J, van Erp 
Dr. E.M.G.J. de Jong 
Manuscriptcommissie: Prof. Dr. T.J.M. de Witte 
Prof. Dr. J. Schalken 
Dr. Α. Hanselaar 
ISBN 90-9010652-9 
Financial support for printing this thesis was kindly provided by ConvaTec B.V., 
Coulter/Immunotech Nederland, Galderma Nederland B.V.. Glaxo Wellcome B.V.. 
Hernial A.G., Janssen-Cilag B.V., LEO Pharmaceutical Products B.V., Novartis 
Pharma B.V., Roche Nederland B.V., Schering A.G. (Center of Dermatology), N.V. 
Varitex and Yamanouchi Pharma B.V. 
Individualität ist das, was mich von der Welt absondert, Liebe das, was mich mit Ihr 
verbindet. Je starker die Individualltat, desto stärker erfordert sie Liebe 
Walther Rathenau (1867-1922) 

CONTENTS 
Chapter 1 General Introduction 
1 1 General aspects of psoriasis 11 
1 2 Flow cytometry 23 
13 Aims of the thesis 31 
Chapter 2 Triple-labelling flow cytometry and development of cell 
isolation procedures 
2 1 TO-PRO-3 iodide, a novel HeNe laser-excitable DNA stain 
as an alternative for propidium iodide in multiparameter flow 
cytometry 39 
Cytometry 1994 17 185-189 
2 2 Multiparameter flow cytometric characterization of 
epidermal cell suspensions prepared from normal and 
hyperproliferative human skin using an optimized 
thermolysin-trypsin protocol 47 
Arch Dermatol Res 1996, 288 203-210 
Chapter 3 In vivo models to study the dynamics of the psoriatic lesion 
3 1 The dynamics of the response of normal skin to single and 
multiple epicutaneous leukotnene B4 applications analysed 
by three-colour flow cytometry 65 
Acta Derm Venereo! (Stockh) 1995 437-441 
3 2 A clinical and flow cytometric validation ol a model to study 
remission and relapse in psoriasis 77 
submitted 
Chapter 4 Clinical and flow cytometric evaluation of new topical 
treatment for psoriasis 
4 1 Topical treatment of psoriatic plaques with la.24 dihydroxy-
vitamin D3 a multiparameter flow cytometncal analysis ot 
epidermal growth, differentiation and inflammation 93 
Acta Derm Venereol (Stockh) 1995 381-385 
4 2 Epidermal cell DNA content and intermediate filaments 
keratin 10 and vimentin after treatment of psoriasis with 
calcipotnol cream once daily, twice daily and in combination 
with clobetasone 17-butyrate cream or betamethasone 17-
valerate cream a comparative flow cytometric study 105 
Br J Dermatol 1996, 135 379-384 
4 3 Flow cytometric assessment of clearance and relapse 
characteristics in psoriasis vulgaris after treatment with 
weekly clobetasol lotion under occlusion versus twice daily 
clobetasol ointment 117 
to be submitted 
Chapter 5 General Discussion 
5 1 Multiparameter flow cytometry as a tool to evaluate 
antipsonatic therapy 129 
in press (Br J Dermatol) 
5 2 In vivo models tor psoriasis 147 
5 3 Innovation of topical antipsonatic therapy 153 
Chapter 6 Summary and Conclusions 161 
Samenvatting en Conclusies 165 
Dankwoord 169 
Curiculum Vitae 171 
List of Publications 173 
Chapter 1 
GENERAL INTRODUCTION 

1.1 General aspects of psoriasis 
EPIDEMIOLOGY, PATHOGENESIS AND MORPHOLOGY 
Psoriasis is a frequently occurring chronic skin disorder with remissions and 
exacerbations. Approximately 2% of worlds population is affected. In general, the 
disease manifests itself at adolescence. Relatively seldom, especially following a focal 
infection, the disease may occur in children. In 5-10% of the patients with psoriasis 
involvement of the joints occurs. Although the pathogenesis of psoriasis remains 
unclear, genetic and environmental factors are causative: psoriasis is supposed to have 
a polygenic inheritance. Environmental factors comprise systemic influences such as 
focal infections, psychological stress and medication, for instance β sympatholytic 
drugs, lithium carbonate and antimalarial drugs. But also topical factors may elicit a 
psoriatic lesion such as trauma of the skin, skin disorders or chemical and physical 
injuries. It is an attractive experimental approach to study the effect of trauma, UVB 
and application of chemical substances on normal skin in order to understand early 
pathogenetic events. 
Figure 1. Psoriatic plaque located on the elbow. 
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The clinical appearance of psoriasis characterized by sharply demarcated erythematous 
plaques (Figure 1) with a symmetrical distribution. Most patients present with this 
"chronic plaque-type" psoriasis. However, in children, an exanthematic distribution 
pattern of small lesions occurs: "psoriasis guttata". In case of severe psoriasis the 
whole bodysurface may be affected resulting in a "erythroderma". Sometimes sterile 
pustules may complicate the manifestation: "pustular psoriasis". Lesions may occur at 
every part of the body, although the face, in general, is spared. Predilection sites are 
the extensor surfaces of elbows and knees, the sacral region and the scalp. The nails 
may exhibit pitting, distal onycholysis (Figure 2) and subungual keratosis. The joints 
may show the picture of psoriatic arthropathy, characterized by a seronegative arthritis 
with a typical radiographic pattern. The extent and the expression of psoriasis differs 
from patient to patient. Also within the same patient the expression pattern can differ 
considerably. 
Figure 2. Psoriasis unguium with distal onycholysis and pitting. 
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The clinical characteristics of the psoriatic lesion are a reflection of cutaneous 
inflammation, epidermal hyperproliferation and disturbed keratinization. In case of a 
severe dominance of inflammation pustule formation is prominent, in case abnormal 
differentiation and epidermal proliferation dominate, excessive scale formation might 
be expected. However, so far no studies are available which conclusively demonstrate 
the correlation between clinical and cell biological features. Also the causes of these 
key processes are unknown so far. 
t ** ж *Л ... ^МЫкшт^, m,. « « . t . .,%»:*'/* 
Figure 3. Histologie section showing typical features of psoriasis: 
epidermal acanthosis, focal parakeratosis, elongated rete ridges and a 
mixed inflammatory infiltrate. 
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The histopathological features of psoriasis consist of epidermal acanthosis, thinning of 
the suprapapillary plate and infiltrate formation in dermis and epidermis. The stratum 
corneum is characterized by parakeratosis, a focal arrangement of DNA containing 
corneocytes without underlying stratum granulosum. Spongiform micropustules of 
Kogoj in the epidermis and microabscesses of Munro in the stratum corneum are 
observed to be filled with polymorphonuclear leukocytes end remnants of these cells. 
Figure 3 and 4 provide some illustration. The highest inflammatory activity of 
polymorphonuclear leukocytes is observed in pustular psoriasis. In exacerbating 
plaque-type psoriasis, the number of infiltrating polymorphonuclear leukocytes 
increases with the progression of lesions. However, a reliable quantitative approach to 
assess the composition of the epidermal infiltrate has to be developed. 
Figure 4. Detail of the psoriatic epidermis showing a microabsces of Munro containing 
polymorphonuclear neutrophils. 
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THERAPY 
There is at present no cure for psoriasis, only suppressive therapy. Therapeutic 
management of psoriasis requires individualisation. Many different topical and 
systemic antipsoriatic treatments are available. The treatment of choice depends upon 
type, extent, and duration of psoriasis, symptoms of the lesions, age, sex, general 
health and concomitant medication. Also social factors (occupation and travel 
distance) and psychological factors (personality, acceptance, motivation) play an 
important role. Different treatment modalities may be combined. In this way, side-
effects are minimised while the clinical efficacy is maintained or even improved. For a 
detailed review on the treatment of psoriasis the reader is referred to the article of 
Greaves et al . 
Topical treatment 
Emollients 
The application of emollients hydrates and softens the scaly and hyperkeratotic surface 
of psoriatic plaques. In about 35% of patients twice-daily application resulted in a 
reduction of itching, pain and of clinical severity and extension. Greasy emollients are 
less accepted by patients. 
Keratolytic agents 
Salicylic acid (2-20% in ointment) is a widely used keratolytic agent. It can be 
combined with coal tar, dithranol or corticosteroids, and then increases the absorption 
of these agents. Applications of high concentrations on large body areas should be 
avoided because of the risk of intoxication. 
Coal tar 
In the treatment of psoriasis coal tar is often combined with ultraviolet В phototherapy. 
Coal tar preparations are frequently used in shampoo preparations. Coal tar therapy is 
safe and usually well-tolerated. Limitations are the unpleasant odour and the irritative 
potential. Contra-indications are erythrodermia and generalized pustular psoriasis. 
Dithranol 
The formation of free radicals by dithranol is responsible for the antipsoriatic activity. 
However, these radicals are also responsible for the irritation, especially of the 
perilesional skin. Dithranol is oxidized to coloured products that stain the skin and 
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clothes brown or purple These side-effects are partly avoided in the so-called "short-
contact regimen" in which the application times of dithranol are between 10 and 60 
minutes Dithranol therapy is very safe 
Corticosteroids 
Topical corticosteroids are the most frequently used therapy against psoriasis 
Advantages are the short-term efficacy, absence of odour and staining, and relatively 
low cost Local side effects consist of thinning of the skin, striae, hypopigmentation, 
teleangiectases, allergic contact dermatitis and tolerance (tachyphylaxis) Withdrawal 
of potent topical corticosteroids may induce a serious relapse, resulting in a 
generalized pustular psoriasis If applied on large body areas topical corticosteroids can 
cause suppression of the pituitary-adrenal axis 
Vitamin D3 analogues 
Calcipotnol is a vitamin D3 analogue that can be applied topically Calcipotnol 50μg/g 
twice daily is indicated in mild-to-moderate psoriasis Up to 100g can be applied 
weekly without significant influence on calcium metabolism No systemic side-effects 
have been observed Local irritation of the skin is reported in 10-25% of patients 
However, this irritation is usually transient 
Photo(chemo)therapy 
Ultraviolet radiation (UVR) is effective in the treatment of psoriasis Phototherapy 
with ultraviolet В (290-320nm) can be used as monotherapy or in combination with for 
instance tar and dithranol Mildly erythematogenic dosages of UVB are given three 
times weekly Side effects are increased ageing of the skin and cutaneous 
malignancies Photochemotherapy combines the photosensitizing drug methoxysalen 
with ultraviolet A (PUVA) in the range of 320-400nm PUVA is a highly effective 
treatment Short-term adverse events are burning, nausea, and pruritus in 10-20% of 
patients The long-term problems consist of photodamage to the skin, pigmentation, 
lentigmes and cancer related to the exposure to UVA Seldom cataract and 
hepatotoxicity have been reported PUVA can be indicated in severe psoriasis vulgaris, 
generalized pustular psoriasis and palmoplanar pustular psoriasis 
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Systemic treatment 
Corticosteroids 
Oral corticosteroids should be reserved for patients with severe erythrodermic or 
generalized pustular psoriasis if other drugs are contraindicated. Prolonged use leads to 
Cushing's syndrome and suppression of the adrenal-pituitary axis. After withdrawal a 
significant risk for the development of a therapy-resistant pustular psoriasis exists. 
Methotrexate 
The folic acid antagonist methotrexate (MTX) blocks cycling cells in G, phase, 
resulting in a reduction of the number of cycling cells. All rapidly cycling tissues are 
affected including the gastrointestinal and the germinative epithelium. Methotrexate 
also has an immunosuppressive effect. Indications are severe psoriasis vulgaris, 
erythrodermic psoriasis, generalized pustular psoriasis, severe psoriatic arthritis and 
severe nail psoriasis. Side-effects of MTX are anorexia, nausea, hair-loss and 
haematological abnormalities. Interstitial pneumonitis is a rare side-effect. 
Furthermore, MTX may be mutagenic. Long-term treatment may cause liver fibrosis or 
cirrhosis. Therefore after 1.5 g MTX (cumulative dose) a liver biopsy is indicated. 
Laboratory investigations should be performed at regular intervals (4-6 weeks). 
Contraindications are pregnancy or pregnancy wish (males and females), disturbed 
renal or hepatic function, gastric ulcer, alcohol abuse. Patient compliance should be 
high. The maximum weekly dose is 15 mg/week, usually administered in 3 oral doses 
at 12-hour intervals (Weinstein-schedule). 
Retinoids 
In the treatment of psoriasis retinoids have antiproliferative and anti-inflammatory 
effects. Furthermore, a normalization of disturbed keratinocyte differentiation occurs. 
Important indications are severe pustular or erythrodermic psoriasis. Retinoids can be 
combined with other treatments. Side-effects are: dryness of eyes, nasal and oral 
mucosa, cheilitis, xerosis, pruritus, palmoplantar desquamation, hair loss, elevation of 
cholesterol, triglyceride and elevation of liver enzymes. During long-term treatment 
hyperostosis of the spine may be observed. However, the causal relationship between 
spinal abnormalities retinoids is discussed . and As retinoids are teratogenic, adequate 
anticonceptive measures should be taken until 2 years post-treatment. Contra-
indications are pregnancy or pregnancy wish, hepatic dysfunction, insufficient patient 
compliance and strongly elevated serum levels of cholesterol or triglycerides. Regular 
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clinical and laboratory examinations are indicated. Before treatment an X ray of the 
spine should be made. 
Cyclosporin 
This relatively new drug inhibits the CD4+ Τ lymphocyte function. Cyclosporin is 
indicated in refractory psoriasis. Neprotoxicity and the development of hypertension 
are serious side-effects. The lowest possible dose should be given. Other side-effects 
are gingival hyperplasia, hypertrichosis, headache, nausea and diarrhoea. Contra­
indications are impaired renal function, hypertension, immunodefficiency, 
malignancies, pregnancy, infections and epileptic disorders. The use of concomitant 
nephrotoxic, cytotoxic, immunosuppressive treatment or radiation therapy should be 
avoided. Frequent clinical and laboratory analysis is indicated during treatment. 
Combined therapy 
As discussed before, a large scala of antipsoriatic approaches exist. Each approach 
with its own advantages and limitations. Combination therapy has the important 
advantage that clinical efficacy is maintained or even improved, while side-effects are 
reduced. Examples of rational combinations are: tar and UVB, dithranol and UVB. and 
retinoids and PUVA (Re-PUVA). Often treatment with MTX, retinoids or cyclosporin 
is combined with topical application of corticosteroids or calcipotriol. Systematic 
search for the most optimal combinations are necessary. 
Development of new treatment modalities 
An important aspect in antipsoriatic drug development is the realization of long-term 
management. The cumulative therapeutic potential has to be high. For example long-
term use of topical corticosteroids is impeded by their side-effects. Therefor new 
antipsoriatic approaches are needed. 
Various new antipsoriatic agents are in clinical investigation. Included are new vitamin 
D3 analogues, new retinoids and new imunomodulators. Hydrocolloid occlusion as a 
monotherapy is effective in the treatment of psoriasis. In combination with topical 
therapy high efficacy can be obtained. New combinations of these therapies could 
mean an important progress in long-term antipsoriatic treatment. In this respect it is of 
importance to study the effect of promising compounds on the acute phase of the 
psoriatic process. New models to induce these initial changes are required. 
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To be able to compare therapy efficacy and to analyze in vivo models for psoriasis a 
quantitative method is required In the next chapters we discuss this issue 
MEASUREMENT OF SEVERITY OF PSORIASIS 
Clinical assessment 
Erythema, induration, desquamation and bodysurface 
The pathologic disturbance of the skin in psoriasis results in macroscopic changes 
clearly visible for the naked eye The psoriatic plaque is characterized by redness 
(erythema), thickening (induration) and scaling (desquamation) The clinical 
assessment of psoriatic lesions is based upon classification of these signs into a 5-
points scale An advantage of this method is that no instrumentation is needed, 
resulting in easy and time-saving assessment However, a few disadvantages exist 
Firstly this kind of assessment is not quantitative, but rather subjective Secondly, a 
significant interobserver variability may be present Furthermore, the clinical signs that 
are estimated may not be a direct reflection of the pathogenetic processes in psoriasis 
Assessment of the percentage bodysurface that is affected by psoriasis is difficult The 
human eye is notoriously poor as an estimator of area fraction It has been shown that 
a considerable variability exists between observers In the frequently used Psoriasis 
Area and Severity Index (PASI), described by Frednkson and Petterson , both the 
percentage of involved body surface and the degree of erythema, induration and 
desquamation are estimated in four body areas Then, using a formula, a value between 
0 and 72 can be calculated This integral approach to assess the severity of psoriasis is 
broadly accepted, but also discussed for the above-mentioned reasons 
Instrumental assessment 
Obviously, further development of methods to measure psoriasis severity is needed 
These methods have to fulfil the following conditions 
(ι) to quantify the response to therapy 
(и) to eliminate the interobserver variability 
(in) to approach the cell biological reality 
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Non-invasive techniques 
Many investigators have developed and applied non-invasive biophysical techniques to 
quantify and monitor psoriasis (image analysis, measurement of transepidermal water 
loss, ultrasound, blood flow, electric techniques). Attempts have been made to quantify 
the size of lesions by image analysis . A videomicroscopic study has been performed 
о 
on treatment of psoriasis with la,24 dihydroxyvitamin D3 . Measurement of 
transepidermal water loss (TEWL) provides information on the barrier function of the 
skin. In psoriasis TEWL is increased. Improvement of psoriatic plaques by topical 
9 10 
therapy has been evaluated by measurement of TEWL ' . Also ultrasound imaging of 
psoriatic skin has been used as technique to evaluate treatment of psoriasis . It was 
shown that skin thickness is significantly increased in psoriatic skin compared to 
normal skin. Furthermore, a differentiation between epidermal and dermal changes was 
possible. By using laser Doppler velocimetry (LDV) it has been shown that skin blood 
12 
flow is increased in psoriatic lesions . Other investigators measured blood flow after 
antipsoriatic therapy " and in the active edge of psoriatic lesions'6 '7. An other non­
invasive technique consists of impedance measurement. The electrical level is 
decreased in psoriasis and returns to normal after different antipsoriatic therapies' "' . 
By these non-invasive bioengineering techniques certain biologic information on 
psoriasis and its treatment are obtained. In general, the efforts for patient and clinician 
are moderate. However, most data deal with descriptive phenomena. This means that 
the third condition for quantitative assessment is not fulfilled. To obtain more specific 
information, the use of invasive techniques seems unavoidable. 
Invasive techniques 
Invasive procedures imply that biopsies are taken from volunteering subjects. Daily 
monitoring of psoriatic lesions is therefore practically impossible. However, an 
advantage over non-invasive procedures is that not only epiphenomena are studied: 
invasive techniques permits access to the pathologic process itself. 
To study changes at the microlevel, immunohistochemistry is the well-established 
approach. Cell biological information is obtained by using monoclonal antibodies 
against certain markers. The following markers are regularly used at the Department of 
Dermatology of the University Hospital Nijmegen" ' : Ki-67 and MIB1 are directed 
against a nuclear antigen present in cycling epidermal cells. Markers for epidermal 
differentiation are filaggrin, involucrin, transglutaminase, keratin 10 (recognized by 
RKSE60) and keratin 16 (recognized by Ks8.12). Information on inflammatory and 
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immunological cells can be obtained by markers against PMNs (elastase), T-
lymphocytes (Ti l ) , monocytes (WT14) and Langerhans cells (OKT6). All these 
mesenchymal cells express the intermediate filament protein vimentin. 
In the present thesis, the changes at the microlevel have been quantified with a 
relatively new method in dermatology for psoriasis research and treatment evaluation: 
multiparameter flow cytometry. Flow cytometry is a technique in which physical 
or/and chemical characteristics of cells (or other particles) are quantified for scientific, 
diagnostic or therapeutic purposes. Single cells pass through a fluid stream in the 
measuring apparatus and different markers can be quantified. This technique is very 
well applicable on epidermal single cell suspensions prepared from normal or psoriatic 
skin . However, it should be realized that no information is given on the histologic 
topography. 
The common elements in all flow cytometers are: a light source, an optical bench to 
focus and direct that light, a liquid stream containing particles flowing through the 
focused light beam, photodetectors and amplifiers to measure and record the intensity 
of light signals and a computer system to analyze these lights signals. The principle of 
flow cytometry is summarized in Figure 5: the particles (i.e. cells, viruses, bacteria, 
fungi, organelles, chromosomes, liposomes) flow rapidly in an aqueous solution and 
pass one or more laser beams at a rate of several hundreds of particles per second. The 
particles are stained by fluorescent dyes, which emit light after excitation by the laser. 
In optimal conditions each particle passes the laser light separately and causes 
scattering of the light (defined by shape, size and granularity of the particle) and/or 
generation of specific fluorescence signals depending on the fluorochromes used to 
stain the particles. Signals of different wave lengths are produced in this way, 
providing quantitative information on different cell parameters. Optical filters are used 
to separate the different emitted wave lengths. The signals are measured by 
photodetectors, amplified and stored in a computer for further evaluation. 
In contrast to immunohistochemistry, flow cytometry provides quantitative 
information of cell characteristics. As a great quantity of cells is measured, the 
statistical reliability is high. Furthermore, flow cytometry permits simultaneous 
measurement of different cell parameters (multiparameter flow cytometry). Flow 
cytometry is a powerful and promising approach to fill the niche for quantitative cell 
biological technology assessment. Therefore, this technique was selected for the 
studies in the present thesis. In the next chapter a short review on the history of flow 
cytometry will be given and applications in dermatology will be introduced. 
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Figure 5. Schematic drawing of a flow cytometer 
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1.2 Flow cytometry 
HISTORY 
The first description of flow cytometry was published in Science in 1934 by 
Moldavan . He introduced the concept of counting cells (blood cells) flowing through 
a capillary tube, by using a photoelectric sensor. In the 1940's fluorescence 
microscopy began to be used in conjunction with fluorescent stains for nucleic acids in 
order to detect malignant cells" . Antibody technology enabled wider use of fluorescent 
stains . The basic principles of modern flow cytometry consist of a synthesis of 
microscopy, blood cell counting instruments and the ink jet technology, which was 
developed in the 1960's for computer printers. In 1969 a microscope-based system was 
described whereby histograms could be generated based on ethidium bromide 
fluorescence of alcohol-fixed cells . Until then, counting of small particles flowing 
through a tube was not successful, because of turbulence in the fluid stream. The 
solution for this practical problem was to apply the principles of laminar flow in the 
flow system. The suspension of particles was injected into the centre of a faster 
flowing stream. In this way turbulence was avoided and reliable counting enabled. 
In 1970 Kamentsky began to produce flow cytometers with helium-neon or argon ion 
28 
laser light sources . The flow cytometer using the argon ion laser was to some extent 
suitable for analysis of DNA content. In 1972 Herzenberg improved his Fluorescence 
Activated Cell Sorter (FACS). This machine (argon ion laser) could detect relatively 
weak fluorescence of cells stained with fluorescein or rhodamine" . The development 
of dual-beam or multibeam flow cytometers enabled three- or four- (or more) 
parameter measurement. This involved a major escalation in cost as adequate 
microprocessors had to be developed. 
Various fluorescent dyes became available. Flow cytometry was used successfully in 
the analysis both of cellular DNA content, RNA content and of functional cellular 
parameters. In Table 1 a brief outline of flow cytometric history from 1944 to 1994 is 
given. In the field of molecular biology and molecular genetics flow cytometry and 
sorting proved its value. Important progress was made in the clinical use of 
fluorescence flow cytometry. In oncology DNA content analysis remains the most 
widely used flow cytometric procedure. Other important applications are the automatic 
performance of the differential leukocyte count and of the blood reticulocyte count, the 
immunophenotyping of human leukaemias and the determination of the relative and 
absolute number of CD4-positive T-cells (HIV-infection). 
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Table 1. Flow cytometric history 1944-1994 
1945 19<Ï0 1955 I9i>0 1465 1970 I97S !9»0 1985 1990 1995 
PHYSICAL Scalier 
PARAMETER С ouller \olume 
CEILULAR Presence Si¿e 
PARAMETER 
REAGENTS 
DNA Stains 
Absorption ічііпсіюп Pulanied fluorescence 
fluorescente 
Opacity Mnliiangle scuter Polarized scalier 
Phase 
Nucleic acid contení Antigen conlonl Nucleic acid sequence 
Piutcin contení 
DNA conlonl RNA contení 
DNA base ratio 
Chromatin structure 
Membrane integrity pi I Calcium 
hnzyiiie асіічіу Membrane potential 
Indocytosis Apoplosis 
Membrane and cytoplasmic viscosity 
Drug uptake and efllux 
I et tin binding sites Sullbydryls/Glutalluone 
Redox slate 
f eulgen si uns L thulium I luce hst dyes 
Präputium [MPI 
Milhraniyon 
TOTO dyes 
Antibodies/ 
Labels 
Functional 
Probes 
fluorescein 
bukaryotic cells 
Rliodannne 
Acndine orange 
Pyronin Y 
rinoflavin Τ 
Tluazole orange 
Texas red/XRITC 
Phycobiliproleins 
Monoclonals Tandem conjugates 
Inzyme substrates Potential probes 
pi 1 probes 
Indo 1 
Viruses Molecules 
С hromusomes Organelles 
1945 1950 1955 1960 19Ò5 1970 1975 19И0 19B5 1990 1995 
In dermatology the normal skin and the pathologically changed skin have been 
extensively studied using flow cytometric techniques. The application of flow 
cytometry in psoriasis-research is discussed in the next chapter. Research on 
premalignant and malignant dermatoses, such as Bowen's disease, actinic keratosis, 
keratoacanthoma, basal cell carcinoma and squamous cell carcinoma, is especially 
focused on ploidy determination. Clinical features as disease progression, local 
invasiveness and metastatic behaviour are possibly correlated with aneuploidy in 
lesions3 . So far, however, this single-parameter DNA content analysis has not been 
successful in distinguishing keratoacanthoma from squamous cell carcinoma . 
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Simultaneous measurement of differentiation markers might be of importance in this 
regard. Flow cytometric measurement of DNA-ploidy in dysplastic nevi, congenital 
nevi and melanomas has been explored as test for melanoma diagnosis and 
prognosis " 6. Aneuploidy has also been detected in clinically benign nevi. This may 
implicate that flow cytometry can detect early premalignant changes which do not 
manifest themselves morphologically. Improved aneuploidy measurement in 
melanomas can be reached by multiparameter flow cytometry by identification and 
exclusion of diploid non-tumour cells . Fundamental research of immunological 
dermatoses has benefited considerably from flow cytometry. Also in pathogenesis-
oriented diagnosis and monitoring of disease activity flow cytometry proved its 
value . 
FLOW CYTOMETRY IN PSORIASIS 
The epidermis consists of different epidermal subpopulations. The majority of cells are 
keratinocytes which express keratin as their intermediate filament. All proliferating 
keralinocytes participate in the cell cycle (Figure 1). 
Four different phases can be recognized. Firstly, the S-phase in which cells replicate 
their DNA. The DNA content increases from diploid (2C) to tetraploid (4C). The 
interval between DNA-synthesis and the next mitosis is referred to as G2-phase 
(G=gap). The cell division phase is called the M-phase (M=mitosis). Cells in G rphase 
are recovering from mitosis or preparing (biosynthesis of enzymes) to enter another 
cell cycle. Probably at a point in early G rphase cells (decision point) "choose" 
whether they remain in the cell cyclus (DNA-synthesis), or escape from it by 
committing themselves to terminal differentiation or by entering a quiescent state (Go-
phase). Figure 2 shows a histogram that represents the DNA distribution of an 
epidermal cell population. Obviously, in hyperproliferative epidermis a relatively large 
amount of keratinocytes will be present with more than diploid cellular DNA content. 
These keratinocytes are in S-, G2- and M-phase. 
The basal keratinocytes can be distinguished by their ability to express the keratin pair 
K5 (58 kD) and K14 (50 kD). As they commit to terminal differentiation, they leave 
the cell cycle, leave the basal layer and begin their migration towards the surface of the 
skin. The keratinocytes then enter the spinous layer and are characterized by a shift in 
keratin synthesis from the K5/14 pair to the K1/K10 pair. Later in the maturation 
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Figure 1. A diagram of the cell cycle 
process keratinocytes synthesize involucrin and filaggrin and activate epidermal 
transglutaminase. Some monoclonal antibodies that react with basal and suprabasal 
epidermal cells are listed in Table 2. 
The first flow cytometric studies on psoriasis consisted of single-parameter 
measurement of DNA content. Nuclei of epidermal cells were stained with fluorescent 
dyes that quantitatively conjugate with DNA. Frequently used fluorochromes were 
ethidium bromide, introduced in 1967 , and propidium iodide (1969)4 . Both dyes 
selectively intercalate with the double-stranded regions of nucleic acids. As they also 
react with RNA, reliable DNA content analysis requires pre-treatment with RNase. 
Techniques to analyse the proliferative activity of normal and abnormal keratinocytes 
were developed and improved * . It was shown that significantly higher numbers of 
cycling cells are present in epidermis from involved psoriatic skin compared to normal 
skin ' Special emphasis was put on the preparation of epidermal cell 
suspensions47-4 . A first flow cytometric evaluation of wellknown antipsoriatic 
therapies was carried out . 
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Figure 2. DNA histogram from epidermal keratinocytes. The peak corresponds with cells in 
GQ/GI-phase. 
Table 2. Monoclonal antibodies reactive with epidermis 
Monoclonal antibody Directed against Source 
RCK105 
RKSE60 
DE-KIO 
K14 
LL002 
Ks8.12 
LL024 
Anti-filaggrin 
Anti-transglutaminase 
Anti-SKALP 
Anti-involucrin 
Ki-67 
MIB-1 
Anti-PCNA 
Anti-BrUrd 
Keratin 5 and 8 
Keratin 10 
Keratin 10 
Keratin 14 
Keratin 14 
Keratin 13 and 16 
Keratin 16 
Filaggrin 
Transglutaminase 
SKALP 
MON 150 
Proliferating cells 
Proliferating cells 
PCNA 
Proliferating cells 
Dept. Mol. Biol., Maastricht 
Dept. Mol. Biol., Maastricht 
1CN 
Sigma 
Novocastra 
Sigma 
Novocastra 
BTI 
BTI 
Dept. Dermatology, Nijmegen 
Dept. Dermatology, Nijmegen 
Dakopatts 
Immunotech 
Boehringer 
Dakopatts 
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From a variety of studies it was concluded that psoriatic hyperproliferation results from 
reduced turnover time and cell cycle time (T
c
) compared to normal skin . The average 
T
c
 for normal skin was calculated to be about 209 hours, whereas in involved psoriatic 
epidermis T
c
 was significantly lower reaching values of 36 hours" . However, evidence 
against this classic assumption is cumulating: a recent study by Van Ε φ et al. using 
flow cytometry in combination with IdUrd labelling showed that there seems to exist 
no major difference between normal and hyperproliferative skin with respect to cell 
cycle time and duration of individual cell cycle phases . This in vivo study strongly 
suggests an increased growth fraction to be a sufficient case for the permanent increase 
of the germinative population in psoriasis, as computer simulations were already 
indicating in 1979 . 
It is important to realize that by using single-parameter flow cytometry no reliable 
discrimination between different epidermal subpopulations can be reached. Therefore 
values for proliferative activity reflect the overall epidermal proliferative activity, 
including all epidermal cells, i.e. basal keratinocytes, suprabasal keratinocytes and 
nonkeratinocytes. Progress in this field was made by the development of double-
labelling procedures. Different investigators performed simultaneous examination of 
epidermal proliferation and keratin expression in normal and psoriatic skin23'5'''56. It 
was shown that the number of basal cells (keratin 5/14) was increased in psoriatic 
epidermis compared to normal epidermis. The number of keratin 10-positive cells was 
decreased in psoriatic lesions. Proliferating cells were especially located in the basal 
layer. The intermediate filament protein vimentin was used to discriminate between 
keratinocytes and non-keratinocytes ' ' 
At the Department of Dermatology in Nijmegen an Epics Elite flow cytometer is 
available for flow cytometric research (see Figure 3). During the investigations 
described in the present thesis two lasers were present in the apparatus: an air-cooled 
488 nm Argon laser and 633 nm HeNe laser. This means that excitation is possible at 
two different wavelengths permitting the measurement of multiple signals. Suitable 
fluorochromes for double-labelling procedures with the Argon laser are propidium 
iodide (DNA stain) and fluorescein which both absorb light at 488 nm and have 
different emission spectra: peak values of 630 nm (red light) and 525 nm (green light), 
respectively. Phycoerythrin is also excitated at 488 nm. Addition of the relatively 
cheap HeNe laser offers the possibility to introduce new fluorochromes, which are 
excitated by the 633 nm-signal. New possibilities for three-colour cytometry are within 
reach. 
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Figure 3. The Coulter Epics Elite flow cytometer 
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1.3 Aims of the thesis 
METHODOLOGY 
Psoriasis is a chronic disease with epidermal hyperproliferation. impaired 
keratinization and cutaneous inflammation. These cell biological features are clinically 
expressed as induration, scaling and erythema of the psoriatic lesion. In clinical 
assessment of disease activity the scores for induration, scaling and erythema are 
estimated on a 5-points scale, resulting in a numerical value. This clinical scoring, 
however, is subjective and introduces inaccuracy. 
In the evaluation of antipsoriatic therapies the quantitative assessment of disease 
activity is essential. Flow cytometry permits simultaneous, quantitative measurement 
of different epidermal cell parameters. This approach might be an alternative for 
clinical scoring. Therefore the first aim of the present thesis is: 
(1) TO DEVELOP AND VALIDATE A NEW APPROACH TO MONITOR 
DISEASE ACTIVITY. 
This new method should permit quantitative measurement and reflect the key 
processes in the pathogenesis of psoriasis. Validation of this method should comprise 
correlation analysis with clinical parameters. 
IN VIVO MODELS 
Several in vivo models for psoriasis exist. These models can be used to study the 
dynamics of epidermal proliferation, keratinization and inflammation. Quantitative 
analysis might reveal aspects of the pathogenesis of psoriasis. In vivo models might 
allow standardized comparison of different antipsoriatic therapies. Therefore the 
second aim is: 
(2) TO CHARACTERIZE POTENTIAL IN VIVO MODELS FOR PSORIASIS. 
The investigated in vivo models in the present thesis are: the tape stripping model 
(Chapter 2.2), the leukotriene B4 model (Chapter 3.1) and the relapse of the psoriatic 
lesion after successful treatment (Chapter 3.2). 
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ANTIPSORIATIC THERAPY 
Knowledge of the cell biological effects of antipsonatic treatments is essential for the 
development of new strategies The action spectrum of promising compounds can be 
differentiated by assessment of their interference with epidermal proliferation, 
keratinization and inflammation Multiparameter flow cytometry might enable 
quantitative comparison of different antipsonatic approaches Furthermore, rational 
combinations of antipsonatic therapies might be developed 
The third aim of the present thesis is. 
(3) TO DEVELOP AND EVALUATE NEW STRATEGIES IN THE TOPICAL 
TREATMENT OF PSORIASIS 
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Chapter 2 
TRIPLE-LABELLING FLOW CYTOMETRY AND 
DEVELOPMENT OF CELL ISOLATION PROCEDURES 

2.1 TO-PRO-3 iodide, a novel HeNe laser-excitable DNA stain as an 
alternative for propidium iodide in multiparameter flow 
cytometry 
Candida Α Ε M van Hooijdonk, Conrad Ρ Glade, Piet E J van Ε φ , 
Department of Dermatology, University Hospital Nijmegen, 
The Netherlands 
Cytometry 1994; 17:185-189 
SUMMARY 
A new red emitting fiuorophore, TO-PRO-3 iodide (TP3), which is best excited by a 
HeNe laser (633 nm), has been compared with propidium iodide (PI) for measuring 
relative DNA content TP3, which has a peak absorbance at 642 nm and emission at 
661 nm. has been tested on peripheral blood lymphocytes (PBL) and keratinocytes in a 
two-laser system As an example, we present a three-color flow cytometric application 
utilizing TP3 in combination with fluorescein-isothiocyanate (FITC) and phvcoerythnn 
(PE) conjugated to monoclonal antibodies in this paper 
A subequihbnum concentration of 1 μΜ TP3, most preferably used in combination 
with RNase treatment, showed to be a powerful alternative for DNA amount 
determination In human- and mouse-Balb/MK-keratinocyte populations with different 
S-phase fractions, PI and TP3 showed a good correlation Finally, in the triple labelling 
experiment we clearly demonstrated that TP3 is readily applied to the analysis ot 
binding of two antibodies and relative DNA content simultaneously 
INTRODUCTION 
For many decades, PI has widely been used as a dye tor measuring relative DNA 
content in single parameter flow cytometry Since many investigators became 
interested in multiparameter analysis, PI has also been used in combination with 
antibody labelling Because of the large spectral overlap of PE and PI fluorescence, 
simultaneous measurement of FITC, PE and PI has been considered not to be 
easy 1 2 1 1 1 5 Recent publications showed the use ot PI for this purpose However, 
compensation difficulties still remain 
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In 1984, Zelenin et al. investigated an alternative DNA stain, 7-amino-actinomycin D 
(7AAD), which has an emission spectrum with a maximum at a longer wavelength 
compared to PI (> 650 nm) . Although the quantum efficiency is low, it can be used in 
combination with FITC- and PE-labelled antibodies using only one single (488 nm) 
excitation beam . The DNA content distributions obtained using 7AAD in this way 
have been disappointingly broad. So others have chosen to use a dual-beam UV and 
488 nm system and have used Hoechst 33342 as the DNA stain1'14. 
Nevertheless, having at our the disposal an inexpensive low-power air-cooled HeNe 
laser (633 nm), we searched for a new red emitting fluorophore which could be excited 
with this laser. Recently, a family of new DNA probes with exceptional spectral 
7 9 
properties has become available from Molecular Probes, Inc. (Eugene, OR) ' . TP3, 
which has peak absorbance at 642 nm and emission at 661 nm, is best excited by the 
HeNe laser at 633 nm. So this makes TP3 a powerful alternative for measuring DNA, 
and hopefully, it can be used in combination with FITC and PE for three-color flow 
cytometry. In this paper, we have compared PI and TP3 in a two-laser system and give 
an example of a triple labelling. 
MATERIALS AND METHODS 
Cell culture and cell preparation 
In this study fixed cell suspensions from lymphocytes, cultured keratinocytes and 
human skin biopsies were used. 
PBL were obtained from a healthy donor and isolated by Ficoll-Isopaque-1077 
(Pharmacia, Uppsala, Sweden) density centrifugation. Light density mononuclear cells 
were washed with PBS, fixed with ice-cold 70% ethanol and stored at -20°C. Human 
keratinocytes were cultured in keratinocyte growth medium (KGM) and growth arrest 
was induced either by using keratinocyte basal medium (K.BM) or KGM supplemented 
IS 
with transforming growth factor-ß (TGF-ß) . 
The mouse keratinocyte line, Balb/MK, was kindly provided by Dr. S.A. Aaronson. 
Balb/MK keratinocytes were either grown exponentially ("cycling" state) or switched 
to maintenance medium ("quiescent" state) under culture conditions as described 
earlier . 
Human skin biopsies, 0.5 cm2 in size and 0.2 mm in thickness, were obtained from 
healthy volunteers from which the homy layer was removed by "sellotape stripping" . 
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Biopsies were trypsinized, cell suspensions fixed in ice-cold 70% ethanol and stored at 
-20°C according to Gommans et al.8 
Staining 
The same staining procedure has been used for PI (Calbiochem, San Diego, CA) as 
well as for TP3 (Molecular Probes, Inc.). Up to one million fixed cells, either 
lymphocytes or keratinocytes, were resuspended in 500 μΐ PBS containing 40 μg/l PI 
or 1 μΜ (671 μ^Ι) TP3 and incubated for 15 min with 50 μΐ 1% w/v RNase (Sigma 
Chemicals Co., St. Louis, MO) . In one experiment TP3 concentrations were varied 
and in another the effect of RNase was tested. Exact conditions are given in the Results 
and Discussion section. Triple labelling was performed using an IgGl-type 
monoclonal antibody recognizing the intermediate filament-type protein keratin 10 
(RKSE60, provided by Prof. F.C.S. Ramaekers, Dept. of Mol. Cell Biology, University 
Hospital Maastricht, The Netherlands) and an IgG2a-type monoclonal antibody against 
another intermediate filament-type protein vimentin (VIM 3B4, Novocastra 
Laboratories Ltd., Newcastle upon Tyne, UK) in combination with TP3. Second-step 
immunofluorescent staining reagents for mouse IgGl and IgG2a monoclonal 
antibodies, conjugated with PE and FITC, respectively, were obtained from Southern 
Biotechnology Associates, Inc., Birmingham, AL. 
Flow cytometry 
Samples were analysed on a Coulter Elite flow cytometer (Coulter, Luton, UK). Cells 
were excited with an air-cooled 488 nm argon laser set at 15 mW (PI-, FITC- and PE 
staining, forward scatter and right angle scatter signals) and with a 10 mW 633 nm 
HeNe laser for TP3 staining. The Coulter Elite emission filters were 520-530 nm BP 
(green; FITC), 555-595 nm BP (orange; PE), 630 nm LP (red; DNA, PI) and 670-680 
nm BP (red; DNA, TP3). At least 10,000 cells were analysed per sample. For triple 
labelling experiments standard electronic compensation was used to remove residual 
spectral overlap between FITC and PE, and minimal compensation in the case of TP3. 
Typical settings for three-color fluorescence on the Coulter Elite were 580, 520, 550 V 
on photomultiplier tubes for green (FLI), orange (FL2), and red (FL3) detectors, 
respectively; and 2, 21 and 2% compensation for (FL1-%FL2), (FL2-%FL1), (FL3-
%FL2), respectively. 
The ratio area/peak discriminates between artifacts due to doublets of diploid cells and 
real single tetraploid (or late S-phase) cells . Multicycle™ software (Phoenix Flow 
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Systems, San Diego, CA) was used to calculate the percentage S-phase positive cells 
from DNA histograms of PI as well as of TP3. 
RESULTS AND DISCUSSION 
TP3 showed to be an excellent alternative for measurement of relative DNA content. In 
addition to its similar staining characteristics to PI, it was superior as DNA stain in 
multiparameter flow cytometry when combined with the use of two antibodies (FITC-
and PE-conjugated). The need for a second laser is only a minor disadvantage, since 
there are many excellent research flow cytometers which are equipped as standard with 
a low-power HeNe laser, for instance the Coulter Elite flow cytometer' . 7AAD and 
Hoechst 33342 have been proposed as alternatives for PI in multiparameter flow 
cytometry ' ' ' . However, in our hands, using epithelial cells, 7AAD gave 
unacceptable high coefficients of variation (CVs) (data not shown). The other 
alternative, Hoechst 33342 staining, requires the use of an expensive UV laser, which 
is not a standard component in many commercial flow cytometers. 
PBL were used to test different concentrations of TP3 in a range from 10 nM to 10 
μΜ. A linear increase in peak position of the TP3 signal up to 2 μΜ was shown. 
Above this concentration, the peak positions decreased, probably because the blue 
color of the dye interferes with the measurement. So therefore we decided to use a 
subequilibrium concentration of 1 μΜ TP3 in our experiments. 
In Figure 1 the effect of RNase treatment on the DNA distributions is shown. Figure 
IB. demonstrates that lower CVs could clearly be obtained by adding 1% w/v RNase 
to the ТРЗ-conlaining cell suspensions. Experimental conditions were identical to 
those when using PI . 
Furthermore, we have used human and mouse keratinocytes, for comparison of PI and 
TP3 with respect to S-phase determination. Human keratinocytes were grown in KGM. 
Additionally, these cells were growth arrested in KGM with TGF-ß or KBM, and 
keratinocytes were restimulated with KGM after growth arrest in KGM with TGF-ß. 
Mouse-Balb/MK-keratinocytes were either grown exponentially or switched to a 
maintenance medium. The aim of the different culture conditions was to obtain cell 
populations with different S-phase fractions. Figure 2 demonstrates the direct 
comparison of histograms using PI and TP3. It clearly shows a very good correlation 
between the percentage S-phase positive cells using either PI or TP3 under all our 
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experimental conditions. This can easily be explained by the similarity of the two 
fluorochromes, both intercalating in ds DNA . 
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Figure 1. The effect of l%w/v RNase added to ТРЗ-containing cell suspensions of PBL. Two 
histograms are shown: (A) without (CV = 7.9%) and (B) with RNase treatment (CV = 3.6%). 
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Figure 2. Comparison between TP3 (dark-shaded bars) and PI (light-shaded bars) with respect to 
cells in S-phase of the cell cycle. Human- (HK) and mouse-Balb/MK-keratinocytes (MK) were 
cultured under different experimental conditions, resulting in different S-phase fractions. 
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Figure 3. An example of a three-color flow cytometric analysis. Epidermal cell suspensions were 
labelled with two monoclonal antibodies and TP3. A: FSC (forward scatter) vs. PE (RKSE60). B: 
FSC (forward scatter) vs. FITC (VIM 3B4). C: PE (RKSE60) vs. FITC (VIM 3B4). D: TP3 (DNA) 
vs. PE (RKSE60) of the VIM 3B4-negative cell population. E: TP3 (DNA) histogram of the VIM 
3B4-negative cell population. F: TP3 (DNA) histogram of the VIM 3B4-positive cell population 
(non-keratinocytes). 
An example of a triple labelling is demonstrated in Figure 3 . Two antibodies, 
recognizing different intermediate filament-type proteins, were used to separate an 
epidermal cell suspension into three different subpopulations. Differentiated 
keratinocytes were keratin 10 (RKSE60, PE)-positive and all non-keratinocytes were 
vimentin (VIM 3B4, FITC)-positive. Relative DNA content was measured using ΙμΜ 
TP3. Typical CVs for the diploid TP3 peak ranged from 3 to 4% in vimentin-positive 
cells and 4 to 8% in keratinocytes. These results were similar to results obtained with 
PI in double labelling experiments16. The advantage of using TP3 incombination with 
FITC and PE is that there is no need for fluorescence compensation for the TP3 signal. 
The DNA signal is plotted on a linear scale and interference of PE and/or FITC 
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fluorescence would result in unreliable DNA histograms. For this reason we think the 
combination of FITC-PI-Cy5 is less useful. 
In summary, we believe that the HeNe laser-excitable fluorochrome TP3 is an 
excellent alternative for PI in measuring relative DNA content. Since electronic 
compensation of the DNA signal is not really necessary, analysis of the binding of two 
antibodies and a reliable DNA measurement can be performed simultaneously. 
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SUMMARY 
Reliable flow cytometric analysis of normal and diseased skin requires pure epidermal 
single-cell suspensions Several methods to separate the dermis from the epidermis are 
available The proteolytic enzyme thermolysin separates the epidermis from the dermis 
at the lamina lucida and therefore permits reliable dermoepidermal separation In the 
present study an optimized cell isolation procedure using thermolysin and trypsin is 
described, which is particularly suitable for punch biopsies A 16-20-h (overnight) 
incubation of biopsies taken from normal and hyperproliferative skin with thermolysin 
(0 5 mg/ml) at 4°C produced a selective separation of the dermis and epidermis After 
a 30-min trypsin incubation (0 25 mg/ml) at 37°C a cell suspension was prepared 
which was characterized by minimal cell damage (cellular debris and clumps), a high 
recovery of basal cells and high quality DNA histograms Furthermore, dermal 
contamination was very low The thermolysin-trypsin separation methodology 
followed by triple-labelling flow cytometry provided a precise quantification of the 
percentage of keratin 10-positive cells, vimentin-positive cells and cells in S- and G2M 
phase Proliferative activity was measured selectively in the basal, the suprabasal and 
the non-keratinocyte compartment at various time intervals during epidermal 
regeneration after sellotape stripping In contrast to the non-keratinocytes, the 
percentage of cells in S- and G2M phase in the basal keratinocytes and in the 
suprabasal compartment increased 44-48 h after stripping The increased proliferation 
following tape stripping was paralleled by an increased invasion of vimentin-positive 
cells into the epidermis and preceded by a decreased number of keratin 10-positive 
cells Thermolysin-trypsin separation followed by three-colour flow cytometry permits 
a highly selective characterization of normal and hyperprohferative epidermis 
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INTRODUCTION 
Flow cytometry is a valuable approach for quantifying the behaviour of normal and 
diseased epidermis under various conditions' A prerequisite for accurate and 
reliable quantification is a high quality of epidermal single-cell suspensions In this 
respect it is essential that the biopsy specimens obtained for preparation of these 
suspensions always contain the whole epidermis Therefore, in hyperproliferative skin 
diseases such as psoriasis, dermatotome (0 4 mm depth) or preferably punch biopsies 
are required However, contamination with dermal cells is inevitable if 
dermoepidermal separation is not part of the cell isolation procedure 
In the past, dermoepidermal separation has been achieved using different methods such 
as suction blisters (mechanical), sodium chloride30 (chemical) and proteolytic 
enzymes, such as trypsin , dispase and thermolysin2 Enzymological methods are 
preferred as they are site-specific, and less time consuming Until recently we have 
used incubation with trypsin in combination with dithioerythntol (DTE) to obtain 
dermoepidermal separation and dissociation of the keratinocytes A limitation of 
this method is the fact that the level of separation is dependent on factors such as 
thickness of the biopsy, purity of the preparation, incubation time and temperature1025 
Dispase is often to obtain samples free from dermal contaminants ' , however, 
changes in the basal compartment and impaired viability have been described 
Thermolysin appears to produce a selective separation of the dermoepidermal junction, 
providing an epidermal sheet with a complete basal layer" Subsequent incubation 
with trypsin provides single-cell suspensions suitable for flow cytometric analysis 
Various incubation times and temperatures have been proposed by different 
authors' " So far, thermolysin-trypsin separation has not been validated in 
hyperproliferative skin 
Multiparameter flow cytometry enables simultaneous measurement of different cell 
parameters Until now three-colour flow cytometry combining dual 
immunophenotyping with quantitative DNA analysis has been impeded by a 
considerable spectral overlap of the fluorochromes used Recently we have 
demonstrated that this problem can be overcome by using the new DNA dye TO-PRO-
3 iodide (TP3) in combination with the fluorochromes phycoerythnn (PE) and 
fluorescein isothiocyanate (FITC) In the present study the contamination with 
dermal cells and the relative numbers of basal cells after dermoepidermal separation 
was quantified using double-labelling flow cytometry In epidermal cell suspensions 
prepared from normal and hyperproliferative skin, a triple-labelling procedure was 
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applied with simultaneous quantification of the basal and differentiated keratinocytes, 
cells of mesenchymal origin and the DNA content of these epidermal subpopulations. 
The aim of the present study was to validate a combined thermolysin-trypsin method 
on normal skin and hyperproliferative skin. Psoriatic lesions and recovery from tape 
stripping were studied using flow cytometry as conditions characterized by epidermal 
hyperproliferation. In particular the following issues were addressed: (1) optimization 
of the thermolysin-trypsin separation procedure in normal and psoriatic skin; (2) 
quantification of epidermal cell characteristics in biopsies taken from normal skin 
following both separation methods using triple-labelling flow cytometry; and (3) 
analysis of epidermal hyperproliferation induced by tape stripping using triple-
labelling flow cytometry following thermolysin-trypsin separation. 
MATERIALS AND METHODS 
Subjects 
Skin samples were obtained from 26 healthy volunteers (16 males, 10 females, age 
range 18-29 years) without signs or history of skin diseases and from the lesionai skin 
of 6 psoriasis vulgaris patients (3 males, 3 females, age range 30-64 years). All 
subjects had given informed consent prior to biopsy. 
Biopsy and tape stripping procedure 
Dermatotome biopsies were taken from normal and lesionai psoriatic skin12. After 
induction of local anaesthesia with ethyl chloride spray (Medica, 's Hertogenbosch, 
The Netherlands), a small dermatotome (Coriotome 6B333, Aesculap, Tuttlingen, 
Germany) with a metal guard was used to obtain skin samples with an area of 1 cm 
and a thickness of 0.2 mm (normal skin; я=10) or 0.4 mm (psoriatic skin; n=6). Punch 
biopsies (3 mm) were taken from normal skin (л=7), from lesionai psoriatic skin (n=6) 
and in the tape stripping experiment (n=28). Local anaesthesia was induced with 
Xylocaine/adrenaline 1:100 000. 
О 
Tape stripping was carried out on the back of seven healthy volunteers . By repeated 
applications of Sellotape adhesive tape the stratum comeum was removed from four 
test areas (± 2 cm2) until the surface was glistening. In total, five punch biopsies were 
obtained from each volunteer, before tape stripping and after 8, 24, 44 and 48 h. At 
each visit erythema, induration and desquamation were assessed clinically using a five-
point scale (0 = not present, 1 = slight, 2 = moderate, 3 = severe and 4 = very severe). 
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Cell isolation procedure 
12 
The trypsin cell isolation procedure has been described previously . In brief, after a 
one-step incubation of the skin specimen in phosphate-buffered saline (PBS) 
containing 0.25 mg/ml trypsin (Sigma T-8253, St. Louis, Mo., USA) and 3.0 mg/ml 
DTE (Sigma, D-8255) for 30 min at 37°C, the dermis was separated with forceps in 
PBS containing 10% heat-inactivated newborn calf serum (HINCS, Life Technologies, 
Paisley, UK). The remaining epidermis was then gently mixed on a vortex to separate 
the keratinocytes, resulting in a single-cell suspension. The stratum comeum was 
discarded. A limitation of this method is that it is not applicable to punch biopsy 
specimens. 
The two-step thermolysin-trypsin separation procedure was tested under different 
concentrations, incubation times and temperatures for both thermolysin (Sigma P-
1512) and trypsin as described in the Results section. After thermolysin incubation (0.5 
mg/ml dissolved in PBS with Ca + and Mg +; Seromed, Berlin, Germany), the dermis 
and epidermis were separated using fine forceps. This separation was visualized in 
normal and psoriatic skin by routine HE staining. Subsequent trypsin-DTE incubation 
provided single-cell suspensions. 
Cells were fixed in 1-3 ml ice-cold ethanol (70% v/v) and kept at -20°C. To be able to 
compare the percentage of intact cells (without debris and clumps) the suspensions 
were not filtered before staining and flow cytometric analysis. 
Flow cytometric analysis 
Flow cytometric validation of the separation method consisted of double-labelling 
procedures. To obtain information on contamination with dermal cells, propidium 
iodide (PI; Calbiochem, San Diego, Calif., USA) staining was combined with staining 
with a monoclonal antibody against the intermediate filament vimentin (Vim3B4, 
Novocastra Laboratories, Newcastle upon Tyne, UK; see Table 1). The relative amount 
of basal and suprabasal cells present in the suspensions was quantified by simultaneous 
staining with the monoclonal mouse antibodies RCK102 and RKSE60 (gifts from Prof. 
F.C.S. Ramaekers, Department of Molecular Biology, University of Maastricht, The 
Netherlands) as primary antibodies. Rabbit antimouse IgG conjugated with fluorescein 
isothiocyanate (RAM-FITC, Dakopatts, Copenhagen, Denmark) was used as 
secondary antibody in these experiments. Cell suspensions were prepared from 
dermatotome and punch biopsies from normal and psoriatic skin with different 
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Separation conditions. From each suspension two samples containing about 1 χ 10 
ethanol-fixed cells were washed in PBS, centrifuged (5 min, 3000 rpm) and 
resuspended in 500 μΐ PBS containing either Vim3B4 (1 50 dilution) or RCK102 (1 30 
dilution) and RKSE60 (1.15 dilution) After 30 mm incubation in the dark at room 
temperature the cells were washed in PBS containing 1% HINCS, centrifuged and 
resuspended in 500 μΐ PBS containing RAM-FITC and HINCS (both 1.50 dilution). 
After 15 min incubation at 5°C the cells were washed and centrifuged as before and 
finally resuspended in 500 μΐ PBS containing 40 μg/ml PI and 0.1% RNase (Sigma, R-
4875) and kept for 10 min in the dark.. 
Table 1, Primary antibodies used in flow cytometric analysis 
Primary 
antibody 
Vim3B4 
RCK102 
RKSE60 
Directed against 
Vimentin 
Keratins S and 8 
Keratin 10 
Present in 
Mesenchymal 
cells 
Basal 
keratinocytes 
Suprabasal 
keratinocytes 
Dilution 
1 50 
1 30 
1 15 
Source 
Novocastra 
Pathology 
Department 
Pathology 
Department 
References 
20 
28 
9 
A triple-labelling procedure was used to quantify epidermal cell characteristics in 
normal and hyperproliferative skin. In preliminary experiments specificity and optimal 
concentrations of the antibodies were tested We have described the staining procedure 
12 
previously The DNA content was measured using the new DNA fluorochrome TP3 
(Molecular Probes, Eugene, Ore., USA). TP3 intercalates with double-stranded DNA 
and permits the measurement of the proliferative activity of cells by quantification of 
the percentage of cells in S- and G2M phase. As TP3 also binds to RNA to some 
extent, it was used in combination with RNase. Primary intermediate filament 
antibodies were RKSE60 (mouse, IgG|) and Vim3B4 (mouse, IgG2a). The second step 
of the indirect immunofluorescent staining was performed with monoclonal goat 
antibodies against mouse IgG, and IgG2a, conjugated with PE and FITC, respectively 
(Southern Biotechnology Associates, Birmingham, Ala, USA) Usually suspensions 
containing about 1-2 χ IO5 cells were used for flow cytometric analysis 
From each sample 5000 gated cells were measured and analysed using an EPICS® 
Elite flow cytometer (Coulter, Luton, UK) equipped with a dual laser system PE, 
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FITC and PI were excited with an air-cooled argon ion laser (15 mW, 488 nm). TP3 
was excited with a HeNe laser (10 mW, 633 nm). Fluorescence was measured using 
bandpass filters of 520-530 nm (green, FITC), 555-595 nm (orange, PE), and 670-
680 nm (red, TP3) and a longpass filter of 630 nm (orange-red, PI). The area/peak 
ratio of the red signal (DNA) was used to discriminate between doublets of diploid 
cells and real single tetraploid cells4. After setting appropriate gates with the EPICS® 
Elite software, the percentages of cells expressing vimentin, and keratins 5, 8, and 10 
were calculated. Using Multicycle™ software (Phoenix Flow Systems, San Diego, 
Calif., USA) the percentages of basal and suprabasal keratinocytes and of non-
keratinocytes in S- and G2M phase of the cell cycle were calculated from DNA 
histograms. 
RESULTS 
Dermoepidermal separation and cell isolation 
Experiments were carried out to establish the optimal analytical procedures, to achieve 
a selective separation of the dermis and epidermis and a maximum number of intact 
epidermal cells. After thermolysin incubation for 1-2 h at 4°C of punch and 
dermatotome biopsies taken from both normal and psoriatic skin no reliable 
dermoepidermal separation was possible (fluorescence microscopic control). A 2-h 
thermolysin incubation at 37°C did not provide sufficient separation in a punch biopsy 
from psoriatic skin. In contrast, the following conditions proved to result in optimal 
cell suspensions: an overnight (16-20-h) incubation with thermolysin (0.5 mg/ml) at 
4°C, followed by a 30-min trypsin incubation (0.25 mg/ml) at 37°C. Figure 1 
illustrates the typical histological appearance of dermoepidermal separation in punch 
biopsies from normal skin and from lesionai psoriatic skin. It can be seen that the 
separation selectively involved the dermoepidermal junction without dissociation of 
the individual keratinocytes. The complete basal cell layer was present in the 
epidermal compartment without any dermal contamination. 
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Figure la-c. Dermoepidermal separation obtained after incubation of punch biopsies from (a) normal 
skin and (b) psoriatic skin with thermolysin (0.5 mg/ml) overnight (16 h) at 4°C). с After removal of 
the psoriatic epidermis from a thermolysin-treated biopsy the remaining dermis is complete (a x400, 
b χ 200) 
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Table 2 summarizes the flow cytometric analysis (double-labelling) of the epidermal 
sheets prepared from normal and lesionai psoriatic skin using trypsin versus 
thermolysin-trypsin separation methods. It can be seen that the numbers of vimentin-
positive cells and the number of naked nuclei was substantially elevated in the 
preparation of psoriatic skin using the trypsin separation method. After 2 h thermolysin 
incubation at 4°C (dermatotome biopsy, normal skin) a significant loss of keratin 5-
positive keratinocytes, i.e. basal cells, was found. However, using the optimized 
thermolysin-trypsin method the number of keratin 5-positive keratinocytes tended to 
be greater than with the trypsin method. 
Table 2. Flow cytometric analysis of epidermal cell suspensions prepared from normal and lesionai 
psoriatic skin using trypsin (/) and thermolysin-trypsin (if) separation methods. 
Biopsy 
procedure 
Dermatotome 
Dermatotome 
Dermatotome 
Punch 
Punch 
Skin 
Normal 
Psoriasis 
Normal 
Normal 
Psoriasis 
Separation 
method 
t 
t 
tt(2h) 
tt (16 h) 
tt (16 h) 
Vimentin-
positive 
cells (%) 
5.9 
9.1 
5.9 
7.1 
6.3 
Keratin 
positive 
10-
keratinocytes 
(%) 
65.6 
26.3 
90.5 
48.1 
29.2 
Keratin 
5-positive 
keratinocytes 
(%) 
28.0 
54.7 
3.0 
38.4 
60.8 
Naked 
nuclei 
(%)a 
0.5 
9.9 
0.6 
6.4 
3.7 
% naked nuclei = 100% - (% keratin 5-positive cells + % keratin 10-positive cells + % vimentin-
positive cells) 
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Figure 2а-с. Discrimination of different epidermal subpopulations with triple-labelling flow 
cytometry, a TP3 (DNA content, red signal) versus the area/peak ratio of the red signal; b Light 
scatter versus log orange fluorescence (keratin 10; for explanation of subpopulations 1, 2 and 3, see 
text); с Light scatter versus log green fluorescence (vimentin). 
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Quantification of the epidermal cell characteristics of normal skin 
Representative flow cytometric dot plots obtained by the triple-labelling procedure are 
given in Fig. 2. Inside the gate (Fig. 2a) all cells with diploid to tetraploid DNA 
content are present. Cell debris (less DNA content) and clumps (higher area/peak ratio 
of the TP3 signal) are excluded from the analysis. Antikeratin 10 staining (RKSE60, 
Fig.2b) resulted in discrimination of keratin 10-positive cells (1), i.e. suprabasal 
keratinocytes, from keratin 10-negative cells (2), i.e. basal keratinocytes Fig. 2b also 
shows a subpopulation of keratin 10-negative cells with a smaller size (light scatter) 
(3). However, no clear separation of this subpopulation was achieved. With respect to 
antivimentin staining, (Vim3B4) two distinct epidermal subpopulations were 
discriminated: a vimentin-positive population with small cell size and a vimentin-
negative population with larger cell size (Fig. 2c). The first population corresponds to 
the cells from subpopulation 3 in Fig. 2b. The second population represents all 
keratinocytes. Cell cycle analysis was performed on histograms representing the 
germinative layer of the epidermis after exclusion of vimentin- and keratin 10-positive 
cells by software gating. The flow cytometric quantification of the different epidermal 
subpopulations using the trypsin separation protocol on dermatotome biopsies versus 
the thermolysin-trypsin protocol on punch biopsies is summarized in Table 3. It can be 
seen that the population separated with thermolysin-trypsin was characterized by a 
decreased percentage of basal cells in S and G2M phases (P = 0 012, Mest assuming 
equal variances, two-tailed), an increased percentage of intact cells (P < 0.01), a 
decreased coefficient of variation of the G) peaks (P = 0.016), and a slightly decreased 
percentage of vimentin-positive (P = 0.79) and keratin 10-positive cells (P = 0.56). 
Table 3. Flow cytometric comparison of the trypsin (l) and Ihe thermolysin-trypsin (it) cell isolation 
procedure on normal skin (mean ± SEM) 
Biopsy 
procedure 
dermatotome 
(и=10) 
punch (n=7) 
Separation 
method 
t 
tt 
Basal cells in 
S+G2M phase 
(%) 
8 8 ± 0 8 
5 5 ± 0 9 
Intact 
cells 
(%) a 
69 ±2 8 
8 8 ± 2 6 
Coefficient 
of variation 
(G,-peak) 
8 0 ± 0 3 
6 6 ± 0 5 
Vimentin-
positive 
cells (%) 
7 5 ± 1 1 
7 2 ± 0 6 
Keratin 10-positive 
keratinocytes (%) 
61 5 ± 4 5 
57 8 ± 3 4 
* % intact cells = % particles with DNA content (2c-4c) without clumps or debris 
Triple-labelling flow cytometry and cell isolation procedures 55 
Quantification of the epidermal cell characteristics of normal skin following tape 
stripping 
In preliminary experiments flow cytometric analysis was performed on cell 
suspensions prepared from dermatotome biopsies taken at different intervals after tape 
stripping using the standard trypsin separation method. Following trypsinization, a 
reliable separation of dermis from epidermis turned out to be virtually impossible in 
these thin specimens with a partially to totally removed stratum corneum and hardly 
any dermis present. This was confirmed by the flow cytometric analysis which gave 
very inconsistent results especially with respect to the numbers of vimentin- and 
keratin 10-positive cells (unpublished data). In contrast, following incubation of punch 
biopsies taken at different intervals after tape stripping with thermolysin-trypsin the 
dermoepidermal separation was reliable, and pure epidermal single-cell suspensions 
could be prepared. 
None of the seven healthy volunteers complained as a result of the tape stripping study. 
The clinical scores at different time intervals after tape stripping are shown in Fig. 3. 
Maximum erythema was observed 36 h after tape stripping. The triple-labelling flow 
cytometric analysis of the dynamics of the tape stripping model is summarized in Fig. 
4. A significant decrease in the relative number of keratin 10-positive keratinocytes 
was observed at 24, 44 and 48 h after tape stripping (P < 0.01, paired /-test, two-tailed; 
Fig. 4a). The relative number of vimentin-positive cells increased after tape stripping 
with a maximum value at 44 h (P < 0.08; Fig. 4b). With respect to epidermal 
proliferation the number of basal cells in S and G2M phases increased significantly at 
44 and 48 h after tape stripping (P < 0.01). Four volunteers showed a peak value after 
44 h. The peak value (all volunteers) was 46.7 ± 2.5 (mean ± SEM). Remarkably, a 
less pronounced but still substantial increase in proliferative activity was also observed 
in the suprabasal compartment of the epidermis (P < 0.01, at 44 and 48 h). The 
proliferative activity of the non-keratinocytes in the epidermis was not influenced by 
tape stripping (Fig. 4c). 
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DISCUSSION 
The epidermis and dermis of biopsies taken from normal and hyperproliferative skin 
can be separated completely following a combined thermolysin-trypsin digestion 
method. In the present study the optimal conditions for this method were developed. 
Furthermore, a reproducible and quantitative analytical method was described to 
measure simultaneously inflammation, differentiation and proliferation in epidermal 
cell suspensions. 
The separation of the dermis from the epidermis has a major influence on the 
composition of the epidermal cell suspension, in particular in the inflamed skin of 
psoriasis. Thermolysin is a proteolytic enzyme which cleaves the lamina lucida and is 
therefore, from a theoretical point of view, an interesting tool to separate the dermis 
from the epidermis. In contrast to the findings of Walzer et al. , our results indicate 
that a 1-2-h incubation with thermolysin at 4°C does not provide a reliable 
dermoepidermal separation. This is supported by Willsteed et al.30 who observed 
intraepidermal separation in four of five cases after thermolysin incubation for 1 h at 
4°C. Even incubation for 2 h at 37°C, as used by Germain et al. does not provide a 
reliable separation in psoriatic skin. The optimized procedure for punch biopsies 
included an overnight (16-20-h) incubation with thermolysin at 4°C24. Figure 1 shows 
that a selective dermoepidermal cleavage can be achieved in punch biopsies following 
the optimized thermolysin procedure. In psoriatic skin, in particular, this method 
proved to reduce dermal contamination, to preserve the integrity of epidermal cells and 
to increase the relative number of basal cells. An intriguing observation was the 
decrease in the percentage of vimentin-positive cells in the biopsies from psoriatic 
skin. The inflammatory infiltrate cells in psoriatic lesions contribute to an absolute 
increase in the vimentin-positive cells. However, in psoriatic plaques the number of 
germinative cells per surface area has been estimated to be increased by a factor of 7 
and the number of suprabasal cells by a factor of 3 . This implies that an absolute 
increase in mesenchymal cells may not represent a relative increase in psoriatic 
plaques, due to the pronounced increase in keratinocyte populations. 
In multiparameter flow cytometry, the DNA fluorochrome TP3 has the advantage of 
minimal spectral overlap with PE. This is in contrast to other DNA dyes, such as 7-
amino-actinomycin D or PI, with which measurements are substantially influenced by 
the electronic compensation for this overlap' . With the three-colour flow cytometric 
approach using TP3, high quality DNA histograms were obtained. Furthermore, 
discrimination of different epidermal subpopulations allowed a highly selective 
58 Chapter 2 
quantification of the DNA content in basal, suprabasal and mesenchymal cells. Using 
the trypsin method and the combined thermolysin-trypsin method the subpopulations 
in epidermal cell suspensions prepared from normal skin were analysed. The 
percentages of vimentin-positive cells and keratin 10-positive keratinocytes (Table 3) 
9 19 
are in accordance with previous results ' . 
Significantly fewer basal cells with hyperdiploid DNA content were present in cell 
suspensions from normal skin prepared according to the thermolysin procedure (5.5%) 
compared with the trypsin procedure (8.8%). This implies that after thermolysin-
trypsin separation, despite the presence of more basal cells, a lower proliferative 
activity was measured in the germinative compartment. One explanation for this 
observation might be the presence of a larger quantity of clumps in the cell suspensions 
prepared with only trypsin, mimicking cells with a more than diploid DNA content. 
Indeed, the mean percentage of intact cells was 88% in the cell suspensions isolated 
according to the thermolysin-trypsin protocol, whereas this percentage was only 69% 
after trypsin separation. Another explanation might be the lack of proliferative activity 
of exclusively those basal cells that were preserved with the thermolysin protocol. As 
we cannot exclude the possibility that the germinative layer contains subpopulations 
with different proliferating potential, there might exist nonproliferating or very slowly 
proliferating epidermal cells in the basal layer which were lost in the trypsin separation 
procedure. These cells might correspond to the stem cells described by Potten and 
Morris . Future research should resolve this question. 
In previous flow cytometric studies the percentage of cells in S and G2M phases in 
suspensions prepared from normal skin varied from 2.9% to 7.0% ' ' ' . However, in 
those studies dermoepidermal separation was obtained with trypsin only, which might 
have resulted in a relatively high number of clumps and therefore in artificially high 
values for the percentages cells in S and G2M phases. The monoclonal antibody Ki-67 
detects a nuclear antigen that is only present in proliferating cells. In an 
immunohistochemical study the growth fraction (number of cycling cells divided by 
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the number of basal cells) of normal epidermis was calculated to be 5.2% . This value 
approximates the percentage of cells in S and G2M phases in the basal compartment of 
5.5 ±0.9% (Table 3). 
Tape stripping, first described by Pinkus , provides a useful method for studying 
epidermal proliferation, differentiation and inflammation in vivo ' ' ' . Using flow 
cytometry, we reconfirmed that maximal epidermal proliferation can be observed 44-
48 h after removal of the stratum comeum. Proliferative activity was mainly located in 
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the basal compartment, but was also present in the suprabasal compartment, and, as 
expected, was not induced in the non-keratinocytes. After tape stripping we observed 
the proliferative activity of the basal cells to be increased by a factor of 8.5 compared 
with unchallenged skin. The decrease in keratin 10 expression (24 h) preceded any 
measurable change in DNA synthesis. Therefore, it is evident that the onset of 
keratinocyte differentiation does not imply a loss of proliferative activity as already 
suggested by Régnier et al. and Bata-Csorga et al. . Using an enzymological assay 
Chang et al. quantified epidermal polymorphonuclear leucocytes (PMNs) after tape 
о 
stripping . Maximal numbers of PMNs were observed 8 h after stripping. In the present 
study, however, clinical scores for erythema were maximal 36 h after tape stripping. 
Interestingly, maximal vimentin expression was observed after 44 h. At this time the 
percentage of vimentin-positive cells was 11.7%. In contrast to the situation in 
psoriasis, following tape stripping (without substantial changes in the total number of 
keratinocytes) the increase in vimentin-positive cells represents a relative increase as 
well as an absolute increase. These cells comprise Langerhans' cells, melanocytes and 
infiltrating cells such as monocytes, lymphocytes and PMNs. In inflamed skin the 
number of infiltrating cells can be approximated from the total number of vimentin-
positive cells by subtracting the number of mesenchymal cells in normal epidermis 
(7.2%). In the tape stripping experiments the maximal number of infiltrating cells was 
4.5%. 
In conclusion, the combined approach of cell isolation with thermolysin-trypsin and 
multiparameter flow cytometry was shown to provide the optimal approach to 
analysing epidermal single-cell suspensions from normal and hyperproliferative skin. 
Different epidermal subpopulations could be discriminated and reliable cell cycle 
analysis performed. Furthermore, the characterization of epidermal cell suspensions 
using triple-labelling flow cytometry provided important information on the 
regeneration of the epidermis in vivo following tape stripping. 
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Chapter 3 
IN VIVO MODELS TO STUDY THE DYNAMICS 
OF THE PSORIATIC LESION 

3.1 The dynamics of the response of normal skin to single and 
multiple epicutaneous leukotriene B4 applications analysed by 
three-colour flow cytometry 
Conrad P. Glade, Rene J.G. Botermans, Piet E.J. van Ε φ , Peter C M . van de 
Kerkhof, Department of Dermatology, University Hospital Nijmegen, The 
Netherlands 
Acta Derm Venereol (Stockh) 1995; 75: 437-441 
SUMMARY 
Leukotriene B4 (LTB4) is a potent chemoattractant and a well-established stimulator of 
DNA-synthesis in keratinocytes. Previously, repeated applications of LTB4 have been 
reported to induce a topically defined tachyphylaxis with respect to the extravasation 
of polymorphonuclear neutrophils. The aim of the present study was to quantify 
epidermal proliferation (% basal keratinocytes in S- and G2M phase), epidermal 
keratinization (% keratin 10-positive keratinocytes) and the appearance of "non-
keratinocytes", including melanocytes, Langerhans' cells and infiltrate cells (% 
vimentin-positive cells) in order to further elucidate the effect of chronic exposition of 
normal skin to LTB4. Using three-colour flow cytometry, we could reconfirm that the 
response to one single epicutaneous application of LTB4 was characterized by a 
marked increase of the percentage of basal keratinocytes in S- and G2M phase, and a 
marked increase of non-keratinocytes. Repeated applications of LTB4 induced a 
moderate increase of the percentage of cells in S- and G2M phase and a moderate 
increase of the percentage of keratin 10-positive keratinocytes. Remarkably, the 
percentage of non-keratinocytes had decreased following repeated applications of 
LTB4, compared to unchallenged normal skin. The present study suggests that chronic 
exposure of normal skin to LTB4 induces changes which differ markedly from the 
histological features of the chronic psoriatic lesion. Therefore, LTB4 is unlikely to be 
responsible for the perpetuation of the psoriatic plaque. 
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INTRODUCTION 
The chemokine leukotriene B4 (LTB4), a metabolite from the 5-lipoxygenase pathway 
in the transformation of arachidonic acid, is a potent chemoattractant for 
polymorphonuclear neutrophils (PMNs) in vitro and in vivo ' . PMNs, human 
keratinocytes in vitro and human cells derived from epidermal biopsies can 
synthesize LTB4. It is well established that epicutaneous application of LTB4 to normal 
skin causes a dose-dependent influx of leukocytes, subsequently followed by 
recruitment of cycling cells resulting in epidermal hyperproliferation ' . As the main 
features of psoriasis consist of increased epidermal proliferation, cutaneous 
inflammation and impaired differentiation, it has been hypothesized that these changes 
in psoriasis might at least to some extent be induced by LTB4. Indeed, compared to 
normal skin, there is a moderately increased LTB4 synthesis in uninvolved skin of 
psoriatic patients . In lesionai psoriatic skin a massive overproduction of arachidonic 
acid metabolites, including LTB4, has been demonstrated . 
Until now the in vivo effect of LTB4 has been assessed by qualitative analysis such as 
histology, immunocytochemistry or ultrastructural studies. Single application of LTB4 
to normal skin results in the induction of intra-epidermal neutrophil microabscesses 
after 24 h, which resolve after 48 to 72 h. Using elastase as a marker enzyme for 
PMNs, maximum elastase activity is measured 18 h after application of LTB410. Not 
only PMNs are attracted by epicutaneous LTB4 application . In the epidermis the 
number of T-lymphocytes reaches a maximum after 48 h. CD la-positive Langerhans' 
cells show a moderate transition from the epidermis to the dermis after application of 
LTB4. Also monocytes accompany PMN invasion . A marked increase of cycling 
cells was demonstrated 72 h after application of LTB4 . A flow cytometric 
quantification of DNA on unselected cell populations revealed an increase of the 
number of non-diploid cells from 3% to 15% 72 h after LTB4 challenge . No 
quantitative data are available on the effect of LTB4 upon differentiation of 
keratinocytes. 
Only to a limited extent can the response to single applications of LTB4 be regarded as 
a model for psoriasis. So far, a single application of LTB4 has never resulted in the 
appearance of a psoriatic lesion. The responses to repeated applications of LTB4 have 
been evaluated by Wong et al.' using standard histology. Only modest histological 
changes, compared to unchallenged skin, have been reported by these authors. Indeed 
Colditz & Movat13 also reported on the "habituation" to LTB4 after repeated 
applications with respect to LTB4-induced Chemotaxis of PMNs. 
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The aim of the present study was to quantify aspects of epidermal proliferation, 
differentiation and inflammation in normal skin following single and repeated 
applications of LTB4. A three-colour flow cytometric method " with simultaneous 
measurement of DNA content and the expression of two intermediate filament proteins 
was used. The following questions were addressed: i) to what extent are the flow 
cytometric analyses of epidermal cell populations compatible with the histological 
findings in skin biopsies taken after one single application of LTB4?, and ii) what is the 
response of normal skin to repeated applications of LTB4 compared to skin challenged 
with one single application of LTB4 and unchallenged skin? 
MATERIALS AND METHODS 
Volunteers, LTB4 applications and biopsy procedure 
Nineteen healthy volunteers (9 males and 10 females, age range 20-29 years) without 
signs or history of skin diseases participated in this study after giving their informed 
consent. Aliquots of lOOng LTB4 (Paesel GmbH, Frankfurt, Germany) dissolved in 10 
μΐ ethanol were applied to the skin of the upper arm through a plastic cylinder obtained 
by cutting the edges from a micro test tube of 0.5ml (Eppendorf, Netheler Hinz GmbH, 
Hamburg, Germany). After evaporation of the ethanol under a stream of nitrogen gas, 
the test sites were marked with eosin and then occluded with impermeable dressings 
(Silverpatch, van der Bend bv, Brielle, The Netherlands) for 6 h. 
Thirteen persons (6 males and 7 females) participated in the "single application study". 
At 0, 8, 24 , 32, 48, 72, 96 and 192 h after LTB4 challenge, keratotome biopsies 
(0.2mm thick and 0.5cm ) were taken using a small dermatome (Coriotome 6B333, 
Aesculap AG, Tuttlingen, Germany). The volunteers were divided at random with 
regard to the different time intervals, and three biopsies were obtained from each 
person. The 0-h test site was challenged with ethanol only. Before biopsies were taken, 
the clinical effects (erythema, induration, desquamation and pigmentation) were scored 
using a 4-point scale (0 = not present, 1 = slightly present, 2 = moderately present. 3 = 
markedly present). Histological studies were performed in four subjects at 24, 48 and 
96 h after application of lOOng LTB4. Routine haematoxylin-eosin (HE) staining was 
carried out on paraffin slides sectioned from 4-mm punch biopsies, taken after 
infiltration of the skin with 1% Xylocain (1:100,000 adrenaline). At each time interval 
three biopsies were obtained. One biopsy was taken from non-challenged skin of one 
individual. 
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Six persons (3 males and 3 females) participated in the multiple application study. 
Every 24 h for 9 consecutive days (with a weekend break of 2 days after the 5th 
application) lOOng LTB4 was applied to the same site of the skin of the upper arm. On 
day 9, lOOng LTB^ in ΙΟμΙ ethanol and ΙΟμΙ ethanol only were applied to a second and 
to a third test site, respectively. Twenty-four hours after these last applications in each 
volunteer three keratotome biopsies were taken from these test sites, as described 
before. Clinical scores were assessed immediately before taking the biopsies. 
Cell isolation procedure 
Epidermal single cell suspensions were prepared as described before16. In short, the 
biopsies were incubated in phosphate-buffered saline (PBS) containing 0.25mg/ml 
trypsin (Sigma, St. Louis, USA) and 3.0mg/ml dithioerythritol (Sigma) for 30 min at 
37°C. Then, in PBS containing 10% heat-inactivated newborn calf serum (HINCS, 
Life Technologies Ltd., Paisley, UK) the dermis was separated from the epidermis 
with fine forceps. The remaining epidermis was gently mixed on a vortex to loosen the 
keratinocytes, resulting in a single cell suspension. After the homy layer had been 
discarded, the suspension was centrifuged, the supernatant removed and the cells fixed 
in 70% ice-cold ethanol. The cell suspension was stored at -20°C until staining and 
flow cytometric analysis. 
Staining procedure 
A triple labelling was performed, using a DNA fluorochrome combined with two 
antibodies against intermediate filaments. Samples of the cell suspensions, containing 
approximately 1-2x10 cells, were stained. The procedure has been described by us in 
detail before16. To assess hyperproliferation, the DNA fluorochrome TO-PRO-3 iodide 
(TP3, Molecular Probes, Eugene, USA) was used . TP3 intercalates with double-
string DNA and permits measurement of the proliferative activity of cells by 
quantification of the percentage of cells in S- and G2M phase. As TP3 also binds to 
RNA to some extent, it was used in combination with RNase. To study the 
inflammatory response we used Vim3B4 (Novocastra Laboratories Ltd., Newcastle 
upon Tyne, UK). This IgG2a-type mouse monoclonal antibody stains vimentin, an 
intermediate filament-type protein which occurs in mesenchymal cells17. In this study, 
PMNs, lymphocytes, monocytes, macrophages, melanocytes and Langerhans' cells 
were stained by Vim3B4. To quantify the effect of topical LTB4 application on the 
differentiation process, we used the IgGl-type mouse monoclonal antibody RKSE60 
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(Dept. of Mol. Biology, University of Maastricht, The Netherlands). RKSE60 is 
directed against keratin 10, an intermediate filament-type protein that is expressed in 
18 
differentiating keratinocytes . Three-colour fluorescence was obtained with the 
fluorochromes fluorescein-isothiocyanate (FITC) and phycoerythrin (PE), which were 
conjugated to monoclonal goat antibodies against mouse IgG2a and mouse IgGl, 
respectively (Southern Biotechnology Associates, Birmingham, USA), in combination 
withTP3. 
Flow cytometric analysis 
In a dual laser system (Epics® Elite flow cytometer, Coulter, Luton, UK) the 
fluorochromes FITC and PE were excited at 488nm (air-cooled argon ion laser, 
15mW) and TP3 at 633nm (HeNe laser, 10mW). Emission spectra were separated with 
bandpass filters of 525 ± lOnm, 575 ± lOnm and 675 ± lOnm, for FITC (green signal), 
PE (orange signal) and TP3 (red signal), respectively. The spectral overlap from PE to 
TP3 was 2% and therefore easily compensated electronically. Compensation for FITC 
in PE was 21%. After correction for clumps and cellular debris by setting appropriate 
gates, 5,000 cells from each sample were analysed. With Elite and Multicycle™ 
software percentages of vimentin- and keratin 10-positive cells and percentage of cells 
in S- and G2M phase were calculated. As this triple labelling procedure allows 
simultaneous assessment of different epidermal cell populations, we were able to 
quantify the proliferative activity of the basal epidermal compartment exclusively. 
RESULTS 
Single application 
The clinical scores at different time intervals after one single LTB4 application are 
shown in Fig. 1. Maximal erythema was reached after 48 h. Maximal induration 
occurred 32 h after LTB4 challenge. Desquamation and pigmentation appeared at 48 h 
and 72 h respectively, and increased slowly, reaching a maximum at 192 h at all test 
sites. 
The histological assessment of the response to epicutaneous application of LTB4 was 
in line with previous reports5-6. A massive infiltration with PMNs was observed 24 h 
after challenge. PMNs were partly grouped together as abscesses and partly scattered 
through the epidermis. In the dermis the infiltrate was pronounced at perivascular and 
subepidermal localizations. At 48 h no microabscesses were present in the epidermis, 
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but some PMNs could be observed. Between the stratum comeum and the stratum 
spinosum an amorphous zone with a granular aspect was identified, and focal 
parakeratosis was observed. A mononuclear dermal infiltrate was seen. At 96 h the 
picture was comparable to the situation after 48 h. No PMNs were seen in the 
epidermis and the dermal infiltrate was mainly located in the perivascular areas. 
0 24 48 72 96 120 144 168 192 
Hours allei single LTB4-appllcatlon 
0 24 48 72 96 120 144 168 192 
Hours alter single LTB4-appllcallon 
0 24 48 72 96 120 144 168 192 
Hours after single LTB4-appllcatlon 
0 *^ * * 
0 24 48 72 96 120 144 168 192 
Hours alter single LTB4-appllcatlon 
Figure 1. Clinical scores (mean ± SEM) at different time intervals after a single application of 100 ng 
LTB4. (0 = not present, 1 = slightly present, 2 = moderately present, 3 = markedly present). The 
number of observations is indicated above the error bars. 
Fig. 2 shows the results of the flow cytometric analysis. In unchallenged normal skin 
the percentage of vimentin-positive cells was 7.5% ± 1.1% (mean ± SEM). After 48 h 
the maximum of 11.2% was reached. The amount of non-keratinocytes then returned to 
levels of ± 5.3%. In the unchallenged skin, the percentage of keratin 10-positive cells, 
i.e. differentiated keratinocytes, was 61.5% ± 4.5%. After a slight decrease the 
percentage returned to the normal level from 96 h onwards. The percentage of basal 
70 Chapter 3 
keratinocytes in S- and G2M phase in the unchallenged skin was 8.8% ± 0.8%. This 
percentage remained more or less stable up to 48 h. From 48 h onwards there was a 
statistically significant increase of basal cells in S- and G2M phase with a maximum of 
21.2% at 72 h (see Table 1), showing a tendency to return to normal at 192 h. 
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Figure 2. Flow cytometric analysis (mean ± SEM) of epidermal cell suspensions prepared from 
biopsies taken from normal skin at different time intervals after a single application of 100 ng LTB4. 
The number of biopsies is indicated above the error bars. 
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Table 1. Comparison of flow cytometric values (mean ± SEM) in unchallenged normal skin, in 
normal skin after single (peak values) and multiple applications of 100 ng LTB4, and in psoriatic skin 
Normal skin Single Multiple Psoriatic skin 
(n=\Q) application application («=38) 
(n=5/6) (л=6) 
%S- and G2M (basal keratinocytes) 88 + 08 21 2 ± 3 7a 1 2 2 ± 1 9 b d 
%vimentin-positive cells 7 5 ± I 1 11 2 ±2 1 4 6 ± 1 4 c d 
%keratin ΙΟ-positive keratinocytes 61 5 ± 4 5 57 3 ± 5 6 68 7 ± 6 Ie 
p<0 05, versus normal skin (unequal variance Mest) 
p<0 01, versus normal skin (paired r-test, n=6) 
Q
 p<0 05, versus normal skin (paired /-test, и=6) 
p<0.05, versus single application (unequal variance r-test) 
Multiple application 
The clinical response to multiple applications was comparable to the response to one 
single application. Both erythema and induration were maximal at 72 h. From 72 h 
onwards a sharp decline of these clinical scores was observed Both desquamation and 
pigmentation slowly increased until 264 h. 
In Table 1 the flow cytometric data of normal unchallenged skin and normal skin after 
single and multiple applications are summarized. Statistical analysis revealed a 
significant increase with respect to keratin 10-expression and proliferative activity, and 
a significant decrease with respect to vimentin expression for multiple challenged skin 
compared to unchallenged skin. The mean percentage of vimentin-positive cells in the 
multiple application sites (4.6%) was significantly lower than the peak value at 48 h in 
the single application series. The percentage of basal keratinocytes with a more than 
diploid DNA content was significantly lower in multiple challenged sites (12.2%) than 
the peak value at 72 h after single application. 
DISCUSSION 
In previous flow cytometric studies, mean percentages of cells in S- and G2M phase of 
2.9% and 4.0% have been measured in normal skin ' . These values refer to the 
proliferative activity of the total cell population present in the cell suspension. The 
value of 8.8% in unchallenged skin (present study), however, reflects the specific 
proliferative activity of the basal keratinocytes and represents a value of 3.1 % for the 
189± 1 3 
15 6 ± 1 7 
36 5 ± 2 3 
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total cell population. Percentages of 57.2 for keratin 10-positive cells and 7.6 for 
vimentin-positive cells were found in healthy skin14. Correction for vimentin-positive 
cells reveals a percentage of 61.9% of keratin 10-positive keratinocytes. As these 
values correspond with the present data, the reproducibility of the flow cytometric 
method is warranted. 
Using histological and flow cytometric analysis we reconfirmed that epicutaneous 
application of one single dose of lOOng of LTB4 consistently yields an inflammatory 
response. A single application of lOOng LTB4 to normal skin resulted in a thin layer of 
parakeratosis after 48 h . Repeated intracutaneous injection of LTB4 in guinea pig ears 
caused epidermal hyperplasia with an unaltered keratinization pattern19. The tendency 
of a temporary decrease of keratin 10-positive keratinocytes after single application of 
lOOng LTB4 to human skin and the appearance of parakeratosis suggest that in vivo 
LTB4 might interfere with the process of keratinization. The present data show that 
there is an increase in epidermal proliferation following single application of LTB4 
(Fig. 2). Other studies confirm the proliferative response 72-96 h after LTB4 
application ' . Although a direct effect of LTB4 on the germinative cell population has 
been described in vitro , an indirect effect via interferences with the suprabasal 
compartment or via the inflammatory response is by no means ruled out. 
Maximal erythema was seen 48 h after single-dose LTB4 application. Interestingly, the 
number of vimentin-positive cells also reached a maximum 48 h after challenge. 
Histological studies have demonstrated that the infiltrate mainly consists of PMNs 
during the first 24 h. However, the maximum percentage of vimentin-positive cells at 
48 h after the application of LTB4 is not exclusively due to high levels of PMN at this 
time interval but is mainly caused by infiltrating T-lymphocytes reaching their 
maximum after 48 h ' . Also monocytes invade the epidermis after LTB4 challenge . It 
is remotely possible that not all PMNs present in the epidermis were analysed flow 
cytometrically. A certain quantity of PMNs might have been captured in the stratum 
comeum and may therefore not reach the cell suspension. Furthermore, some PMNs 
degenerate at the moment of extravasation, resulting in pycnotic nuclei and 
vacuolisation . 
During the first 3 days, the clinical response to single and repeated applications of 
LTB4 proved to be similar. However, during the chronic LTB4 exposure the erythema 
began to subside from 72 h onwards, in spite of the five following applications. This 
response is compatible with the "tachyphylaxis" of the LTB4 induced accumulation of 
PMNs, as reported by Wong et al. and by Colditz & Movat ' . Besides a 
In vivo models lo study the dynamics of the psoriatic lesion 73 
quantification of epidermal proliferation, percentage of vimentin-positive cells and 
percentage of keratin 10-positive keratinocytes in unchallenged and LTB4-challenged 
normal skin, Table I provides these data in psoriatic skin without epicutaneous LTB4 
challenge16. It can be concluded that (i) compared to unchallenged skin (întra-
individual comparison), repeated applications of LTB4 induce a decrease in the number 
of vimentin-positive cells, an increase of keratin 10-positive keratinocytes, and an 
increase of epidermal proliferation;, (ii) compared to the maximum values reached by 
one single application LTB4 (inter-individual comparison), a reduced responsiveness 
was observed in the repeatedly challenged skm with respect to the number of vimentin-
positive cells and epidermal proliferation; and (iii) comparing the present data with 
observations in the psoriatic plaques (without epicutaneous LTB4 challenge), multiple 
applications of LTB4 induce far less hyperproliferation, far less intra-epidermal 
accumulation of vimentin-positive cells and not a reduction but an increase of the 
number of keratin 10-positive keratinocytes. 
In conclusion, the present data indicate that LTB4 cannot be a major factor in the 
perpetuation of epidermal proliferation and inflammation, and the reduction of keratin 
10 expression in the chronic psoriatic lesion. However, in an early stage of the 
psoriatic process, changes similar to one single application might be of pathogenetic 
significance. 
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SUMMARY 
Psoriasis is a chronic disease with remissions and relapses. Aim of the present study 
was to develop and evaluate a model to analyse remission and relapse characteristics in 
psoriasis vulgaris after successful treatment with clobetasone propionate under 
different experimental conditions: alcoholic solution under occlusion, occlusion and 
non-treatment. Fifteen patients participated in the study. The study was divided into a 
clinical and flow cytometric evaluation. They were performed on two different 
psoriatic lesions in the same patient. All lesions were treated with clobetasone 
propionate up to a maximum of 23 days. Only cleared lesions were investigated as 
follows. For the clinical evaluation the area of the cleared lesion was divided into three 
test sectors: (1) was treated daily with an alcoholic solution under occlusion, (2) was 
treated with occlusion and (3) was left untreated for the observation period of 28 days. 
For the flow cytometric evaluation, the healed lesion was left completely untreated and 
unoccluded for the observation period of 35 days and biopsies were taken (i) before the 
start of the clobetasone propionate therapy, (ii) at clearance, (iii) at relapse from 
pinpoint lesions and (iv) at relapse from the visibly unaffected skin of the cleared 
lesion. Multiparameter flow cytometric analysis with markers for epidermal 
proliferation (% basal keratinocytes in S- and G2M phase), differentiation (% keratin 
10 positive keratinocytes) and inflammation (% vimentin positive cells) was 
performed. 
The clinical evaluation scheme worked well and was able to discriminate between the 
different therapy modalities. At the end of the clinical evaluation 30% of sector 1 
showed characteristic features of a relapse, 50% of sector 2 and 80% of sector 3. The 
results demonstrate that occlusion has an inhibitory effect on the tendency to relapse 
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after successful treatment with clobetasone propionate. This tendency was enhanced by 
the alcoholic solution applied. 
The flow cytometric analysis showed at clearance a very low proliferative activity of 
the basal compartment. This activity increased in the visibly unaffected skin of the 
healed lesion at the time of relapse and was highest in the pinpoint lesions. 
Interestingly, at relapse the proliferative activity in the suprabasal compartment of the 
visibly unaffected skin had increased to values identical to the pinpoint lesions. 
The present model allows standardized comparison of different approaches for 
maintenance therapy in psoriasis vulgaris. Quantitative information on these processes 
can be obtained by multiparameter flow cytometry. 
INTRODUCTION 
Maintenance treatment is an important approach in patients with fast relapsing 
psoriasis. Several authors have indicated that early psoriatic lesions differ from the 
chronic established psoriatic plaque . In acute psoriatic lesions polymorphonuclear 
leukocytes, monocytes and mast cells are a dominating feature in contrast to a more 
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modest appearance of these cells in the chronic plaque ' . Whereas the advancing edge 
of the psoriatic plaque does not yet contain skin associated antileukoproteinase, the 
central zone of the psoriatic does . The therapeutic relevance of the distinction of the 
acute and chronic stage of the psoriatic lesion is indicated by the observation that 
acitretin monotherapy is poorly effective in chronic plaque psoriasis but very effective 
in acute instable psoriasis . 
Before the therapeutic responsiveness of acute relapsing psoriasis can be studied, 
approaches to quantify characteristics of relapsing psoriasis are mandatory. The aim of 
the present study was to provide a standardized model for analysis of relapse following 
corticosteroid induced clearing of a psoriatic lesion. This model was validated by a 
clinical study of the relapse characteristics under three post-therapy conditions: (1) 
daily application of an alcoholic solution under occlusion, (2) occlusion and (3) left 
untreated for the observation period of 28 days. In particular the following questions 
were addressed: what are the dynamics of reoccurrence of erythema, induration and 
desquamation under each of the above-mentioned post-therapy conditions, using a 
semiquantitative 5-point scale? Can a relapse clearly be defined by clinical parameters 
and can the clinical evaluation be used to differentiate between the different post-
therapy conditions? 
78 Chapter 3 
An alcoholic solution was chosen in this study in preparation for a clinical study with a 
specific active agent to be administered in an alcoholic solution. 
In addition to the clinical validation in 15 lesions, a flow cytometric study of relapse 
characteristics was performed in a further 13 lesions in the same patients. The 
conditions for the lesions used for the flow cytometric evaluation were the same as for 
sector (3) in the clinical evaluation: after clearing the lesion with clobetasol it was left 
unoccluded and untreated. Biopsies were taken: (i) before the start of clobetasol 
therapy, (ii) at clearance, (iii) at relapse from pinpoint lesions, and (iv) at relapse from 
the visibly unaffected skin of the cleared lesion. Using a multiparameter technique 
with simultaneous assessment of epidermal DNA content (TO-PRO-3 iodide) and 
expression of intermediate filaments keratin 10 and vimentin we were able to measure 
the dynamics of changes of quantitative parameters for epidermal proliferation, 
differentiation and inflammation during clearance and relapse " . As flow cytometry 
was performed on epidermal cell suspensions prepared from 3-mm punch biopsies 
these cell biological aspects could be measured in both pinpoint lesions and visibly 
unaffected skin of the same lesion simultaneously. 
MATERIALS AND METHODS 
Subjects and test lesions 
Male and female patients over 18 years with chronic plaque psoriasis were recruited 
after written informed consent was obtained. The patient was to have at least two 
lesions with a minimal size of 10 cm not directly located above the elbow or knee. 
The score for erythema, thickness, and scaling had to be at least grade 2 (assessment 
on a 5-point-scale: 0 = not present, 1 = mild, 2 = moderate, 3 = severe, 4 = very 
severe). Exclusion criteria were pregnancy or lactation and known allergy to the test 
medications: clobetasone 17-propionate, the alcoholic solution or to the hydroactive 
dressing. Systemic treatment with antipsoriatic or immunosuppressive drugs and UVB 
therapy were not allowed. 
A clinical test lesion and a flow cytometric test lesion were selected in each patient. 
Both lesions were treated twice daily with clobetasone 17-propionate lotion (Glaxo 
Wellcome, Nieuwegein, The Netherlands) under hydroactive occlusion 
(Cutinova®Thin, Beiersdorf, Hamburg, Germany) until clearance or for maximally 23 
days. Clearance was defined as no induration, no desquamation and no or only a mild 
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erythema (grade 1 ). Patients whose lesions did not clear by day 23 were excluded from 
further participation. 
Clinical study 
The study design was an open intraindividual comparison. For the clinical evaluation, 
3 sectors - each 1.8 cm in size - were marked in the area of the healed test lesion. 
Sector 1 was treated once daily with an alcoholic solution (Schering AG, Berlin, 
Germany) containing 5.0 g isopropylmyristat and 74.0 g isopropanolol in 100 ml 
solution under hydroactive occlusion, sector 2 with hydroactive occlusion and sector 3 
was left untreated and unoccluded. Patients visited the department on day 7, 11, 14, 17, 
20, 23, 26, and 29 (end of study) after clearance for evaluation of clinical scores, 
itching, burning and adverse events. Relapse was defined as an at least grade 2 
erythema with additionally at least grade 2 thickness and/or scaling. Photographic 
documentation was performed at recruitment, at clearance, at relapse and at the end of 
study. 
Flow cytometric study 
From the test lesion chosen for the flow cytometric study, 3-mm punch biopsies were 
obtained (i) before treatment with clobetasone 17-propionate, (ii) at clearance, (iii) at 
relapse from pinpoint lesions and (iv) from the visually unaffected skin of the former 
lesion for flow cytometric analysis. After healing the cleared lesion was left untreated 
and unoccluded and observed for a period of 35 days. The observation period in the 
flow cytometric study was one week longer compared to the clinical study in order to 
permit a further development of initial psoriatic lesions in this experimental group. 
Relapse was defined as the clinical occurrence of pinpoint lesions in the area of the 
cleared lesion. Clinical scores were assessed before treatment and at clearance. 
Epidermal single cell suspensions were prepared shortly after biopsying using the 
combined thermolysin-trypsin separation method as described previously and stored 
in 70% ethanol at -20°C until staining. Approximately 1-2x10 cells were 
simultaneously labelled with the DNA fluorochrome TO-PRO-3 iodide (TP3, 
Molecular Probes, Eugene, USA) and mouse antibodies directed against intermediate 
filaments vimentin (Vim3B4, IgG2a, Novocastra Laboratories Ltd., Newcastle upon 
Tyne, UK) and keratin 10 (RKSE60, IgG,, Dept. of Mol. Biology, University of 
Maastricht, The Netherlands). Emitting fluorochromes were TP3 in combination with 
fluorescein-isothiocyanate (FITC) and phycoerythrin (PE), which were conjugated to 
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subtype-specific monoclonal goat antibodies against mouse IgG2a and mouse IgG,, 
respectively (Southern Biotechnology Associates, Birmingham, USA). 
From each sample 5,000-10,000 gated cells were measured and analysed using an 
EPICS" Elite flow cytometer (Coulter, Luton, UK) equipped with a dual laser system. 
PE and FITC were excited with an air-cooled argon ion laser (15mW, 488nm). TP3 
was excited with a HeNe laser (lOmW, 633nm). Fluorescence was measured using 
bandpass filters of 520-530nm (green, FITC), 555-595nm (orange, PE), and 670-
680nm (red, TP3). The area/peak ratio of the red signal (DNA) was used to 
discriminate between doublets of diploid cells (clumps) and real single tetraploid 
cells . After setting appropriate gates with the EPICS Elite software percentages of 
vimentin- and keratin 10 positive cells were calculated. Using Multicycle™ software 
(Phoenix Flow Systems, San Diego, USA) the percentages of basal (vimentin negative 
and keratin 10 negative) and suprabasal keratinocytes (vimentin negative and keratin 
10 positive) in S- and G2M phase (proliferation) of the cell cycle were calculated from 
DNA histograms. 
Statistical analysis 
Paired values were analysed with the paired two-sample t-test for means. For unpaired 
data the two-sample t-test assuming equal variances was used. With ANOVA (single-
factor) durations of remission were compared. ANOVA (two-factor) and Duncans 
multiple range test was performed to analyse clinical scores. 
RESULTS 
Fifteen patients were recruited, 9 male and 6 female. All of them were included in the 
safety analysis. The 15 patients had a mean age of 53.9 ± 9.5 years (mean ± SD). The 
mean duration of disease was about 20 years with a minimum of 4 years and a 
maximum of nearly 60 years. 
Clinical study 
In 10 out of the 15 patients the test lesions could be cleared within the 23 days allowed 
for the clobetasone propionate treatment. The mean clearing time was 16.4 ± 1.8 days 
(range 8-23 days). The cleared lesion was divided into three sectors and monitored 
over a period of 28 days. One patient did not appear for observation after day 23. This 
patient had a relapse in all 3 sectors on day 11 and the results were included in the 
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Figure la-c. Clinical scores (mean ± SEM) assessed on a 5-point scale (0=not present, l=mild, 
2=moderate, 3=severe, 4=very severe) for erythema (a), induration (b), and desquamation (с) of 10 
psoriatic lesions during treatment- and remission period at different test sectors: sector 1, alcoholic 
solution and occlusion ( · ) , sector 2, hydroactive occlusion only ÇZ): sector 3, no occlusion (A). 
Significance is expressed as compared to occlusion only: + (P < 0.05) and ** (P < 0.01) 
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evaluation. In the observation period of 28 days the relapse percentage was 30% (3 
patients) in sector 1 - alcoholic solution with occlusion - ; 50% (5 patients) in sector 2 -
occlusion only - and 80% (8 patients) in sector 3 - no treatment. Intraindividual 
comparison of the three sectors showed that relapse always occurred earlier or at the 
same time in sector 3 compared to sector 2 and earlier or at the same time in sector 2 
compared to sector 1. 
Fig. la-c summarizes the assessment of clinical scores for erythema, induration and 
desquamation during the study. It can be seen that during the observation period of 28 
days for all clinical scores significant differences developed between occluded and 
non-occluded areas. Occlusion has an inhibitory effect on erythema, induration and 
desquamation. However, the effect is more pronounced with respect to induration and 
desquamation compared to erythema. Comparing the alcoholic solution under 
occlusion with occlusion alone, there is only a significant difference for the 
desquamation score at the end of the study. 
Flow cytometric study 
Thirteen of 15 patients participated in the flow cytometric study. One patient preferred 
not to be biopsied, in the other patient no suitable test area was left for the flow 
cytometric study. In 11 of the 13 test lesions clearance was reached (mean time 18.1 ± 
1.9 days; mean ± SEM). In the observation period of 35 days 7 (64%) of the 11 cleared 
test lesions relapsed. The mean time until relapse was 17.9 ± 4.4 days (mean ± SEM). 
Although the durations of the remission periods of the untreated test lesions from both 
the clinical and the flow cytometric study differed substantially in some patients (up to 
23 days) no significant differences for the whole groups existed (ANOVA single-factor 
analysis). 
The results of the flow cytometric analyses on 36 samples are summarized in Fig. 2a-d. 
At the beginning before treatment with clobetasone propionate the psoriatic lesions 
were characterized by a high percentage of vimentin positive cells, a low number of 
keratin 10 positive keratinocytes and a high number of basal keratinocytes in S- and 
G2M phase. At clearance (n = 11) a marked and significant improvement of all markers 
was found. In the basal and the suprabasal compartment proliferation was substantially 
decreased. 
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Figure 2a-d. Flow cytometric analysis (mean ± SEM) of markers for % vimentin positive cells (a), % 
keratin 10 positive keratinocytes (b), and % keratinocytes in S- and G2M phase in basal (c) and 
suprabasal (d) compartments 
At relapse (n = 7) from each test lesion 2 biopsies were obtained: one from the 
pinpoint lesions and one from the visibly unaffected skin of the cleared lesion. The 
flow cytometric analysis of the pinpoint lesions revealed a return to the psoriatic 
phenotype for all markers. No significant differences existed between the psoriatic 
lesions before treatment and the pinpoint papules at relapse. Significant differences 
were observed between the percentage of keratin 10 positive keratinocytes at clearance 
and the visibly unaffected skin of the cleared lesion at relapse (P < 0.05). In the visibly 
unaffected skin of the cleared lesion at relapse the percentage of keratinocytes in S-
and G2M phase was significantly higher compared to clearance in the basal (P < 0.01) 
and in the suprabasal (Ρ < 0.05) compartment. Also with respect to the relative number 
of vimentin positive cells in the visibly unaffected skin of the cleared lesion at relapse 
showed values that were intermediate between the situation at clearance (N.S.) and 
relapsed skin (P < 0.05). All flow cytometric parameters including the proliferative 
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Figure 3a-c. Correlation between erythema and percentages of vimentin positive cells (a), induration 
and percentages of basal keratinocytes in S- and G2M phase (b), and desquamation and percentages of 
keratin 10 positive keratinocytes (c) in psoriatic lesions before and after clearance with clobetasol 
propionate lotion under hydroactive occlusion 
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activity in the basal compartment were significantly different between the involved and 
the visibly unaffected skin of the cleared lesion at relapse. Remarkably, at relapse the 
proliferative activity in the suprabasal compartment in both the pinpoint and the visibly 
unaffected skin was comparable. In Fig. 3 we compared clinical features of 
inflammation (erythema), impaired differentiation (desquamation) and 
hyperproliferation (induration) with the cell biological markers of these processes. It 
can be seen that in all cases a strong correlation exists between clinical and flow 
cytometric parameters (Fig. 3a, erythema score versus % vimentin positive cells: r = 
0.76, Ρ < 0.0001; Fig. 3b, desquamation score versus % keratin 10 positive 
keratinocytes: r = -0.73, Ρ < 0.0001; Fig. 3c, induration score versus % basal 
keratinocytes in S- and G2M phase: г = 0.74, Ρ < 0.0001). 
DISCUSSION 
In the present study we provide a model to study the dynamics of the fast relapsing 
psoriatic lesion after successful treatment with clobetasone propionate applied twice 
daily under occlusion. In the clinical part of the study, three different post-treatment 
modalities were compared on different sectors of the cleared lesion and observed for 
28 days. From a second lesion of the same patient biopsies were taken before 
clobetasol treatment, at clearance, and at relapse from pinpoint lesions and from the 
visibly unaffected skin. Flow cytometric analysis of the samples permitted quantitative 
measurement of the epidermal changes with respect to proliferation, differentiation and 
inflammation. 
Defining clinical clearance as maximally grade 1 erythema, no induration and no 
desquamation, we observed a mean clearing time of 17.3 days (range 7-28 days, η = 
21). Other studies describe clinical healing after 6-10 days3 and 12 days" after 
treatment with clobetasol propionate under occlusive dressings. In one study , 
however, clearance criteria allowed a grade 3 erythema and in the other study these 
criteria were not mentioned. In most studies the clearance percentage after treatment 
with clobetasone propionate under occlusive dressings has been reported to be 100%. 
In contrast, the present study revealed a percentage of clearing in only 75% after 3 
weeks of treatment with clobetasone propionate twice daily under occlusive dressings. 
AH markers for epidermal proliferation, differentiation and inflammation significantly 
decreased during remission induction. Epidermal proliferation was even totally 
blocked in some patients as also shown by Goodwin et al. . This implies that the 
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situation at clearance was substantially different from the situation before therapy and 
constituted a suitable starting point to study the process of change towards the psoriatic 
phenotype. In comparison to treatment with clobetasone propionate under hydroactive 
dressings treatment of psoriatic plaques with the vitamin D3 analogues Tacalcitol® 
(ointment 4μg/g) once daily or with calcipotriol (cream 5(^g/g) twice daily J 
interfered predominantly with epidermal proliferation resulting in a reduction of the 
number of basal keratinocytes in S- and G2M phase by 34%. Vitamin D3 analogues 
affected epidermal differentiation and inflammation less vigorously. 
In the clinical part of the study the observation period after successful treatment with 
clobetasone propionate was 28 days. In this period 8 relapses (80%) occurred in the 
unoccluded sectors of the 10 cleared lesions. Occlusion reduced this percentage to 50% 
(5 relapses) and the combination of alcoholic solution and occlusion showed a further 
reduction to 3 relapses (30%). The 28-day observation period proved to be appropriate 
to show differences between different treatment modalities. The unoccluded sector of 
the clinical part was identically handled and therefore comparable to the lesion for the 
flow cytometric analysis. In the present study the relapse periods of the untreated 
sectors of the cleared lesion from the clinical part and the cleared lesion from the flow 
cytometric part showed no significant intraindividual variation, which implicates that 
within-patient comparison of topical treatment is justified. 
The occlusion did not only reduce the number of relapses but had also significant 
influence on the clinical scores for erythema, induration and desquamation. As already 
mentioned above the combination of the alcoholic solution with hydroactive dressing 
further reduced the number of relapses compared to occlusion only. In particular the 
effect on the desquamation of the lesion was marked (Fig. lc). No adverse events were 
encountered in association with the use of the alcoholic solution. Furthermore no 
influence on burning or itching of the lesion was reported. Therefore the alcoholic 
solution seems a safe vehicle for future research with active agents. 
To study the early development of psoriatic lesions different approaches have been 
used in the past. Early lesions such as pinpoint papules, the margins of spreading 
plaques and relapsing psoriasis have been studied as models to investigate this process. 
Influx of polymorphonuclear leukocytes, monocytes and mast cells have been 
described as early events in developing lesions " . In spreading plaques and pinpoint 
lesions dermal or vascular changes have been described to precede epidermal 
changes " . One report, however, showed epidermal differentiation to be altered prior 
to vascular changes in the spreading psoriatic plaque . 
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The present evaluation of relapse after successful treatment with clobetasone 
propionate provides a new approach to study an early age of the psoriatic lesion the 
visibly unaffected skin of a healed lesion adjacent to newly developed pinpoint lesions 
The number of non-keratinocytes in the "unaffected skin at relapse" is not significantly 
different compared to the situation at clearance. In this '"unaffected stage of relapsing 
skin" the percentage of cells in S- and G2M phase m the basal cell population is 
intermediate between percentages at clearance and of lesionai skin. However, the 
percentage of suprabasal keratinocytes in S- and G2M phase in unaffected relapsing 
skin was already substantially increased with values comparable to lesionai skin This 
model shows that the proliferative activity in the suprabasal compartment is an early 
aspect of epidermal proliferation in the pathogenesis of psoriasis. 
In summary, we validated a model to analyse clearance and relapse characteristics of 
the psoriatic lesion, using clinical and flow cytometric parameters. It is attractive to 
speculate that this model will provide a new approach to compare different 
antipsoriatic maintenance therapies in vivo under standardized circumstances. 
Occlusion of psoriatic plaques with hydroactive dressings delays the process of 
relapse. Multiparameter flow cytometry provides quantitative information on these 
processes with respect to epidermal proliferation, differentiation and inflammation 
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CLINICAL AND FLOW CYTOMETRIC EVALUATION 
OF NEW TOPICAL TREATMENT FOR PSORIASIS 

4.1 Topical treatment of psoriatic plaques with la,24 
dihydroxyvitamin D3: a multiparameter flow cytometrical 
analysis of epidermal growth, differentiation and inflammation 
Conrad P. Glade, Piet E.J. van Ε φ , Candida A.E.M. van Hooijdonk, Maria E. 
Eibers, Peter C M . van de Kerkhof, Department of Dermatology, University 
Hospital Nijmegen, The Netherlands 
Acta Derm Venereo! (Stocka) 1995; 75: 381-385 
SUMMARY 
The clinical efficacy and tolerability of the vitamin D 3 analogues calcitriol, calcipotriol 
and 1 a,24 dihydroxyvitamin D 3 in the treatment of psoriasis have been assessed in 
various clinical studies. In vitro and in vivo investigations have shown interference of 
these compounds with epidermal growth, keratinisation and inflammation. In this study 
we quantified the in vivo cell biological effects during treatment of psoriatic plaques 
with la,24 dihydroxyvitamin D3. By using a flow cytometric triple labelling procedure 
we could discriminate different epidermal subpopulations, permitting precise 
assessment of epidermal cell cycle kinetics. Twenty patients with plaque-type psoriasis 
were treated in a double-blind placebo-controlled left-right comparative study with 
la,24 dihydroxyvitamin D3 ointment ^ g / g applied once daily) for 8 weeks. 
Epidermal cell suspensions prepared from keratotome biopsies taken before and after 
treatment were stained with TO-PRO-3 iodide (a new DNA fluorochrome) and 
monoclonal antibodies against keratin 10 (as a marker for differentiation) and vimentin 
(as a marker for inflammation), simultaneously. The flow cytometric analyses showed 
a significant decrease of proliferating basal keratinocytes in verum-treated lesions, 
whereas such a decrease was not observed in placebo-treated lesions. The amount of 
keratin 10-positive keratinocytes increased and the presence of vimentin-positive cells 
decreased in cell suspensions derived from both verum- and placebo-treated lesions, 
but these effects were not significant. We conclude that multiparameter flow cytometry 
promises to be an adequate approach to assess the interference of antipsoriatic 
treatments with cutaneous inflammation, epidermal proliferation and keratinisation. 
Topical la,24 dihydroxyvitamin D3 seems to exert its in vivo antipsoriatic effect 
mainly through an inhibition of epidermal growth. 
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INTRODUCTION 
In 1985 Morimoto & Kumahara described a patient with senile osteoporosis whose 
psoriasis cured after oral administration of la hydroxy vitamin D3, a prodrug of 
calcitriol . Their observation caused a renewed interest in the class of vitamin D3 
analogues as an antipsoriatic principle ' . During the last decade the clinical efficacy of 
lct,25 dihydroxyvitamin D3 (calcitriol) ' and several of its derivatives, including 
la monohydroxyvitamin D3 , calcipotriol " and la,24 dihydroxy-vitamin D3 (la,24 
(OH)2D3) (Tacalcitol)13"15 has been documented. Calcipotriol (5(Vg/g), la,24 (OH)2 
D3 (2-4μg/g) and calcitriol (3-15μg/g) can be applied topically. Calcipotriol and la,24 
(OH)2 D3 exert a decreased calcitropic effect compared to calcitriol'5,16. Furthermore, 
neither hypercalcemia nor hypercalciurea were observed in patients who received a 
daily total dose of 80 μg la,24 (OH)2 D3 for 7 days' . Calcitriol induced irritation of 
the skin at concentrations of 15μ§^ in 6.3% of the patients, whereas concentrations of 
3μ§^ caused irritation in 3.4% of patients ' . Irritation of the skin, especially of the 
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face, was seen in 4.3-19,5% of patients treated with calcipotriol ' . Remarkably, with 
respect to la,24 (OH)2D3, so far, only a slight irritation has been reported in less than 
1% of patients . Therefore, la,24 (OH)2D3 has expanded the horizon of vitamin D3 
treatment of psoriasis, as facial and flexural lesions can be treated with this analogue 
without significant irritation. 
In vitro data on mouse and human keratinocytes and in vivo data on guinea pigs, but 
also studies in psoriatic patients have shown the capability of la,24 (OH)2D3 to 
suppress DNA synthesis and to induce epidermal differentiation ' . These findings 
have been confirmed in psoriasis in vivo by a previous immunohistochemical study 
from our department, showing a substantial inhibitory effect of la,24 (OH)2D3 with 
respect to epidermal proliferation and a significant modulation of cutaneous 
inflammation and keratinisation . Histological scoring of stained sections, however, is 
semi-quantitative. A more objective and quantitative method is required for an accurate 
and reliable assessment of the effect of antipsoriatic therapy. 
Multiparameter flow cytometry allows a simultaneous, quantitative, statistically 
accurate analysis of different cell parameters and is a useful tool for studies on skin 
pathology ' . Triple labelling combining double immunophenotyping and assessment 
of DNA content is impeded by a considerable spectral overlap " . Only to a limited 
extent could these difficulties be overcome29'30. Recently, by using the new DNA stain 
TO-PRO-3 iodide (TP3), we were able to design a procedure in which DNA content 
and expression of two intermediate filament proteins were measured simultaneously in 
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single cell suspensions from epidermis . Simultaneous discrimination and 
quantification of three different epidermal subpopulations, i.e. non-keratinocytes, 
differentiated and basal keratinocytes, became possible, allowing a precise 
quantification of the proliferative activity of the basal compartment. 
The aim of the present study was to quantify flow cytometrically in terms of epidermal 
proliferation, differentiation and inflammation, the response of the psoriatic lesion to a 
therapeutical concentration of la,24 (OH)2D3 (4μg/g Tacalcitol ointment applied once 
daily). 
MATERIALS AND METHODS 
Patients and skin samples 
Twenty patients (11 females and 9 males; age range 22-66 years, mean age 43.5 years) 
with symmetrically distributed chronic plaque psoriasis participated in the 
investigation, after informed consent had been given. The mean duration of psoriasis 
was 20.2 years. The study design was a placebo-controlled double-blind left-right 
comparison. la,24 (OH)2D3 (Tacalcitol, Hernial AG, Hamburg, Germany) was 
manufactured in an ointment base consisting of paraffinum subliquidum, 
diisopropyladipat and vaseline album. The verum comprised 4μg/g la,24 (OH)2D3 
ointment. The placebo contained the ointment base only. In the previous 2 months, the 
patients had not received systemic therapy, and in the previous 4 weeks no topical 
treatment had been applied. After an initial wash-out phase of 2 weeks patients were 
treated for 8 weeks with la,24 (OH)2D3 on one body halve and placebo on the other 
body halve. The maximum dose of lct,24 (OH)2D3 was 40 μg per day. Before and 
during treatment clinical improvement was assessed using the Psoriasis Area and 
Severity Index, including scoring for erythema, induration and scaling using a five 
point scale. Blood investigations were carried out every 2 weeks. 
In each patient two symmetrically localised lesions were selected for the cell biological 
assessment. Before treatment keratotome biopsies (0,4 mm thick and ± 1 cm ) using a 
small dermatotome (Coriotome 6B333, Aesculap AG, Tuttlingen, Germany) were 
taken from these lesions. After 8 weeks of treatment biopsies were taken from the 
same areas. In this way, from each patient four biopsies (two la,24 (OH)2D3-treated 
and two placebo-treated) were obtained. Before initiation of the study Medical Ethical 
Committee approval had been obtained. 
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Preparation of cell suspension 
Epidermal cell suspensions were prepared using a modification of a trypsinisation 
procedure previously described by Gommans et al. . In brief, the biopsies were 
washed in phosphate-buffered saline (PBS) and floated with dermal side downwards 
on a solution containing 0.025% w/v trypsin (Sigma, St. Louis, USA) and 0.3% w/v 
dithioerythritol (Sigma, St. Louis, USA) in PBS for 30 min at 37° С Then, in a 
solution containing 10% v/v heat inactivated newborn calf serum (HINCS, Life 
Technologies Ltd., Paisley, UK) in PBS, the dermis was peeled off with a fine forceps. 
After the basal cells had been removed by waving in the solution, the dermis was 
discarded. After gentle agitation ("Vortex"mixer) of the remaining epidermis for 1 
min, the transparent homy layer was removed. The epidermal cells obtained in this 
way were centrifuged , resuspended in 2-3 ml ice-cold ethanol (70% v/v) and stored at 
- 20°C until use. 
Sta in ing procedure 
A triple labelling was performed. DNA content was measured using the new DNA 
fluorochrome TO-PRO-3 iodide (TP3, Molecular Probes, Eugene, USA). To assess 
epidermal keratinisation, the IgG
r
type monoclonal antibody RKSE60 (gift from Prof. 
F.C. Ramaekers, Department of Molecular Biology, University of Maastricht, The 
Netherlands) was used. RKSE60 is directed against keratin 10, an intermediate 
filament-type protein of 56.5 kD that is exclusively expressed in suprabasal, i.e. 
differentiating keratinocytes in normal and psoriatic skin . To assess epidermal 
inflammation, the IgG2a-type monoclonal antibody Vim3B4 (Novocastra Laboratories 
ltd., Newcastle upon Tyne, UK) was used. Vim3B4 is directed against vimentin, the 
intermediate filament-type protein that is expressed in cells of mesenchymal origin34'35. 
In the epidermis Vim3B4 stains non-keratinocytes, i.e. dendritic cells and (especially 
in psoriatic skin) inflammatory infiltrate cells. The second step of the indirect 
immunofluorescent staining was performed with monoclonal goat antibodies against 
mouse IgG! and IgG2a, conjugated to phycoerythrin (PE) and fluorescein-
isothiocyanate (FITC), respectively (Southern Biotechnology Associates, Birmingham, 
USA). 
Aliquots (750μ1) of the cell suspensions, which contained 1-2 χ 10 cells, were washed 
in PBS, filtered to remove clumps and horny material, and resuspended in 500μ1 of a 
solution with Vim3B4 diluted 1:50 and RKSE60 diluted 1:15 in PBS. After incubation 
for 30 min at room temperature in the dark, the cells were washed in PBS containing 
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1% HINCS, resuspended and incubated for 15 min at 5°C in a solution of 500μ1 PBS, 
containing 2μ1 goat-anti-mouse-PE, ΙΟμΙ goat-anti-mouse-FITC, ΙΟμΙ normal goat 
serum and 5μ1 HINCS. After a third washing step DNA staining was performed by 
addition of 300μ1 TP3 (ΙμΜ in PBS) and 50μ1 RNase (lmg/ml in PBS) (Sigma, St. 
Louis, USA). 
Flow cytometric analysis 
From each sample 5,000 gated cells were measured and analysed using an EPICS® 
Elite flow cytometer (Coulter, Luton, UK), equipped with a dual laser system. Both 
FITC and PE were excited with an air-cooled argon ion laser (15mW, 488nm). TP3 
was excited with a HeNe laser (lOmW, 633nm). After determination of the electronic 
compensation for spectral overlap in earlier experiments, which was minimal in the 
case of TP3, fluorescence was measured using bandpass filters at 525nm (green, 
FITC), 575nm (orange, PE) and 675nm (red, TP3). The ratio area/peak of the red 
signal (DNA) was used to discriminate between doublets of diploid cells and real 
tetraploid cells . After setting appropriate gates with the Elite software, percentages of 
vimentin- and keratin 10-positive cells were calculated. With the aid of Multicycle™ 
software (Phoenix, Flow Systems, San Diego, USA) the percentage of basal 
keratinocytes in SG2M phase of the cell cycle was calculated from DNA histograms. 
RESULTS 
Clinical response 
Thirteen patients showed a moderate to marked improvement of their psoriatic lesions. 
One patient, who also showed a marked improvement, was withdrawn from the study 
after 6 weeks because of an exacerbation of psoriatic arthritis, requiring additional 
medication. The mean PASI score showed a significant reduction after 8 weeks of 
treatment for both la,24 (OH)2D3- and placebo-treated lesions. la,24 (OH)2D rtreated 
lesions showed a mean reduction of the PASI score of 48%. The pretreatment PASI 
score was 5.3 ± 0.4 (mean ± SEM) and the posttreatment PASI score was 2.8 ± 0.4 (p 
< 0.0001, Wilcoxon test for matched pairs). The mean PASI score in placebo-treated 
lesions decreased 28% (pretreatment 5.4 ± 0.4 and posttreatment 3.9 ± 0.4, ρ < 
0.0001). Comparison of posttreatment PASI scores between the lct,24 (OH)2D3- and 
placebo-treated lesions showed a significant difference in favour of the la,24 (OH)2D3 
treated lesions (p < 0.01). 
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Figure 1. Clinical scores before and after 8 weeks treatment with la,24 dihydroxyvitamin D3 ( 4 μ ^ ) 
ointment (shaded bars) and ointment base only (black bars). 
As shown in Fig. 1 the clinical severity scores for erythema, induration and 
desquamation of the biopsied lesions all showed a significant reduction, which was 
more substantial for la,24 (OH)2D3-treated lesions. The mean score for erythema in 
la,24 (OH)2D3-treated lesions decreased from 3.2 ± 0.1 to 2.2 ± 0.1 (p < 0.0004), and 
in placebo-treated lesions from 3.2 ±0.1 to 2.7 ± 0.1 (p < 0.008). The mean score for 
induration showed a reduction from 3.2 ± 0.1 to 1.6 ± 0.2 (p < 0.0003) in la,24 
(OH)2D3-treated, and a reduction from 3.2 ± 0.1 to 2.3 ± 0.1 (p < 0.0007) in placebo-
treated lesions. With respect to desquamation the mean score in loc,24 (OH)2D3-treated 
lesions decreased from 3.1 ± 0.1 to 1.3 ± 0.2 (p < 0.0003), and in placebo-treated 
lesions from 3.1 ± 0.1 to 1.8 ± 0.2 (p < 0.0007). Comparison of posttreatment clinical 
scores revealed a significant difference. The reductions of erythema, induration and 
scaling were more substantial at the lcc,24 (OH)2D3-treated sites compared to placebo-
treated sites at the levels ρ < 0.005,/? < 0.008 and ρ < 0.02, respectively. 
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The blood investigations, in particular calcium metabolism, did not show any 
significant aberration. No side-effects were seen during the study period. In none of the 
patients was any skin irritation noticed. 
Flow cytometric results 
Typical DNA histograms representative for untreated and treated psoriatic plaques are 
shown in Fig. 2. Fluorescence of TP3 (red signal) was measured of cells which were 
vimentin-negative (green signal) and keratin 10-negative (orange signal). By 
distinction of subpopulations in this way, DNA content of the basal keratinocytes 
could be assessed. In this example, in the psoriatic lesion before treatment, we found a 
percentage of cells (i.e. of basal keratinocytes) in S- and G2M phase of 17.5%. Eight 
weeks later this percentage was reduced to 12.8%. Data analysis was restricted to 
patients from whom all four epidermal cell suspensions contained a cell amount of at 
least 30%. In this way, paired data from 12 patients were obtained. 
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Figure 2. DNA histograms of epidermal cell suspensions prepared from keratotome biopsies taken 
from psoriatic plaques (a) before and (b) after 8 weeks treatment with la,24 dihydroxyvitamin D3 
( 4 μ ^ ) ointment. 
For placebo-treated lesions the average percentage of cells in S- and G2M phase was 
17.8 ± 1.8% before treatment. After treatment a tendency of a reduction was seen to 
15.1 ± 1.2% (p < 0.35, Wilcoxon test for matched pairs). In lct,24 (OH)2D3-treated 
lesions the mean pretreatment percentage of cells in S- and G2M phase was 20.0 ± 
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1 9% After 8 weeks of treatment a more substantial and significant decrease to 13 2 ± 
1 1 (p < 0 01) was seen The mean pretreatment percentage of vimentin-positive cells 
proved to be 15 1 ± 2 4% for la,24 (OH)2D3-treated lesions and 162 + 2 5% for 
placebo-treated lesions After 8 weeks a reduction was seen for both sides to 12 9 ± 
1 4% (p < 0 66) and 13 2 ± 1 8% (p < 0 14), respectively In neither case was this a 
significant reduction With respect to keratin 10 expression, the mean pretreatment 
percentage of positive cells was 37 7 ± 3 7% for la,24 (OH)2D3-treated lesions and 
35 2 ± 3 0% for placebo-treated lesions The mean posttreatment percentages showed 
an increase to 43 4 ± 3 5 % {p < 0 43) and 47 9 ± 3 7% (p < 0 02), respectively 
DISCUSSION 
In the present investigation we assessed the effect of topically applied la,24 (OH)2D3 
ointment (4μg/g) on proliferation, differentiation and inflammation in the psoriatic 
plaque using multiparameter flow cytometry In la,24 (OH)2D3-treated lesions we 
found a statistically significant reduction of the percentage of basal cells in S- and G2M 
phase (as marker for proliferation) from 20 0% to 13 2% This reduction was less and 
not significant in placebo-treated lesions The amount of keratin 10-positive 
keratinocytes (as marker for differentiation) increased after 8 weeks The decrease of 
vimentin-positive cells (as marker for inflammation) was in the same range for both 
1 ct,24 (OH)2D3- and placebo-treated lesions 
The clinical efficacy of la,24 (OH)2D3 D3 ointment (4μg/g once daily) as a topical 
antipsonatic agent is confirmed in this study The mean reduction of the PASI score, as 
a result of 8 weeks' treatment with la,24 (OH)2D3 proved to be 48% (present study) 
This reduction is in line with our previous report showing 49% reduction of PASI 
23 
scores by la,24 (OH)2D3 Following а 6 weeks' treatment with calcipotnol ointment 
(50μ&^) twice daily and betamethasone valerate ointment twice daily, the mean 
reduction of PASI scores were 68 8% and 61 4%, respectively So far, however, no 
comparative studies of calcipotnol and la,24 dihydroxyvitamin D3 are available The 
absence of skin irritation and hypercalcemia in all patients validates earlier statements 
on la,24(OH) 2 D 3 1 5 
In vitro, la,24 (OH)2D3 has been shown to inhibit proliferation of keratinocytes16192° 
In the immunohistochemical study la,24 (OH)2D3 proved to inhibit recruitment of 
cycling epidermal cells profoundly In the present study a reduction of the percentage 
basal cells in S- and G2M phase of 34% was reached In a previous flow cytometncal 
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study from our department on the in vivo effect of calcipotriol, a 31% reduction of the 
percentage of cells in S- and G2M phase from 11.8% (before treatment) to 8.2% (after 
6 weeks' treatment) was shown . An important methodological difference between the 
two studies is that the percentage of cells in S- and G2M phase was limited to the basal 
keratinocytes only in the present study, in contrast to all epidermal cells in the previous 
study. By using a triple labelling method, non-keratinocytes and differentiated 
keratinocytes were excluded, which permits a precise and specific assessment of 
epidermal cell cycle kinetics. 
The absence of a significant change in the relative number of keratin 10-positive cells 
after treatment with la,24 (OH)2D3 could suggest that basal and suprabasal 
compartments maintain the same relative size before and after treatment. Previous flow 
cytometric studies, however, have demonstrated the relative numbers of keratin 10-
positive cells in untreated psoriatic plaques (46.6%) to be reduced compared to normal 
skin (57.2%) . This means that, though a normalization of keratin 10 expression can 
be produced by calcipotriol , la,24 (OH)2D3 does not seem to influence this 
expression significantly. 
In vitro studies have demonstrated a direct effect of la,24 (OH)2D3 on inflammatory 
cells. A dose-dependent induction of differentiation and suppression of antibody 
response to Τ cell dependent antigen by la,24 (OH)2D3 has been shown j8. The 
functional properties of neutrophils in vitro were nol modulated by la,24 (OH) 2 D 3 1 5 2 1 . 
In a previous in vivo study, an 8-week treatment period of lct,24 (OH)2D3 had resulted 
in a significant reduction of the number of Τ cells, monocytes and neutrophils in the 
inflammatory infiltrate of the psoriatic lesion . However, in the present study only a 
tendency of a reduction of the relative number of vimentin-positive cells, i.e. all 
mesenchymal cells, including the infiltrate cells, was observed. This discrepancy might 
be explained by the fact that the total number of cells present per surface area 
(mesenchymal cells and keratinocytes) has decreased following treatment . This 
implicates that the decrease in the absolute number of vimentin-positive cells was in 
the same range as the decrease of all epidermal cells obtained from the biopsy. Further 
studies will unravel the relative changes in populations of infiltrate cells during 
treatment. 
The present study lends support for the hypothesis that topical la,24 (OH)2D3 exhibits 
its antipsoriatic potential mainly through an inhibiting effect on epidermal growth. The 
influence on epidermal inflammation and keratinisation is limited. Three-color flow 
cytometry seems to be an attractive tool to make an objective assessment of the effect 
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of antipsoriatic therapy on different cell parameters. Validation of the usefulness of 
this single measurement for proliferation, differentiation and inflammation can be 
reached by evaluation of other therapy modalities. 
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4.2 Epidermal cell DNA content and intermediate filaments keratin 
10 and vimentin after treatment of psoriasis with calcipotriol 
cream once daily, twice daily and in combination with 
clobetasone 17-butyrate cream or betamethasone 17-valerate 
cream: a comparative flow cytometric study 
Conrad Ρ Glade, Piet E.J van Εφ, Peter С M. van de Kerkhof 
Department of Dermatology, University Hospital Nijmegen, The Netherlands 
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SUMMARY 
Calcipotriol and corticosteroids, two therapy modalities frequently prescribed in the 
treatment of psoriasis, are often used in combination The aim of the present study was 
to determine whether the cell biological response pattern of concurrent use of 
calcipotriol and corticosteroids is different from calcipotriol monotherapy. Forty 
patients with a chronic plaque psoriasis were divided at random in four parallel groups 
and treated for 8 weeks with (1) calcipotriol cream (50 \iglg once daily); (2) 
calcipotriol cream twice daily, (3) calcipotriol and clobetasone 17-butyrate (0 5 mg/g) 
creams, and 4) calcipotriol and betamethasone 17-valerate (1 mg/g) creams. Before 
and after treatment keratotome biopsies were taken and single cell suspensions 
prepared for flow cytometric analysis Flow cytometric multiparameter quantification 
of markers for proliferation (TO-PRO-3), differentiation (antikeratin 10) and 
inflammation (antivimentin) was used to evaluate all four therapy modalities. 
A statistically significant decrease of the percentage of basal cells in S- and G2M-phase 
(proliferation) was obtained with all therapy modalities, except for calcipotriol 
monotherapy applied once daily A significant reduction of the number of vimentin-
positive cells (non-keratinocytes) was observed following combined treatment with 
calcipotriol and clobetasone butyrate. In contrast, monotherapy with calcipotriol had 
virtually no effect on the number of vimentin-positive cells. 
It can be concluded that: (i) calcipotriol monotherapy, applied once daily was less 
antiproliferative compared with twice daily applications of calcipotriol or the 
combined treatment with corticosteroids and that (ii) the combination of calcipotriol 
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and corticosteroids proved to have a marked effect on the percentage of non-
keratinocytes, in contrast to the modest effect of calcipotriol. 
INTRODUCTION 
Vitamin D 3 analogues interfere with various characteristics of the psoriatic plaque: 
epidermal hyperprol i feration, impaired differentiation and cutaneous inflammation. In 
vitro studies demonstrated that calcipotriol inhibits proliferation and stimulates 
differentiation in cultured human keratinocytes. Several inflammatory processes are 
modulated by calcipotriol. " In vivo, topical application of calcipotriol to psoriatic 
plaques resulted in decreased epidermal DNA synthesis and a shift of the expression 
6 9 
pattern of epidermal cytokeratins towards normalization. " Furthermore calcipotriol 
has been reported to influence different cytokines and to change the numbers of 
several immunocytes (polymorphonuclear leukocytes, CD la positive cells, Τ 
8 9 11 12 
lymphocytes, monocytes) in psoriatic plaques. ' ' ' Interference with epidermal 
proliferation has been reported to be the most conspicuous effect of calcipotriol 
treatment, whereas interference with inflammation is less marked.9 Using absolute 
counts, however, a significant reduction of infiltrate cells in the epidermis has been 
о 
claimed. In this respect it is of relevance that the combination of topical treatment 
with calcipotriol and low-dose systemic cyclosporin (2 mg/kg/day) proved to be a 
highly effective combination, indicating that the immunomodulating effect of 
cyclosporin might compensate for the relatively low immunosuppressive capacity of 
calcipotriol in vivo. 
Double-blind, placebo-controlled studies showed that effective and safe antipsoriatic 
therapy can be obtained with calcipotriol in a concentration of 50 μg/g. ' In a right-
left comparison calcipotriol induced a significantly larger reduction in PASI score 
compared with 0-1% betamethasone 17-valerate ointment. In a parallel group study 
no significant difference in the reduction of PASI score was demonstrated between 
calcipotriol and betamethasone, but patients' efficacy assessment was significantly in 
favour of calcipotriol.17 Calcipotriol ointment was also more effective and better 
accepted than short-contact dithranol therapy.18 However, an important limitation of 
calcipotriol monotherapy twice daily is the occurrence of irritative dermatitis in 10-
20% of patients.19 Once daily application of calcipotriol might decrease side-effects 
while maintaining clinical efficacy. Also concurrent use of topical calcipotriol and 
topical corticosteroids might reduce the frequency of irritative dermatitis while 
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maintaining or even improving the clinical result. Recently, a large multicentre study 
was initiated to establish the clinical efficacy and tolerability of a once-daily schedule 
of calcipotriol treatment and a combination of calcipotriol with a low and a medium 
strength corticosteroid. The results of this study (Leo Pharmaceutical Products, 
Denmark, data on file) will be published as a full report. 
The aim of the present study was to analyse the response pattern of psoriatic skin with 
respect to epidermal proliferation (percentage basal cells in S- and G2M-phase), 
epidermal differentiation (percentage cells expressing the differentiation marker 
keratin 10) and cutaneous inflammation (relative number of vimentin-positive cells) to 
various treatment schedules: (1) calcipotriol cream once daily; (2) calcipotriol cream 
twice daily; (3) calcipotriol cream in combination with clobetasone 17-butyrate cream 
(0-5 mg/g); or (4) calcipotriol cream in combination with betamethasone 17-valerate 
cream (1 mg/g). These response patterns were evaluated using a recently developed 
flow cytometric multiparameter technique with simultaneous quantification of DNA 
content and two intermediate filament proteins in epidermal single cell 
suspensions. Single cell suspensions were prepared from skin samples of 40 
patients who participated in the above-mentioned comparative double-blind parallel 
group multicentre study at the Department of Dermatology, Nijmegen. 
MATERIALS AND METHODS 
Patients and biopsies 
Forty patients with stable chronic plaque psoriasis participated in the study after 
informed consent. No systemic treatment had been used for at least 6 weeks. Excluded 
were patients who were pregnant, breastfeeding or expected to become pregnant. After 
a wash-out period of 2 weeks, in which only an emollient (Danatekt") was permitted, 
patients were at random assigned to one of four therapy groups. These consisted of 8 
weeks treatment with a morning application of calcipotriol cream 50 μg/g and an 
evening application of either (1) vehicle of calcipotriol cream, (2) calcipotriol cream 
50 μg/g, (3) clobetasone butyrate cream 0-5 mg/g or (4) betamethasone valerate cream 
1 mg/g on psoriatic lesions of extremities and trunk. Assessment of clinical scores for 
erythema, induration and desquamation (five-point scale) and of the area of the 
psoriatic lesions was performed every 2 weeks. Patients were withdrawn from the 
study before 8 weeks treatment if all lesions had cleared. Before and after treatment in 
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total two keratotome biopsies (thickness 0 4 mm, 2 cm ) were taken from the same test 
lesion for flow cytometric analysis 
Cell isolation procedure 
Epidermal single cell suspensions were prepared as described before.21 Briefly, the 
keratotome biopsies were incubated in phosphate-buffered saline (PBS) containing 
0-25 mg/ml trypsin (Sigma, St Louis, MO, U.S A.) and 3 0 mg/ml dithioerythritol 
(Sigma) for 30 min at 37°C. Then, in PBS containing 10% heat-inactivated newborn 
calf serum (HINCS, Life Technologies Ltd., Paisley, U K.) the dermis was separated 
from the epidermis with a fine forceps. The remaining epidermis was gently mixed on 
a vortex to loosen the keratinocytes, resulting in a single cell suspension. After 
discarding the homy layer, the suspension was centrifuged, the supernatant removed 
and the cells fixed in 70% ice-cold ethanol. The cell suspension was stored at -20°C 
until staining and flow cytometric analysis. 
Staining procedure 
Triple labelling was performed, using a DNA fluorochrome combined with two 
antibodies against intermediate filaments. The procedure has been described by us in 
detail before To assess proliferation, the DNA fluorochrome TO-PRO-3 iodide 
(TP3, Molecular Probes, Eugene, OR, U.S.A.) was used TP3 intercalates with 
double-stranded DNA and permits measurement of the proliferative activity of cells by 
quantification of the percentage of cells m S- and G2M-phase. As TP3 also binds to 
RNA to some extent, it was used in combination with RNase To study inflammation 
Vim3B4 (Novocastra Laboratories Ltd, Newcastle upon Ту ne, U K ) was used This 
IgG2a-type mouse monoclonal antibody stains vimentin, an intermediate filament-type 
22 
protein which occurs in mesenchymal cells. In the present study, PMNs, 
lymphocytes, monocytes, macrophages, melanocytes and Langerhans cells were 
stained by Vim3B4 The IgGl-type mouse monoclonal antibody RKSE60 (Department 
of Molecular Biology, University of Maastricht, The Netherlands) was used as 
differentiation marker. RKSE60 is directed against keratin 10, an intermediate 
filament-type protein that is expressed in differentiating keratinocytes Three-
colour fluorescence was obtained with the fluorochromes fluorescein-isothiocyanate 
(FITC) and phycoerythnn (PE) which were conjugated to monoclonal goat antibodies 
against mouse IgG2a and mouse IgGl respectively (Southern Biotechnology 
Associates, Birmingham, AL, U S Α.), in combination with TP3 
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Approximately 1-2 χ 10 cells of the cell suspensions were washed in PBS, filtered to 
remove clumps and homy material, and resuspended in 500 μΐ of a solution with 
Vim3B4 diluted 1 50 and RKSE60 diluted 1 15 in PBS After incubation for 30 mm at 
room temperature in the dark, the cells were washed in PBS containing 1% HINCS, 
resuspended and incubated for 15 min at 5°C in a solution of 500μ1 PBS, containing 
2μ1 goat-anti-mouse-PE, 10μ1 goat-anti-mouse-FITC, 10μ1 normal goat serum and 5 μΐ 
HINCS After a third washing step DNA staining was performed by addition of 300μ1 
TP3 (1μιτιο1/1 in PBS) and 50 μΐ RNase (1 mg/ml in PBS) (Sigma, St Louis, MO, 
U S A ) 
Flow cytometric analysis 
The flow cytometric measurements and analysis were performed before the treatment 
codes were revealed From each sample 5,000-10,000 gated cells were measured and 
analysed using an EPICS Elite flow cytometer (Coulter, Luton, U K ) equipped with a 
dual laser system PE and FITC were excited with an air-cooled argon ion laser (15 
mW, 488 nm) TP3 was excited with a HeNe laser (10 mW, 633 nm) Fluorescence 
was measured using bandpass filters of 520-530 nm (green, FITC), 555-595 nm 
(orange, PE), and 670-680 nm (red, TP3) The area/peak ratio of the red signal (DNA) 
was used to discriminate between doublets of diploid cells (clumps) and real single 
tetraploid cells After setting appropriate gates with the EPICS Elite software 
percentages of vimentin- and keratin 10 positive cells were calculated Using 
Multicycle™ software (Phoenix Flow Systems, San Diego, CA, U S A ) the 
percentages of basal keratinocytes in S- and G2M-phase of the cell cycle (proliferation) 
were calculated from DNA histograms 
Statistical analysis 
Changes in the relative numbers of vimentin-positive cells, keratin 10 positive 
keratinocytes and basal cells in S- and G2M-phase before and after treatment were 
analysed using the paired Mest for means (two-tail) Differences between therapies 
were assessed using the two-sample Mest assuming equal variances (two-tail) 
Analysis of the correlation between clinical and flow cytometric scores was performed 
by calculation of the Pearson correlation coefficient 
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RESULTS 
Clinical response 
Of 40 included patients 39 completed the present study. One subject was withdrawn at 
week 4 because of severe generalized itching and worsening of psoriasis. This patient 
had used calcipotriol cream twice daily for 3 weeks. All four therapy regimens resulted 
in a statistically significant reduction of PASI scores. Percentages were 50% 
(calcipotriol once daily, D), 64% (calcipotriol twice daily, DD), 58% (calcipotriol in 
combination with clobetasone, DC) and 55% (calcipotriol in combination with 
betamethasone, DB). Between the four therapies no statistically significant difference 
in the decrease of the PASI score could be demonstrated. Clearance of the test lesions 
was reached in 10 subjects: values for each therapy group were 2 (D), 1 (DD), 3 (DC) 
and 4 (DB). In 5 subjects even clearance of all lesions was reached. These patients all 
had used calcipotriol in combination with a corticosteroid (DC: 3, DB: 2). 
Flow cytometric analysis 
From one patient the initial keratotome biopsy proved to contain exclusively the most 
superficial layers of the epidermis. Therefore, flow cytometric assessment was 
performed on 76 epidermal cell suspensions obtained from test lesions of 38 patients. 
The percentage of intact cells per sample (corrected for debris and clumps) (mean ± 
standard error of the mean) was 78-1 ± 1-2 (range 48-7 - 93-5). The clinical scores and 
the flow cytometric analyses of all biopsies before and after treatment are shown in 
Figure 1. It can be seen that the percentage of vimentin-positive cells correlates with 
the clinical expression of inflammation, i.e. erythema (r = 0-26, Ρ < 005), that the 
relative number of keratin 10 positive keratinocytes (differentiation) correlates 
inversely with the score for desquamation (r = -0-40, Ρ < 001), and that the 
percentage of basal keratinocytes in S- and G2M-phase (proliferation) correlates with 
the induration score of the psoriatic test lesions (r = 0-53, Ρ < 0Ό001). 
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1 2 
Desquamation score 
Induration score 
Figure 1. Correlation of clinical scores and flow cytometric analyses (means ± SEM) of all test 
lesions (n = 76). (a) Percentages of vimentin-positive cells vs. erythema score, (b) Percentages of 
keratin 10 positive keratinocytes vs. desquamation score, (c) Percentages of basal keratinocytes in S-
and G2M phase vs. induration score. 
Evaluation of new topical treatment for psoriasis 111 
Table 1. Percentages of vimentin positive cells, keratin 10 positive keratinocytes and basal 
keratmocytes in S- and G2M phase in epidermal cell suspensions prepared from keratotome biopsies 
taken from test lesions of psoriasis patients during treatment (means ± SEM) 
Vimentin Keratin 10 S and G2M 
Baseline After Baseline After Baseline After 
treatment treatment treatment 
Calcipotnol n = 9 10 8 ± 2 0 8 5 ± 1 0 41 0 ± 5 3 50 2 ± 3 9 14 I ± 2 3 1 0 8 ± 2 2 
once daily 
Calcipotnol n = 9 109±2 2 8 4 ± I 1 44 3 ± 4 4 54 3 ± 4 I 15 2 ± 1 2 10 1 ± 1 9* 
twice daily 
Calcipotnol/ n = 9 14 4± 1 8 7 8 ± 0 8* 35 7 ± 3 3 4 8 2 ± 5 3* 16 1 ± 2 5 8 9 ± 1 0 * * 
clobetasone 
17-butyrate 
Calcipotnol/ n = l l 15 5 ±2 8 10-7 ± 1 5 37 9 ± 4 2 40 5 ± 3 1 16 5 ± 2 3 8 7 ± 1 3 * * 
betamethasone 
17-valerate 
*/** Significant differences (compared to baseline) at the Ρ < 0 05 and Ρ < 0 01 level, respectively 
Table 1 summarizes the expression of the markers for proliferation, differentiation and 
inflammation before and after treatment. All therapy regimens except the once daily 
application of calcipotriol resulted in a statistically significant decrease of the 
percentage of basal keratinocytes in S- and G2M-phase. Following calcipotnol once 
daily and twice daily the reductions of this parameter were 24% (P = 0 24) and 34% (P 
< 0Ό5), respectively, whereas the reductions following treatment with 
calcipotriol/clobetasone 17-butyrate and calcipotriol/betamethasone 17-valerate were 
44% (P < 001) and 47% (P < 0-01), respectively With respect to the number of 
vimentin-positive cells a statistically significant decrease was reached in the 
calcipotriol/clobetasone butyrate-treated group (47%, Ρ < 005). Values for the other 
therapy groups were 29% (P = 019) for calcipotriol/betamethasone, 2 1 % (P = 0-34) 
for calcipotriol once daily and 23% (P = 0-42) for calcipotriol twice daily The 
percentage of differentiated keratinocytes (keratin 10 positive) increased in all therapy 
groups. Statistical significance was only reached with calcipotriol/clobetasone butyrate 
(35%, Ρ < 0-05). 
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DISCUSSION 
From the present flow cytometric evaluation the following conclusions were drawn: (i) 
twice daily treatment with calcipotriol cream results in a substantial decrease of the 
percentage of cells in S- and G2M-phase in the basal cell layer, without a significant 
effect on the percentage of vimentin-positive cells; (ii) once daily treatment with 
calcipotriol cream does not result in a significant reduction of the percentage of cells in 
S- and G2M-phase in the basal cell layer; (iii) combination of calcipotriol and topical 
steroids results in a more marked decrease of the epidermal proliferative activity 
compared to calcipotriol treatment; (iv) a marked reduction of the percentage of 
vimentin-positive cells is observed following the concurrent use of calcipotriol and 
topical steroids whereas calcipotriol monotherapy has virtually no effect on this 
marker, and (v) an increase of the relative number of differentiated keratinocytes is 
only reached after concurrent use of calcipotriol and corticosteroids. 
In the present study the effect of the different treatment schedules was assessed using 
flow cytometric quantification of epidermal growth, and of markers for differentiation 
and inflammation. These markers were chosen in analogy to the clinical features of the 
psoriatic lesion, i.e. erythema, induration and desquamation that are assessed in the 
PASI score. In previous studies the methodology was evaluated in epidermal 
hyperproliferation induced by sellotape stripping, after application of leukotriene B4 
to normal skin27 and in psoriatic patients before and following treatment. ' In Figure 1 
the correlation between the percentage of basal cells in S- and G2M-phase and 
induration, between the percentage of vimentin-positive cells and erythema, and 
between the percentage of keratin 10 positive keratinocytes and scaling further 
substantiates the relationship between clinical features of the psoriatic lesion and the 
cell biological equivalent. 
In a previous immunohistochemic study it was shown that calcipotriol ointment twice 
daily had a minor effect on cutaneous inflammation. In a recent study using the same 
flow cytometric analytical method it was shown that Tacalcitol (la,24 
dihydroxyvitamin D3, 4 μg/g) ointment, applied once daily, had a substantial effect on 
epidermal proliferation (34% reduction of the percentage basal keratinocytes in S- and 
G2M-phase) without a significant effect on the percentage of vimentin-positive cells. 
The present study on calcipotriol demonstrates a similar preponderance of the 
antiproliferative effect. As once daily treatment with calcipotriol cream had a minor 
effect on epidermal growth of the psoriatic lesion, twice daily application seems to be a 
more optimal approach. 
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Insight in the in vivo action of antipsonatic treatments helps to define promising 
combination schedules. The present study indicates that concurrent use of calcipotnol 
and a topical corticosteroid has a more pronounced effect on epidermal 
hyperproliferation and inflammation, compared to monotherapy with calcipotriol. In 
this respect it is of interest that after clobetasol 17-propionate monotherapy, the 
reduction of the percentage of basal cells in S-and G2M-phase was 72% and the 
reduction of the percentage of vimentin-positive was 62% (unpublished data). 
Surprisingly, a marked difference between both combination therapies was observed 
with respect to the expression of the differentiation-related keratin 10· the increase 
after treatment with calcipotnol and clobetasone 17-butyrate was 35% and following 
treatment with the combination of calcipotnol and betamethasone 17-valerate 7%. 
In conclusion, the present flow cytometric study lends support for the hypothesis that 
the effect of calcipotriol once daily is inferior to calcipotriol twice daily and that the 
combination of calcipotriol and a corticosteroid has a better antipsonatic efficacy 
compared to calcipotriol monotherapy. 
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4.3 Flow cytometric assessment of clearance and relapse 
characteristics in psoriasis vulgaris after treatment with weekly 
clobetasol lotion under occlusion versus twice daily clobetasol 
ointment 
Conrad P. Glade, Carine J.M. van der Vleuten, Piet E.J. van Ε φ , 
Peter C.M. van de Kerkhof, Department of Dermatology, University Hospital 
Nijmegen, The Netherlands 
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SUMMARY 
Clearance and relapse characteristics of clobetasol lotion under hydrocolloid occlusion 
once weekly versus clobetasol ointment twice daily were assessed in a comparative 
flow cytometric study. Quantitative analysis of markers for epidermal proliferation, 
differentiation and inflammation was performed on epidermal single cell suspensions 
prepared from 3 mm punch biopsies taken from 15 patients with psoriasis vulgaris 
before therapy, at clearance and 6 weeks after clearance. After treatment both therapy 
regimens resulted in substantial changes of all flow cytometric parameters, but 
clearance was induced earlier in the corticosteroid under hydrocolloid occlusion-
treated group. With respect to the relapse phase no difference was observed between 
both treatments. 
INTRODUCTION 
Various studies showed the beneficial effect of hydrocolloid occlusive dressings 
(HCD) in the treatment of psoriasis vulgaris1"3. This mode of occlusion proved to 
interfere directly with epidermal growth and differentiation . The combination of HCD 
with topical corticosteroids has a high therapeutic potential, up to normalization of the 
psoriatic skin4: Van de Kerkhof et al. showed that weekly treatment of psoriasis with 
triamcinolone lotion and HCD for 3 weeks resulted in total clearing in 20% of 
patients5. Juhlin et al. found clearance in all 15 patients treated with betamethasone 
lotion under HCD once weekly for 2 weeks. In the latter study the psoriatic lesions 
relapsed after 4-8 weeks6. Following treatment with clobetasol under HCD twice daily 
clinical healing was observed after 6-10 days and relapse occurred after 12 days . 
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Volden et al. demonstrated complete remission after 12 days of combined therapy with 
clobetasol lotion and HCD applied once weekly. The time until relapse was 1 to 6 
о 
months in 4 of 21 patients . From these studies it can be concluded that a strong 
clinical response can be obtained with topical steroids in combination with HCD. 
However, comparative studies with respect to clearance and relapse characteristics of 
topical corticosteroids without HCD versus the combination of topical corticosteroids 
with HCD have not been carried out so far. With respect to the duration of remission 
after treatment with topical corticosteroids under HCD, variations between 6-10 days 
and 6 months and even longer have been reported. In order to circumvent the 
variability of these clinical studies a quantitative characterization of the major cell 
biological processes before, during and following treatment might provide important 
information for the understanding of the dynamics of antipsoriatic therapy. As 
multiparameter flow cytometry permits simultaneous quantification of different cell 
parameters ' , we performed a quantitative flow cytometric analysis of markers for 
epidermal proliferation, differentiation and inflammation in patients who were treated 
with clobetasol ointment twice daily or clobetasol lotion once weekly under HCD. 
These patients participated in a multicentre clinical study on efficacy and posttreatment 
remission of both treatments . Biopsies for flow cytometric analysis were taken at the 
Nijmegen centre before treatment, at clearance and 6 weeks after clearance. We 
addressed the following questions: 
1) What are the flow cytometric characteristics of psoriatic lesions before treatment, 
after treatment with clobetasol ointment only and clobetasol lotion under HCD and 6 
weeks after treatment? 
2) Is there any difference between both therapy regimens? 
MATERIALS AND METHODS 
Patients, treatment and biopsies 
Nineteen patients with psoriasis vulgaris were included and at random divided in two 
treatment groups. They had received no topical treatment for at least 2 weeks or 
systemic treatment for at least 2 months. All patients gave written consent. In each 
patient one test lesion was selected and treated with clobetasol ointment twice daily 
(n=9) or clobetasol lotion under HCD (Duoderm Extra Thin®, ConvaTec) once weekly 
(n=10) until clearance was observed or alternatively for a maximal period of 6 weeks. 
The definition of clearance was: erythema score 0 or 1 (5-point scale), no induration 
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and no desquamation. Patients visited the out-patient department every second week 
until a relapse occurred, ι e clinical scores for erythema, induration and desquamation 
higher than 1,0,0 respectively For flow cytometric analysis from each patient 3 mm 
punch biopsies were taken before therapy, at clearance and 6 weeks after clearance 
Cell isolation procedure 
The preparation of epidermal single cell suspensions has been described by us before 
In brief, the biopsy was washed in phosphate buffered saline (PBS) After overnight 
(16h) incubation at 4°C of the skin specimen with thermolysin (Sigma P-1512, St 
Louis, USA, 0 5 mg/ml dissolved in PBS with C a ^ and Mg++, Seromed, Berlin, 
Germany) dermis and epidermis were separated with a fine forceps Then the 
remaining epidermis was incubated in 2 ml PBS containing 0 25 mg/ml trypsin (Sigma 
T-8253) and 3 0 mg/ml DTE (Sigma, D-8255) for 30 min at 37°C After adding 200 μΐ 
heat-inactivated newborn calf serum (HINCS, Life Technologies Ltd , Paisley, UK) the 
epidermis was gently mixed on a vortex to separate the keratinocytes resulting in a 
single cell suspension Then the stratum comeum was discarded After centnfugation 
the solution was resuspended The cells were fixed in 2 ml ice cold ethanol and kept at 
-20°C until staining and flow cytometric analysis 
Triple labelling and flow cytometric analysis 
A triple labelling was performed, using a DNA fluorochrome combined with two 
antibodies against intermediate filaments' To assess hyperprohferation, the DNA 
fluorochrome TO-PRO-3 iodide (TP3, Molecular Probes, Eugene, USA) was used 
TP3 intercalates with double string DNA and permits measurement of the proliferative 
activity of cells by quantification of the percentage of cells in S- and G2M phase As 
TP3 also binds to RNA to some extent, it was used in combination with RNase To 
study inflammation Vim3B4 (Novocastra Laboratories Ltd, Newcastle upon Tyne, 
UK) was used This IgG2a-type mouse monoclonal antibody stains vimentin, an 
intermediate filament-type protein which occurs in mesenchymal cells ι e 
polymorphonuclear neutrophils, lymphocytes, monocytes, macrophages, melanocytes 
and Langerhans' cells To quantify the differentiation process, the IgGl-type mouse 
monoclonal antibody RKSE60 (Dept of Mol Biology, University of Maastricht, The 
Netherlands) was used RKSE60 is directed against keratin 10, an intermediate 
filament-type protein that is expressed in differentiating keratinocytes Three-colour 
fluorescence was obtained with the fluorochromes fluorescein-isothiocyanate (FITC) 
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and phycoerythrin (PE) which are conjugated to monoclonal goat antibodies against 
mouse IgG2a and mouse IgGl respectively (Southern Biotechnology Associates, 
Birmingham, USA), in combination with TP3 
Approximately 1-2 χ 10 cells of the cell suspensions were washed in PBS, filtered to 
remove clumps and homy material, and resuspended in 500 μΐ of a solution with Vim 
3B4 diluted 1 50 and RKSE60 diluted 1 7 in PBS After incubation for 30 mm at room 
temperature in the dark, the cells were washed in PBS containing 1% HINCS, 
resuspended and incubated for 15 min at 5°C in a solution of 500 μΐ PBS, containing 2 
μΐ goat-anti-mouse-PE, 10 μΐ goat-anti-mouse-FITC, 10 μΐ normal goat serum and 5 μΐ 
HINCS After a third washing step DNA staining was performed by addition of 300 μΐ 
TP3 (ΙμΜ in PBS) and 50 μΐ RNase (lmg/ml in PBS) (Sigma, St Louis, USA) 
From each sample 5,000-10,000 gated cells were measured and analysed using an 
EPICS® Elite flow cytometer (Coulter, Luton, UK) equipped with a dual laser system 
PE and FITC were excited with an air-cooled argon ion laser (15 mW, 488 nm) TP3 
was excited with a HeNe laser (10 mW, 633 nm) Fluorescence was measured using 
bandpass filters of 520-530 nm (green, FITC), 555-595 nm (orange, PE), and 670-680 
nm (red, TP3) The area/peak ratio of the red signal (DNA) was used to discriminate 
between doublets of diploid cells (clumps) and real single tetraploid cells After setting 
appropriate gates with the EPICS Elite software percentages of vimentin- and keratin 
10-positive cells are calculated Using Multicycle™ software (Phoenix Flow Systems, 
San Diego, USA) the percentages of basal and suprabasal keratinocytes and of non-
keratinocytes in S- and G2M phase (proliferation) of the cell cycle were calculated 
from DNA histograms 
Statistical analysis 
For comparison of paired values a paired two-sample t-test for means was used 
Unpaired data were analysed with a two-sample t-test assuming equal variances 
RESULTS 
Patients and biopsies 
Of 19 patients, 15 completed the study One patient did not attend any visits after 
clearance of the test lesion and three discontinued treatment Of the patients who 
discontinued treatment, one developed a bacterial infection of the test lesion requiring 
additional therapy and for two the antipsonatic response was unsatisfactory All 
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remaining 15 patients showed clearance after 6 weeks or less and visited the out-
patient department every second week at least until a relapse had occurred In total 
forty-five punch biopsies were obtained for flow cytometric analysis 
Clearing phase 
The clinical response for both therapy regimens is summarized in Fig la The sum 
score is defined as the total of the erythema-, induration- and desquamation score of 
each test lesion As well before as after treatment both therapy groups were not 
statistically different with respect to the sum score The mean time until clearance was 
18 5 days in the clobetasol lotion-HCD treated group (n=9) and 28 days in the 
clobetasol ointment group (n=6) 
The results of the flow cytometric analysis are shown in Fig lb-d Both the lotion 
under HCD as the ointment regimen resulted in a significant decrease of proliferative 
activity of the basal compartment (p<0 0001 and p<0 01) The amount of vimentin-
positive cells was substantially reduced (p<0 005 and p<0 02) With respect to 
epidermal differentiation the percentage of keratin 10-positive keratinocytes increased 
(p<0 0003 and p<0 001) No statistically significant difference was observed between 
the two therapies With one exception the flow cytometric values showed no 
significant difference between the two therapies Only before therapy the amount of 
vimentin-positive cells was higher in the lotion-HCD-treated group compared to the 
clobetasol ointment group (p<0 05) 
No correlation could be demonstrated between flow cytometric parameters before 
therapy and the clearance time 
Relapse phase 
Thirteen out of 15 patients showed a clinical relapse after 6 weeks The mean time 
until relapse was 29 days after the discontinuation of the treatment with clobetasol 
lotion under HCD One patient in the latter group remained without relapse After 
treatment with clobetasol ointment the mean time until relapse was 37 5 days The 
mean clinical sum score 6 weeks after clearance was 4 1 in the lotion under HCD-
treated group and 3 2 in the ointment-treated group (Fig 2a) Compared to the 
corresponding scores at clearance these changes were statistically significant (p<0 002 
and p<0 01, respectively) 
Evaluation of new topical treatment for psoriasis 121 
IS 20 
Clearегке time Clearance time 
Cleeience time 
1 0 15 2 0 
Cleerence time 
Figure la-d. Clinical sum scores (a) and flow cytometric scores (b-d) (mean ± SEM) of psoriatic 
lesions before treatment and at clearance. Values are given for weekly applications of clobetasol 
lotion under HCD (•) versus twice daily applications of clobetasol ointment ( _ ). 
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Figure 2a-d. Clinical sum scores (a) and flow cytometric scores (b-d) (mean ± SEM) of psoriatic 
lesions at clearance and 6 weeks after clearance. Values are given for weekly clobetasol lotion under 
HCD versus twice daily clobetasol ointment. 
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In Fig. 2b-d the results of the flow cytometric analysis are summarized. Compared to 
the situation at clearance the mean proliferative activity was substantially increased 6 
weeks after clearance in both lotion-HCD and ointment-treated lesions (p<0.002 and 
p<0.05). The number of vimentin-positive cells present in the epidermal compartment 
increased in both therapy groups (p<0.03 and p<0.05). The percentage of keratin 10-
positive keratinocytes decreased (pO.01 and p=0.17). Statistical analysis of the flow 
cytometric values 6 weeks after clearance revealed no difference between both 
therapies. 
DISCUSSION 
In the present study a flow cytometric analysis of clearance and relapse characteristics 
of psoriatic lesions after treatment with clobetasol lotion under HCD once weekly 
versus clobetasol ointment twice daily is presented. In all patients both therapy 
regimens resulted in clearance of the test lesions. However, clinical clearance was 
reached earlier in lesions under occlusion. For both therapies the flow cytometric 
assessment revealed substantial changes in cell biological parameters during and after 
therapy. In this respect no difference was demonstrated between both therapies. 
In Table 1 the mean flow cytometric values for all 15 lesions are compared. With 
respect to epidermal proliferation at clearance a strong reduction of the number of 
basal keratinocytes in S- and G2M phase is demonstrated. The value of 3.1 % is even 
lower than the value of 5.5% which represents the proliferative activity of normal 
skin . In 4 out of 15 patients these percentages ranged from 0.1 to 0.5%. This means 
that after treatment DNA synthesis was almost totally suppressed in some patients. 
These data correspond with Goodwins , who investigated thymidine uptake of 
lesionai and uninvolved psoriatic skin before and after treatment with topical 
corticosteroids under polyethene occlusion. Like in the present study, he described a 
totally suppressed uptake in some patients and a rebound in all patients after treatment 
had been stopped. In some of these patients DNA synthesis was also totally suppressed 
in the uninvolved skin. As Baxter et al.1 and Fry et al.1 both observed a decreased 
mitotic index in psoriatic lesions after treatment with occlusive dressings without 
adjunct treatment, the reduced proliferative activity is not exclusively a result from the 
application of corticosteroids. The present study, showing the relative fast clearance in 
the lesions treated with the combination of clobetasol lotion and HCD compared to the 
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lesions treated with clobetasol ointment monotherapy illustrates the additional value of 
HCD in treating psoriasis. 
At clearance of the test lesions the amount of keratin 10-positive keratinocytes reached 
values present in normal skin . Such suggests that after treatment a normalization of 
the psoriatic epidermis was reached with respect to differentiation. This effect is not 
only due to the topical corticosteroids. In an immunohistochemical study Gerritsen et 
al. demonstrated that filaggrin and involucrin expression (markers for late 
keratinization) increased substantially in psoriatic plaques after application of HCD for 
3 weeks. 
Table 1. Comparison of flow cytometric values (mean ± SEM, n=15) of epidermal single cell 
suspensions prepared from 3 mm punch biopsies taken from all test lesions before therapy, at 
clearance and 6 weeks after clearance. 
Before therapy At clearance 6 weeks after clearance 
% Basal keratinocytes in S- and 11 ± 0.9 3.1 ±0.7 9.3 ± 0.9 
GjM phase 
% Keratin 10-positive 29 ±2.9 56 ±3.4 36 ±5.0 
keratinocytes 
% Vimentin-positive cells 6.3 ± 0.6 2.4 ±0.4 5.8 ±0.7 
The intermediate filament protein vimentin is expressed in cells from mesenchymal 
origin. Therefore, in psoriasis vimentin occurs in the epidermal non-keratinocytes, i.e. 
lymphocytes, polymorphonuclear neutrophils, monocytes, macrophages, melanocytes 
and Langerhans' cells. After both therapy regimens the amount of epidermal non-
keratinocytes decreased substantially, resulting in values even lower compared to 
normal skin . As immunological parameters remained unaffected during HCD 
treatment of psoriatic plaques the reduction of vimentin-positive cells in the psoriatic 
epidermis in the present study are totally due to the anti-inflammatory properties of the 
corticosteroids. A more moderate reduction of the amount of vimentin-positive cells in 
psoriatic epidermis is observed after treatment with several vitamin D3 analogues. 
After 6 weeks treatment with la,24 dihydroxyvitamin D 3 ointment (4μg/g once daily) 
a reduction of 20% was obtained10. After treatment with 8 weeks calcipotriol (50 μg/g 
twice daily) this percentage was in the same range: 23 % (data on file). 
In conclusion, flow cytometric analysis demonstrated a strong interference of two 
different antipsoriatic therapy regimens with epidermal proliferation, differentiation 
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and inflammation. The combination of clobetasol lotion once weekly with HCD 
shortened the period until clearance was reached compared to clobetasol ointment 
twice daily The remission time after clearance was not substantially different for both 
therapies. Also the assessment of flow cytometric parameters 6 weeks after clearance 
showed comparable patterns. This indicates that with respect to relapse characteristics 
the use of topical corticosteroids under HCD is comparable to the classical 
corticosteroid treatment. 
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Chapter 5 
GENERAL DISCUSSION 

5.1 Multiparameter flow cytometry as a tool to evaluate 
antipsoriatic therapy 
Conrad P. Glade, Piet E.J. van Ε φ , Jan B.M. Boezeman, Peter C M . van de 
Kerkhof, Department of Dermatology, University Hospital Nijmegen, The 
Netherlands. 
in press (Br J Dermatol) 
SUMMARY 
Objective comparison of different antipsoriatic therapies requires quantitative 
assessment of disease severity. However, clinical assessment with the widely used 
Psoriasis Area and Severity Index (PASI) introduces inaccuracy. An alternative is the 
quantitative analysis of different epidermal cell parameters using multiparameter flow 
cytometry. Our aim in the present study was to compare the clinical and flow 
cytometric approach to monitor disease activity and to evaluate antipsoriatic efficacy. 
Clinical scores for erythema, induration and scaling were assessed and biopsies for 
flow cytometric analysis were obtained from the psoriatic plaques of 89 patients before 
and after treatment with different therapeutic regimens consisting of vitamin D3 
analogues and corticosteroids. In total, 219 epidermal cell suspensions were analysed 
using triple-labelling, with the simultaneous staining of markers for epidermal 
proliferation (DNA dye TO-PRO-3), differentiation (antikeratin 10), and inflammation 
(antivimentin). 
Correlation analysis was performed on 166 paired values obtained from 83 patients. A 
highly significant correlation was observed between erythema and the percentage of 
vimentin-positive cells, between scaling and the percentage of keratin 10-positive 
keratinocytes, and between induration and the number of basal keratinocytes in S- and 
G2M phase, when all 166 biopsies were assessed. The latter correlation remained in the 
same range if the analysis was restricted to the 83 pretreatment biopsies. In contrast to 
the clinical scores, the flow cytometric analysis permitted a clear separation between 
the antiproliferative and anti-inflammatory or keratinization-enhancing effects of 
antipsoriatic treatment. The vitamin D3 analogues proved to exert a mainly 
antiproliferative effect. The combination of calcipotriol and a topical corticosteroid 
improved all cell biological markers substantially, and clobetasol monotherapy had a 
powerful effect on these markers. In conclusion, multiparameter flow cytometry has 
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been shown to be a sensitive tool to evaluate the growth inhibiting, anti-inflammatory 
and keratinization-enhancing effects of antipsoriatic therapies. 
INTRODUCTION 
In the evaluation of antipsoriatic therapies, quantitative assessment of disease severity 
is essential. A popular and frequently-used method for clinical assessment is the 
Psoriasis Area and Severity Index (PASI). In this scoring system, described by 
Fredriksson and Pettersson , the percentage involvement and degree of erythema, 
induration and desquamation is estimated in four body areas. Using a formula, an 
ordinal value between 0 and 72 can be calculated. However, the authors stated that the 
PASI score should not to be regarded as an "exact" numerical value, since the severity 
rating is subjective. Marks et al demonstrated a wide inter-observer error of even 
well-designed clinical assessment techniques, especially with respect to the calculation 
of the involved areas. Various groups have emphasized the potential for reaching 
inaccurate conclusions when clinical assessment alone is used . Therefore, there is 
clearly a need for objective measurements of psoriasis severity. 
Flow cytometry permits quantitative analysis of different cell parameters and can be 
applied to epidermal single-cell suspensions prepared from normal and diseased skin . 
In analogy to the clinical signs which reflect the pathological changes in psoriasis, we 
developed a triple-labelling procedure with simultaneous staining of markers for 
epidermal proliferation (DNA content), differentiation (anti-keratin 10), and 
inflammation (anti-vimentin) ' . Recently, with the development of a dermo-epidermal 
separation method using thermolysin, it has become possible to perform this flow 
cytometric procedure on cell suspensions prepared from 3mm punch biopsies . 
In the present study we have analysed 219 epidermal single cell suspensions prepared 
from keratotome and punch biopsies of psoriatic plaques from 89 patients before and 
after treatment with different therapy regimens consisting of vitamin D3 analogues and 
topical corticosteroids. Our aim in the study was to compare the clinical and flow 
cytometric approaches in monitoring disease activity and to establish whether flow 
cytometry is a valuable tool to evaluate and compare antipsoriatic therapies. We 
addressed in particular: to what extent the clinical scores for erythema, induration and 
desquamation correlate with the percentage of vimentin-positive cells, the percentage 
of basal keratinocytes in S- and G2M phase and the percentage of keratin 10-positive 
keratinocytes, to what extent the improvement of clinical parameters reflects a change 
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in the cell biological markers, whether the method of preparation of cell suspensions 
influences the association of clinical and flow cytometric scores, and whether clinical 
and flow cytometric scores vary with different antipsoriatic therapies. 
MATERIALS AND METHODS 
Patients, treatment regimens and biopsy procedures 
Data from 89 patients in total with psoriatic plaques were analysed. Patients' details 
have been described in our flow cytometric studies on the treatment of psoriatic 
plaques with la,24 dihydroxyvitamin D3 ointment (Tacalcitol ), 4μg/g applied once 
daily for 8 weeks or placebo, calcipotriol, 5(^g/g once daily, twice daily or in 
combination with the topical corticosteroids clobetasone 17-butyrate. 0.5mg/g, and 
û 
betamethasone 17-valerate, lmg/g, for 8 weeks , and after treatment with clobetasol 
17-propionate (unpublished data). Before the wash-out period of 2 weeks, 
representative psoriatic lesions were selected. Clinical scores for erythema, induration 
and desquamation of these test lesions were assessed, on a 5-point scale, before and 
after treatment. Scoring was performed by one investigator only, to avoid the 
interobserver error described by Marks et al . Skin samples of the selected test were 
obtained simultaneously with clinical scoring. In this way 219 single-cell suspensions, 
derived from 152 keratotome biopsies and 67 punch biopsies, were prepared for flow 
cytometric analysis. 
Single-cell suspensions and staining 
Epidermal cell suspensions from keratotome biopsies were prepared using a trypsin 
separation method. The cell isolation procedure on punch biopsies consisted of dermo-
epidermal separation with thermolysin and subsequent incubation with trypsin. In flow 
cytometric studies of epidermis, the quality of cell suspensions is essential. As 
enzymatic and mechanic methods are used to separate the cells, membrane antigens are 
easily damaged. Therefore, we decided to use a multiparameter technique with 
simultaneous quantification of the DNA content and of the intermediate filaments. 
These filaments are resistant to breakdown and antibodies are well-studied. Several 
keratins are highly expressed in the epidermis. Keratin 10 is a well-known epidermal 
differentiation marker. Vimentin is expressed in all epidermal mesenchymal cells, i.e 
dendritic cells and (especially in psoriatic skin) inflammatory infiltrate cells. A detailed 
description of both cell isolation methods and the staining procedure for 
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multiparameter flow cytometric analysis have been published . Cells after isolation 
were fixed in 70% w/v ethanol until required for staining. 
Multiparameter flow cytometry by the simultaneous measurement of fluorescein-
isothiocyanate (FITC), phycoerythrin (PE) and propidiumiodide (PI) is considered 
difficult because of the large spectral overlap of PE and PI. Hoechst 33342 and 7AAD 
have been proposed as alternatives to PI in multiparameter flow cytometry. However, 
in our hands, 7AAD gave unacceptably high coefficients of variation (CVs). Hoechst 
33342 staining requires an expensive ultraviolet laser, which is usually not present in 
commercial flow cytometers. On the contrary, many research flow cytometers are 
equipped with a low-power HeNe laser (633 nm), which excites TO-PRO-3 iodide 
(TP3) (peak absorbance at 642 nm). The quality of staining with TP3 has been 
extensively studied by our group . At a concentration of 1 μτηοί/ί, typical cell cycle 
histograms of peripheral blood lymphocytes showed a CV of 3.6%. The determination 
of human and mouse cell lines S-phase fractions with TP3 and PI showed a good 
correlation. Combined with FITC and ΡΕ, TP3 was superior than PI as a DNA stain in 
multiparameter flow cytometry. 
Spectral overlap of the fluorochromes used proved to be minimal. After a first 
incubation for 30 min with anti-vimentin (Vim3B4, mouse IgG2a, Novocastra 
Laboratories Ltd., Newcastle upon Tyne, U.K.) and anti-keratin 10 (RKSE60, mouse 
IgGl, Department of Molecular Biology, University of Maastricht, The Netherlands) a 
second incubation for 15 min with the fluorochromes FITC and PE conjugated to 
monoclonal goat antibodies against mouse IgG2a and mouse IgGl (Southern 
Biotechnology Associates, Birmingham, AL, U.S.A.), respectively, was performed. 
After a third washing step, DNA staining was performed by addition of 300μ1 TP3 
(1μπιο1/1 in phosphate buffered saline (PBS)) (Molecular Probes, Eugene, OR, U.S.A.) 
and 50μ1 RNAase (lmg/ml in PBS) (Sigma, St. Louis, MO, U.S.A.). 
Flow cytometric analysis 
The flow cytometric analysis of triple-stained cell suspensions has been described 
before7'8. From each sample, 5,000-10,000 gated cells were measured and analysed 
using an EPICS Elite flow cytometer (Coulter, Luton, U.K.) equipped with a dual 
laser system. PE and FITC were excited with an air-cooled argon ion laser (15mW, 
488nm). TP3 was excited with a HeNe laser (lOmW, 633nm). Fluorescence was 
measured using bandpass filters of 520-530nm (green, FITC), 555-595nm (orange, 
PE), and 670-680nm (red, TP3). The area/peak ratio of the red signal (DNA) was used 
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to discriminate between doublets of diploid cells (clumps) and real single tetraploid 
cells . After setting appropriate gates with the EPICS" Elite software, the percentages 
of vimentin-positive cells, differentiated keratinocytes (vimentin-negative and keratin 
10 positive) and basal keratinocytes (vimentin-negative and keratin 10 negative) were 
calculated. Using Multicycle™ software (Phoenix Flow Systems, San Diego, CA, 
U.S.A.) the percentages of basal keratinocytes in the S- and G2M phases of the cell 
cycle (proliferation) were calculated from DNA histograms. 
Statistic analysis 
Analysis of the correlation between clinical and flow cytometric scores was performed 
by calculation of the Pearson correlation coefficient. In the placebo-controlled 1 a,24 
dihydroxyvitamin D3 study four biopsies were obtained per patient and the 
corticosteroidmonotherapy study three biopsies were obtained per patient. Therefore, 
to avoid within-person variability, correlation analysis was restricted to paired values, 
i.e. before and after treatment, with omission of the values of the placebo-treated 
lesions. This resulted in 166 paired values obtained from 83 patients. To compare the 
flow cytometric scores before treatment for both cell isolation procedures, the paired t-
test for means (two-tail) was used. 
RESULTS 
In all the 219 investigated flow cytometric samples, the number of intact cells was at 
least 30% (without debris and clumps). Coefficients of variation of the Gl-peaks were 
< 10. In Figure 1 we show the results of the correlation-analysis of clinical and flow 
cytometric scores, which was restricted to 166 paired values of 83 patients. It can be 
seen that high clinical scores for erythema correlate with high percentages of vimentin-
positive cells (Fig. la; correlation coefficient r = 0.41, Ρ < 0.0001), that the 
desquamation score inversely correlates with the number of keratin 10-positive 
keratinocytes (Fig.lb; r = -0.44, Ρ < 0.0001) and that the induration of a psoriatic 
plaque correlates with its proliferative activity (Fig.lc; г = 0.66, Ρ < 0.0001). High 
correlation coefficients were shown between the clinical scores of the psoriatic 
plaques: 0.79 (erythema and desquamation), 0.84 (erythema and induration), and 0.87 
(induration and desquamation) with Ρ < 0.0001 (Table 1). However, the coefficients of 
the flow cytometric values were -0.38, Ρ < 0.0001 (vimentin and keratin 10); 0.37, Ρ < 
0.0001 (vimentin and SG2M) and -0.13, (not significant) (SG2M and keratin 10). 
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To exclude a possible effect of the treatment regimen on the degree of correlation, 
analysis of coefficients was also performed on values from biopsies obtained before 
treatment (n = 83). Table 1 shows that the correlation coefficients of clinical scores of 
untreated lesions only were reduced to 0.23 (P < 0.05, erythema and desquamation), 
0.54 (P < 0.0001, erythema and induration), and 0.52 (P < 0.0001, induration and 
desquamation), whereas the correlations between the flow cytometric values remained 
below the level of statistical significance or strongly changed. Furthermore, it can be 
seen from Table 1 that, compared to the assessment on all lesions, the correlation in 
untreated lesions between basal cells in S- or G2M phase, and induration, remained in 
the same range (r = 0.52; Ρ < 0.0001). The association between erythema/vimentin and 
desquamation/keratin 10 was reduced to the lower values of 0.22 (P < 0.05) and -0.19 
(not significant), respectively. To find out whether a change in clinical scores was 
reflected in changes in the flow cytometric scores, correlation analysis was performed 
on the differences of these scores before and after treatment. Figure 2 clearly shows 
that some degree of correlation exists. Quantitative analysis revealed correlation 
coefficients of г = 0.14 (not significant, Fig. 2a), г = -0.28 (Ρ < 0.01, Fig 2b) and r = 
0.19 (P = 0.08, Fig 2c). 
Table 1. Correlation coefficients of clinical and flow cytometric scores (relative percentage of cells) 
of all psoriatic lesions (n = 166) and psoriatic lesions before treatment (n = 83) 
n=166 
% Vimcntin 
% Keratin 10 
% SGjM-phase 
Erythema 
Induration 
Desquamation 
n=83 
% Vimentin 
% Keratin 10 
% SG2M-phase 
Erythema 
Induration 
Desquamation 
% Ρ 
Vimentin 
-positive 
1 
-0 38 <0 0001 
0.37 <0 0001 
0.41 <0.0001 
0.44 <0 0001 
0.37 <0 0001 
1 
-0.19 0 086 
0.084 0 45 
0 22 0.044 
0 35 0 0010 
0.093 0 40 
% Keratin Ρ 
10-posittve 
1 
-0.13 0.087 
-0.32 <0 0001 
-0 40 <0 0001 
-0.44 <0 0001 
1 
0 25 0.021 
0.16 0.14 
-0012 0 9 1 
-0 19 0.080 
% basal cells Ρ 
in S- or G¡M-
phase 
1 
0 62 <0 0001 
0 66 <0.000l 
0 61 <0.000l 
1 
0 44 <0 0001 
0 52 <0 0001 
0 32 <0 0036 
Erythema Ρ 
I 
0 84 <0.0001 
0 79 <0.0001 
1 
0 54 <0 0001 
0 23 0 036 
Induration Ρ 
1 
0.87 <0.0001 
1 
0.52 <0 0001 
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Figure la-c. Correlation of clinical scores and flow cytometric values (mean ± SEM) of 166 test 
lesions. The erythema score versus the percentage of vimentin-positive cells (a), the desquamation 
score versus the percentage of keratin 10-positive keratinocytes (b), and the induration score versus 
the percentage of basal keratinocytes in S- or G2M-phase (c). The number of biopsies is indicated 
above the error bars. 
General discussion 135 
a 
. 9 
: : : : 
Ш:і:-:-:-:-:-: 
to 
\ 
1 
e 
28 
:•::¥ 
Ш; 
И ^ 
:: : 
1 2 
Difference erythema score 
b * 
-
I 
21 
1 
31 : 
22 
2 
1 2 3 
Difference desquamation score 
8 
• 
10 
5 
С 
< 
-
\ 
AH 
! I 
11 fi ш 
ιβ 
1 2 
Difference Induration score 
Figure 2a-c. Correlation of differences before and after treatment of clinical and flow cytometric 
parameters (mean ± SEM) of 83 test lesions. The erythema score versus the percentage of vimentin-
positive cells (a), the desquamation score versus the percentage of keratin 10-positive keratinocytes 
(b), and the induration score versus the percentage of basal keratinocytes in S- or G2M-phase (c). The 
number of biopsies is indicated above the error bars. 
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Table 2. Comparison of pretreatment flow cytometric values (relative percentage of cells) of punch 
and dermatotome biopsies prepared by different cell isolation procedures {n = 102) Δ implies the 
difference of values obtained by punch biopsies and dermatotome biopsies as a percentage of the 
value in dermatotome biopsies 
(Д= [D.m^^UM'"^! χ 100%) 
[ Dermaioiome] 
Clinical score 
Erythema 
Induration 
Desquamation 
2 
3 
1 
2 
3 
1 
2 
3 
4 
Flow cytometric 
score 
Vimentin (%) 
S- or G2M-phase (%) 
Keratin 10(%) 
Dermatotome 
17.4 
142 
98 
14 2 
196 
50 3 
45 4 
35 2 
36 8 
Punch 
64 
7 1 
103 
93 
124 
29 8 
32 1 
26 6 
26 6 
Δ(%) 
63 
50 
-5 1 
35 
35 
41 
29 
24 
28 
Ρ 
<0 001 
<001 
N S 
<001 
< 0 05 
<0 05 
< 0 05 
< 0 05 
N S 
In the present study, epidermal single-cell suspensions were prepared according to two 
different methods. Cell isolation of dermatotome biopsies (area 1 cm", thickness 0.4 
mm) was obtained after a one-step trypsin incubation method. Three millimetre punch 
biopsies were processed using a two-step thermolysin-trypsin separation method. The 
question was addressed as to whether the cell isolation procedures influence the flow 
cytometric results. Therefore, in Table 2, the mean pretreatment flow cytometric values 
of each clinical score are given for both methods of cell isolation. It can be seen that all 
corresponding flow cytometric parameters (except for psoriatic plaques with an 
induration score of 1 and very scaly lesions were significantly lower, in epidermal cell 
suspensions prepared from punch biopsies, compared to dermatotome biopsies. 
The results of the flow cytometric analysis, comparing both absolute and relative 
changes after different antipsoriatic therapy regimens and after placebo therapy, are 
given in Figure 3. With respect to epidermal proliferative activity (Fig. 3a, percentage 
basal keratinocytes in S and G2M phase), 8 weeks of placebo treatment resulted in a 
reduction of 15% compared to the pretreatment situation. Both calcipotnol cream 
(5(^g/g, applied twice daily) and la,24 dihydroxyvitamin D 3 
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Figure 3a-c. Comparison of the absolute (mean ± SEM) and relative (%) changes of flow cytometric 
parameters after different antipsoriatic treatments with respect to the the percentage of basal 
keratinocytes in S- or G2M-phase (a), the the percentage of vimentin-positive cells (b), and the 
percentage of keratin 10-positive keratinocytes (c). DV = calcipotriol once daily and vehicle once 
daily; TAC = Tacalcitol (la,24 dihydroxyvitamin D3) ointment once daily; DD = calcipotriol twice 
daily; DC = calcipotriol once daily and clobetasone butyrate once daily; DB = calcipotriol once daily 
and betamethasone valerate once daily; С = clobetasol 17-propionate. 
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ointment (4μ{>/§, applied once daily) resulted in a reduction in proliferative activity of 
34%. The application of calcipotriol cream 5(Vg/g once daily, however, resulted in a 
reduction of only 23%. The combination of topical corticosteroids and calcipotriol 
further increased the effect on epidermal proliferation. The reduction of proliferative 
activity in psoriatic plaques, treated for a maximum of 3 weeks with clobetasol 
propionate under hydrocolloid occlusion, proved to be 76%. With respect to the 
number of vimentin-positive cells (Fig. 3b) placebo treatment and monotherapy with 
the vitamin D3 analogues resulted in a reduction of less than 23%. This is in contrast to 
treatment regimens comprising corticosteroids (combination or monotherapy), where a 
reduction of 31%-65% was observed. In Figure 3c, we indicate the effect of different 
antipsoriatic therapies on the number of keratin 10 positive keratinocytes 
(differentiation marker). Monotherapy with the vitamin D3 analogues la,24 
dihydroxyvitamin D3 and calcipotriol (once daily or twice daily) resulted in an increase 
of 15%-23%. A combination of calcipotriol and topical steroids did not seem to 
increase this percentage substantially. In contrast, the monotherapy of psoriatic plaques 
with clobetasol propionate under occlusion increased the number of keratin 10 positive 
keratinocytes by 87%, compared to an increase of 36% for placebo. 
In Figure 4 we summarize the effect of the different antipsoriatic therapies on the 
clinical scores of the test lesions. Therapy regimens using topical corticosteroids 
proved to have a more pronounced effect on erythema compared with monotherapy 
with vitamin D3 analogues. The effect of placebo on the reduction of the erythema 
score was only 15% (Fig. 4a). All therapies showed a substantial reduction (50% or 
more) with respect to the induration score, in contrast to placebo (28%, Fig. 4b). The 
mean desquamation score was reduced by 42% after treatment with placebo, which 
implies that this parameter is placebo-sensitive. Mono or combination therapy using 
vitamin D3 analogues showed reductions in desquamation values of 58%-81% (Fig. 
4c). 
DISCUSSION 
A highly significant correlation was observed between erythema and the percentage of 
vimentin-positive cells, between scaling and the percentage of keratin 10-positive cells, 
and between induration and the percentage of basal cells in S- and G2M phase, if all 
166 biopsies are considered. The latter correlation remained equally pronounced, 
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Figure 4a-c. Comparison of the absolute (mean ± SEM) and relative (%) changes of clinical scores 
after different antipsoriatic treatments with respect to erythema (a), desquamation (b), and 
induration (c). 
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whereas the other two associations were less prominent, if the analysis was restricted 
to 83 biopsies taken from untreated skin. 
The percentage of vimentin-positive cells consists, to a large extent, of inflammatory 
cells. Although erythema, i.e. vasodilatation, is part of cutaneous inflammation, the 
appearance of inflammatory cells in the epidermis might have a different dynamic. In 
the marginal zone of spreading psoriatic plaques, significant changes in the 
microvasculature are visible well before the appearance of an inflammatory 
infiltrate ' . Therefore, the incomplete correlation between the percentage of 
vimentin-positive cells in the epidermis and erythema can be explained by the partly 
independent dynamic of the microvasculature and the appearance of an infiltrate in the 
epidermis. Induration of the psoriatic plaque is supposed to be related to epidermal 
proliferation. Indeed, the high correlation between the percentage basal cells in S- and 
G2M phase, and the induration score, is in line with this commonly held belief. As the 
formation of scale in the psoriatic plaque represents impaired differentiation, the 
distribution between the number of basal (keratin 10-negative) and suprabasal (keratin 
10-positive) keratinocytes was presumed to be indicative of the desquamation score. 
However, due to the reduction of keratin 10 at some sites in the psoriatic lesion, this 
differentiation marker does not seem to visualize all suprabasal cells . We also should 
reconcile the observation that keratin 10 is not a marker which includes all aspects of 
differentiation. Therefore, the correlation between scaling and keratin 10 expression 
has to be an incomplete one. 
A description of the improvement in psoriatic plaques can be made clinically. The 
PASI score has been popular and practical, and adequate for comparative analysis. 
However, the interobserver variability is large . It has been suggested by van de 
Kerkhof that the scores of erythema, induration and scaling should be considered 
separately, as these markers provide information on the anti-inflammatory versus the 
antiproliferative capacity of treatment. The present study, however, suggests that the 
three scores are, to a large extent, correlated, which implies that the sum of these 
scores might be a more appropriate reflection of the psoriatic process. Such a sum 
might be the combined result of the cell biological denominator of the three processes. 
But we have to consider the possibility that this correlation, at least to some extent, is 
introduced by the unblinded investigator who, biased by a severe erythema, scaling or 
induration, might overinterpret the remaining signs. An important aspect of flow 
cytometric assessment during experimental treatment of psoriasis is the discrimination 
between antiproliferative, keratinization-enhancing and anti-inflammatory effects in 
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vivo. As demonstrated by correlation studies, the clinical parameters do not adequately 
permit this separation. 
Vimentin can be used as a marker for epidermal infiltrate, showing higher values in 
psoriatic compared to normal skin. In Table 2, we compared pretreatment flow 
cytometric values of both separation methods in psoriatic skin, with equal erythema 
scores. As the epidermal infiltrate is assumed to be equal, and interference by 
treatment is excluded, the difference in the numbers of vimentin-positive cells may be 
accounted for by dermal infiltration. The data in Table 2 show that the biopsy and 
preparation procedure has a clear impact on the flow cytometric values reached. The 
objective for developing the dermo-epidermal separation method, using thermolysin on 
punch biopsies, was to obtain high quality cell suspensions with low dermal 
contamination and a high yield of basal cells . Indeed, for each erythema score, the 
number of vimentin-positive cells is significantly lower in cell suspensions prepared 
from punch biopsies compared to dermatotome biopsies, indicating low dermal 
contamination. The suprabasal compartment (keratin 10-positive) is significantly 
smaller in cell suspensions prepared from punch biopsies, indicating the presence of a 
larger quantity of basal cells. It seems likely that a 0.4 mm dermatotome biopsy does 
not always contain all epidermal cells. Furthermore, in contrast to thermolysin, 
enzymatic separation with trypsin sometimes cleaves above the dermo-epidermal 
junction, resulting in a loss of basal cells. A lower proliferative activity in the basal 
compartment was found in the cell suspensions prepared from punch biopsies. This 
might be the result of less clumping in the cell suspension, as clumps mimiek cells 
with a tetraploid DNA content. Another explanation for the lower percentage of basal 
cells in S- and G2M phase might be the yield of a larger quantity of non- or slowly-
proliferating stem cells, which have been suggested to be located at the tips of the rete 
•J '4.15 
ridges 
Although a comparison of different studies is hazardous due to preselection bias and 
subjective factors in clinical scoring, we have summarized the flow cytometric and 
clinical assessments of the efficacy of several topical antipsoriatic treatments in 
Figures 3 and 4). As different preparation methods were used, it is important to 
consider relative improvement only and to refrain from a comparison of absolute 
values. The placebo (the application of a bland emollient) had a substantial effect on 
the percentage of keratin 10-positive keratinocytes (a 36% increase in average counts). 
This effect on cell biology is in line with the tendency of the placebo to improve 
desquamation (by 42%), whereas induration and erythema are improved by 28% and 
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16%, respectively. Previously, we have demonstrated a reduction in the suprabasal 
expression of involucrin and the restoration of filaggrin expression during treatment 
with a hydrocolloid . In the present study, we again suggest that improvement in the 
suprabasal compartment results from the artificial restoration of the skin barrier by an 
ointment. 
The flow cytometric quantification reveals a comparable effect of calcipotriol, once or 
twice daily, with respect to the percentage of keratin 10-positive keratinocytes and the 
percentage of vimentin-positive cells. However, the reduction of basal cells in S- and 
G2M phase was comparable for la,24 dihydroxyvitamin D3 ointment (Tacalcitol ) 
once daily and calcipotriol twice daily, whereas once daily calcipotriol had a smaller 
effect on this proliferation marker. A comparison of clinical markers suggests that 
calcipotriol once and twice daily, and la,24 dihydroxyvitamin D3 ointment once daily, 
induce an improvement well above that seen with placebo, with la,24 
dihydroxyvitamin D3 ointment tending to be slightly less effective. The twice daily 
application of calcipotriol resulted in a greater improvement in scaling. Monotherapy 
with vitamin D3 analogues had a small effect on the percentage of vimentin-positive 
cells and the percentage of keratin 10-positive keratinocytes, at a level comparable 
with placebo. Interestingly, the addition of a topical corticosteroid to calcipotriol 
substantially enhanced the reduction of the percentage of vimentin-positive cells and, 
to a lesser extent, compensated for the abnormally low number of keratin 10-positive 
keratinocytes. Therefore, flow cytometric analysis suggests a powerful antipsoriatic 
effect for combination treatment of calcipotriol and a topical corticosteroid. This is, to 
some extent, expressed at the clinical level by the erythema score (see Fig. 4a). 
Clinical practice, however, has shown that the combination of calcipotriol and a topical 
corticosteroid has a major effect on recalcitrant psoriatic plaques. Treatment with a 
potent corticosteroid, such as clobetasol 17-propionate, is the most powerful topical 
antipsoriatic treatment available. Its effect on the percentage of basal keratinocytes in 
S- and G2M phase, the percentage of vimentin-positive cells and the percentage of 
keratin 10-positive keratinocytes, is enormous. This effect is clearly seen clinically. 
In conclusion, the clinical severity scores of psoriatic plaques are correlated to such an 
extent that they do not permit a separation between the effects on hyperproliferation, 
inflammation, and differentiation by antipsoriatic treatment. Triple-labelling flow 
cytometry permits the demonstration of antipsoriatic effects beyond the clinical scores, 
as assessed by the investigator, and further permits differentiation between the anti-
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inflammatory, growth inhibiting and keratinization-enhancing capacity of antipsonatic 
treatments 
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5.2 In vivo models for psoriasis 
The psoriatic plaque comprises different stages of the psoriatic process in a focal 
distribution pattern. Hot spots and cold spots or acute and chronic sites exist'. Analysis 
of the initiation and the development of the psoriatic lesion is of pathogenetic 
relevance. Models for psoriasis might supply a practical tool to study these processes. 
Also from a therapeutical point of view it is important to develop models for psoriasis. 
As the therapeutic intervention of relapsing psoriasis might be different from the 
management of the chronic lesion, it is important to discriminate between models for 
early or chronic psoriasis. Three models have been investigated in the present thesis: 
(1) The response of normal skin to tape stripping (Chapter 2.2). 
(2) The response of normal skin to epicutaneous application of leukotriene B4 
(Chapter 3.1). 
(3) The relapse of the psoriatic lesion after corticosteroid-induced remission 
(Chapter 3.2). 
TAPE STRIPPING 
The epidermal regeneration following tape stripping is a well reproducible response of 
normal skin which consists of epidermal hyperproliferation and abnormal 
keratinization as also observed in the psoriatic plaque" . In Chapter 2.2 it was shown 
that the three cell biological key features of the psoriatic plaque indeed are observed 
following tape stripping. The dynamics of the changes proved to be consistent: before 
the percentage of basal cells in S- and G2M phase increased, a significant decrease of 
the number of differentiated cells was observed. This suggests that the suprabasal 
compartment might have a regulatory role in the initiation of hyperproliferation in the 
basal compartment. 
From a therapeutic point of view it is of relevance that the vitamin D3 analogue 
calcipotriol4, topical corticosteroids and acitretin6 inhibit epidermal hyperproliferation 
following tape stripping. Ciclosporin does not exhibit such an effect. The present flow 
cytometric technique demonstrates a large difference (factor 8.5) between normal skin 
and tape stripped skin with respect to the proliferative activity of the basal 
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compartment. Multiparameter flow cytometry promises to be an adequate tool to assess 
and compare the interference of different therapies with epidermal proliferation, 
keratinization and inflammation in psoriasis. 
LEUKOTRIENE B4 
Cutaneous inflammation is an important aspect of the psoriatic lesion. Leukotriene B4 
(LTB4) is a potent chemoattractant present in large amounts in psoriatic scales8. The 
response of normal skin to single and multiple applications of LTB4 is evaluated using 
multiparameter flow cytometry in Chapter 3.1. This quantitative analysis reveals that 
single application of LTB4 induces a cell biological pattern comparable to that of the 
psoriatic lesion, (an increase of the percentage of cells in S- and G2M phase, a decrease 
of the number of differentiated cells and an increase of the number of vimentin-
positive cells). In contrast, repeated applications of LTB4 result in only a minor 
epidermal hyperproliferation, a decreased number of vimentin-positive cells and an 
increased number of differentiated cells. 
Based on these observations it can be concluded that: 
(1) LTB4 is not relevant in the maintenance of the psoriatic lesion. 
(2) LTB4 might be of pathogenetic importance in the acute stage of the psoriatic 
process. 
RELAPSING PSORIASIS 
Perhaps the prevention of the reoccurrence of new lesions is as important as the 
treatment of existing lesions in the long-term management of psoriasis. However, so 
far no models to analyse this question are available. By the development of such 
models new insights in the early stage of psoriasis as well as new information on the 
effect of treatments of early psoriasis can be obtained. In Chapter 3.2 the relapse 
following corticosteroid-induced clearance has been characterized both clinically and 
flow cytometrically. In 80% of patients a relapse occurred within 4 weeks. Occlusion 
reduced this percentage to 50%. The flow cytometric analysis revealed that 
symptomless skin located between the relapsing papules already demonstrates a high 
proliferative activity in the suprabasal compartment, whereas the proliferative activity 
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in the basal compartment still remains "virtually normal". Therefore it can be 
concluded that the proliferative activity in the suprabasal compartment is an early 
phenomenon in the relapse of the psoriatic lesion. It is attractive to speculate that this 
model will permit studies on the prevention of new lesions by maintenance therapy. 
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Figure 1. Dot plot of the durations of the remission periods of psoriatic lesions after treatment with 
clobetasol propionate versus the percentages of basal keratinocytes in S- and G2M phase (mean ± 
SEM) at clearance (r = 0.76, Ρ < 0.0001). 
To illustrate and emphasize the specific power of the flow cytometric approach in 
analysing the relapse of the psoriatic lesion, Figure 1 is introduced. It shows a dot plot 
of the duration of the remission period following discontinuation of treatment with 
clobetasol propionate versus the percentages of basal cells in S-and G2M phases of in 
total 25 patients (Chapter 3.2 and 4.3). It is evident that those patients with low 
percentages of basal keratinocytes in S- and G2M phase at clearance showed a 
relatively short remission period. In contrast, those patients with higher percentages 
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had relatively longer remission periods. Decreased proliferative activity seems to 
imply a quick relapse. One might speculate that these psoriatic lesions were 
overtreated, resulting in an unstable situation and therefore a short remission time. This 
phenomenon might be the clue to the rebound effect of intensified topical 
corticosteroids as observed in some patients. 
CONCLUSIONS 
(1) Both the tape stripping model as the relapse model suggest that changes in the 
suprabasal compartment occur well before hyperproliferation of the basal 
compartment. 
(2) Repeated applications of leukotriene B4 to normal skin result in a cell biological 
response totally different from the psoriatic lesion. Single application 
approaches the features of the psoriatic lesion during some days. 
(3) Corticosteroid-induced remission constitutes a promising model to evaluate the 
effect of antipsoriatic drugs on the reappearance of new lesions. 
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5.3 Innovation of topical antipsoriatic therapy 
INTRODUCTION 
For the general practitioner or dermatologist who is confronted with a patient suffering 
from psoriasis different approaches of topical treatment are available (see Chapter 1.1). 
Tar and dithranol are considered to be effective and safe if the right precautions are 
taken. However, regimens based on tar or dithranol are often very energy- and time-
consuming and therefore usually restricted to in-patient treatment. Topical therapy 
with corticosteroids combines high efficacy and comfort for the patient. Advantageous 
is that corticosteroids are easy to apply and that they are odourless and colourless. 
However, long-term monotherapy with topical corticosteroids induces skin atrophy and 
striae. Therefore, new antipsoriatic strategies are needed. 
In recent years, topical treatment of psoriasis has been developed in two directions. 
Firstly, the introduction of the vitamin D3 analogues induced an expansion of the 
therapeutic arsenal against psoriasis. Secondly, the principle of hydrocolloid occlusion 
in combination with corticosteroids meant an important progress. 
In the following sections these issues are discussed. 
VITAMIN D3 ANALOGUES 
In vitro data demonstrate the interference of several topical vitamin D3 derivatives with 
various characteristics of the psoriatic plaque (see Chapter 4.1 and 4.2). During the last 
decade the clinical efficacy of calcitriol (la,25 dihydroxyvitamin D3), calcipotriol and 
Tacalcitol (la,24 dihydroxyvitamin D3) has been documented 'J. In comparison to 
calcitriol, both calcipotriol and Tacalcitol exert a decreased calcitropic effect 
Calcipotriol monotherapy (5(^g/g ointment twice daily) has been shown to be at least 
equally effective as a third-class corticosteroid ' . Comparative studies demonstrated 
that calcipotriol was also more effective than tar therapy or short-contact dithranol 
therapy9. However, an important limitation is the calcipotriol-induced irritative 
dermatitis that occurs in up to 25% of patients . 
One way to reduce the frequency of this dermatitis could be the combination of 
calcipotriol (the only registered vitamin D3 analogue in the Netherlands) with topical 
corticosteroids. Another way could be to reduce the calcipotriol application to only 
once daily. A third way could be the development of vitamin D3 analogues with less 
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irritative potential. Remarkably, with respect to Tacalcitol (2μg/g ointment twice daily) 
only a slight irritation was reported in less than 1% of Japanese patients . 
Therefore we were interested to establish both the quantitative efficacy and the 
tolerability of (1) calcipotriol monotherapy versus the combination of calcipotriol and 
corticosteroids (Chapter 4.1) and (2) antipsoriatic therapy with Tacalcitol (Chapter 
4.2). 
The conclusions are as follows: 
(1) Vitamin D3 analogues seem to exert their in vivo antipsoriatic effect mainly 
through an inhibition of epidermal growth. 
(2) The cell biological effect of calcipotriol applied once daily is inferior to 
calcipotriol twice daily. This effect was also reflected clinically in a large 
multicentre comparative study". 
(3) The antiproliferative potential of Tacalcitol (once daily) and calcipotriol (twice 
daily) is comparable, although the clinical efficacy of Tacalcitol tended to be 
slightly inferior; so far no comparative clinical studies are available. 
(4) Concurrent use of calcipotriol and a topical corticosteroid has a marked 
antiinflammatory effect compared to calcipotriol monotherapy. 
(5) Combination of calcipotriol and a topical corticosteroid reduces the frequency 
of irritative dermatitis compared to calcipotriol monotherapy. 
(6) The low irritative potential of Tacalcitol permits treatment of facial and flexural 
psoriatic lesions (see Fig. 1) . 
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Figure 1. Facial psoriatic lesion before (a) and after 8 weeks treatment (b) with Tacalcitol (la,24 
dihydroxyvitamin D3) 4 μ ^ once daily. During treatment the clinical signs of the lesion almost 
totally disappeared and no irritation developed. 
COMBINATION OF TOPICAL CORTICOSTEROIDS AND 
HYDROCOLLOID OCCLUSION 
In the treatment of recalcitrant psoriatic plaques the use of strong antipsoriatic 
corticosteroids is inevitable. The total exposure to corticosteroids might be reduced by 
using these agents in combination with hydrocolloid occlusion. Various studies 
demonstrated the therapeutic effect of hydrocolloid occlusive dressings alone on 
psoriasis13"15. It has been shown that a strong clinical response can be obtained with 
topical corticosteroids in combination with hydrocolloid occlusion (see Chapter 4.3). 
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However, comparative clinical and flow cytometric studies between steroid 
monotherapy and the above-mentioned combination therapy with respect to clearance 
and relapse have not been carried out so far. 
The conclusions with respect to these issues can be summarized as follows: 
(1) Both corticosteroid monotherapy twice daily and topical corticosteroids once 
weekly under hydrocolloid occlusion exert a strong and comparable 
antipsoriatic efficacy with respect to both clinical and cell biological 
parameters. 
(2) Clearance of psoriatic plaques seems to be induced earlier with the combination. 
(3) With respect to the relapse phase no difference in clinical and cell biological 
parameters between both treatments can be demonstrated. 
Hydrocolloid occlusion is a valuable approach to enhance bioavailability of topical 
drugs. It is attractive to speculate that other topical treatments might benefit from 
hydrocolloid occlusion. 
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Summary and Conclusions 
In the first part of Chapter 1 a general review on the epidemiology, the pathogenesis 
and the morphology of psoriasis is given Several antipsonatic therapeutic modalities 
are described Furthermore, the clinical assessment of the severity of the psoriatic 
lesion is discussed This assessment is subjective and therefore inaccurate Clearly, a 
need for quantitative analysis of disease activity exists In the second part of Chapter 1 
a short review on the history of flow cytometry is presented It is explained why 
multiparameter flow cytometry seems to be an attractive tool to quantify aspects of 
epidermal proliferation, keratinization and cutaneous inflammation of the normal and 
pathological skin In the last part of Chapter 1 the three major aims of the present 
thesis are presented 
(1) To develop and validate a new approach to monitor disease activity This 
new method should permit quantitative measurement and reflect the key 
processes in the pathogenesis of psoriasis 
(2) To characterize potential m vivo models for psoriasis 
(3) To develop and evaluate new strategies in the topical treatment of 
psoriasis 
In Chapter 2 methodological aspects of multiparameter flow cytometry are described 
The new DNA fluorochrome TO-PRO-3 iodide is introduced This HeNe laser-excited 
fluorochrome proves to be an excellent alternative for propidium iodide in 
multiparameter flow cytometry An important advantage of TO-PRO-3 iodide is the 
relatively small spectral overlap with phycoerythnn This means that only a minor 
electronic compensation for this overlap is needed, resulting in optimal measurements 
High-quahly cell suspensions are essential in flow cytometry of epidermal cells 
Development and validation of a new dermo-epidermal separation method using the 
enzyme thermolysin are described In contrast to separation with only trypsin this 
method is also applicable on punch biopsies 
Multiparameter flow cytometry proves to be an optimal approach to analyse epidermal 
single-cell suspensions from normal and hyperproliferative skin Epidermal 
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subpopulations can be discriminated and reliable cell cycle analysis can be performed. 
Quantitative evaluation of the tape stripping model reveals that the proliferative 
activity in the basal compartment is increased by a factor 8.5 during epidermal 
regeneration after standardized injury. 
It is concluded that multiparameter flow cytometry promises to be an adequate tool to 
evaluate antipsoriatic therapy. 
In Chapter 3 two other in vivo models for psoriasis are investigated: (1) single and 
multiple applications of leukotriene B4 to normal skin and (2) the relapse of psoriatic 
skin after treatment with topical corticosteroids under occlusion. Flow cytometric 
analysis shows that the effect of chronic applications of leukotriene B4 to normal skin 
is markedly different from the cell biological features of the psoriatic plaque. In 
contrast, single challenge produces changes comparable to psoriasis. Therefore, 
leukotriene B4 does not seem of great importance for perpetuation of the chronic 
psoriatic plaque, but may play a role in the initiation of the psoriatic lesion. 
Clinical and flow cytometric analysis shows that the third in vivo model (relapse of 
psoriatic skin after clearance) is an adequate model to study early events in the 
psoriatic lesion. Furthermore, this model allows standardized comparison of different 
approaches for maintenance therapy in psoriasis. It is demonstrated that the 
proliferative activity in the suprabasal compartment seems to be an early characteristic 
of relapse after clinical clearance of the psoriatic lesion. 
Chapter 4 describes the effects of the vitamin D3 analogue 1,24 dihydroxyvitamin D3 
(Tacalcitol), the effects of different combinations of calcipotriol (Daivonex) and 
topical corticosteroids, and the effects of corticosteroid monotherapy (with or without 
hydrocolloid occlusion) on epidermal growth, keratinization and inflammation. 
Vitamin D3 analogues seem to exert their antipsoriatic effect mainly through an 
inhibition of epidermal growth. In contrast, topical corticosteroids (monotherapy or 
combination therapy) have a marked antiinflammatory effect which is clinically 
expressed by the erythema score. The combination of calcipotriol and corticosteroids 
proves to have a strong antipsoriatic potential. With respect to relapse characteristics 
the use of topical corticosteroids under hydrocolloid occlusion is comparable with the 
classical corticosteroid treatment. 
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In Chapter 5 the results of the various investigations of the present thesis are 
summarized and discussed. With respect to the aims of the thesis the following 
conclusions are formulated: 
(1) Multiparameter flow cytometry is an accurate and attractive tool to 
monitor psoriatic disease activitity. Strong correlations exist between 
clinical and flow cytometric parameters, especially between the 
induration score and the proliferative activity of the basal compartment. 
(2) Multiparameter flow cytometry permits quantitative characterization and 
evaluation of in vivo models for psoriasis. Single application of 
leukotriene B4 to normal skin and the relapsing psoriatic skin following 
topical steroid treatment are adequate models for early psoriasis. 
(3) New developments in topical treatment of psoriasis are promising. 
Multiparameter flow cytometry is an adequate tool to quantify and 
compare the cell biological effects of these new antipsoriatic strategies. 
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Samenvatting en Conclusies 
In het eerste deel van Hoofdstuk 1 wordt een algemeen overzicht gegeven van de 
epidemiologie, de Pathogenese en de morfologie van psoriasis Meerdere 
antipsoriatische behandelingsmodaliteiten worden beschreven Daarnaast wordt de 
klinische bepaling van de ernst van een psoriatische laesie besproken Deze bepaling is 
subjectief en inaccuraat Derhalve bestaat er een duidelijke behoefte naar quantitative 
analyse van ziekteactiviteit In het tweede deel van Hoofdstuk 1 wordt in een kort 
overzicht de geschiedenis van de flowcytometne geschetst Aangegeven wordt waarom 
multiparameter flowcytometne een zo aantrekkelijk instrument is om aspecten van 
epidermale groei, keratinisatie en cutané infiammale te quantificeren in de normale en 
pathologisch veranderde huid In het laatste deel van Hoofdstuk 1 worden de drie 
doelstellingen van deze thesis gepresenteerd 
(1) De ontwikkeling en validering van een nieuwe methode om 
ziekteactiviteit te vervolgen Voorwaarden hierbij zijn de mogelijkheid 
tot quantitative bepalingen en de weerspiegeling van de elementaire 
processen in de Pathogenese van psoriasis 
(2) De karakterisering van potentiële in vivo modellen voor psoriasis 
(3) De ontwikkeling en evaluatie van nieuwe lokale 
behandehngsmodaliteiten voor psoriasis 
Hoofdstuk 2 beschrijft methodologische aspecten van de multiparameter 
flowcytometne Het nieuwe DNA-fiuorochroom TO-PRO-3 jodide wordt 
geïntroduceerd Dit door de HeNe-laser geexciteerde fluorochroom blijkt in de 
multiparameter flowcytometne een uitstekend alternatief te zijn voor propidiumjodide 
Een belangrijk voordeel van TO-PRO-3 jodide is de relatief geringe spectrale overlap 
met phycoerythnne Dit betekent dat voor deze overlap nauwelijks elektronische 
compensatie nodig is Dit resulteert in optimale metingen 
Celsuspensies van hoge kwaliteit zijn essentieel voor flowcytometne van epidermale 
cellen De ontwikkeling en validering van een nieuwe dermo-epidermale 
scheidingsmethode met het enzym thermolysine wordt beschreven In tegenstelling tot 
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scheiding met alleen trypsine kan deze methode ook toegepast worden op 
punchbiopten. 
Multiparameter flowcytometrie blijkt een optimale methode te zijn ter analyse van 
epidermale celsuspensies van normale en hyperproliferatieve huid. Meerdere 
epidermale subpopulaties kunnen onderscheiden worden en betrouwbare 
celcyclusanalyse kan uitgevoerd worden. Kwantitatieve analyse van het tape-stripping-
model laat zien dat tijdens de epidermale regeneratie na gestandaardiseerd trauma de 
proliferatieve activiteit in het basale compartiment toeneemt met een factor 8,5. 
We concluderen dat multiparameter flowcytometrie een veelbelovend instrument lijkt 
te zijn ter evaluatie van antipsoriatische therapieën. 
In Hoofdstuk 3 worden twee andere in v/vo-modellen voor psoriasis bestudeerd: (1) 
éénmalige en multiple applicatie van leukotriëne B4 op de normale huid en (2) de 
relapse van psoriatische huid na behandeling met lokale corticosteroïden onder 
occlusie. Flowcytometrische analyse toont aan dat het effect van chronische applicaties 
van leukotriëne B4 op de normale huid duidelijk verschilt van de celbiologische 
kenmerken van de psoriatische plaque. Eenmalige applicatie, daarentegen, resulteert in 
met psoriasis vergelijkbare veranderingen. Dus lijkt leukotriëne B4 niet van groot 
belang voor de instandhouding van de chronische psoriatische plaque, maar speelt 
mogelijk een rol bij de initiatie van de psoriatische laesie. 
Klinische en flowcytometrische analyse van het derde in v/vo-model (relapse van 
psoriatische huid na clearance) demonstreert dat dit een adequaat model is ter 
bestudering van vroege processen in de psoriatische laesie. Daarnaast maakt dit model 
een gestandaardiseerde vergelijking van verschillende methoden van 
onderhoudstherapie bij psoriasis mogelijk. De relapse van de psoriatische laesie na 
klinische clearance wordt gekarakteriseerd door met name proliferatieve activiteit in 
het suprabasale compartiment. 
Hoofdstuk 4 beschrijft de effecten van vitamine D3-derivaat 1,24 dihydroxyvitamine 
D3 (Tacalcitol), de effecten van verschillende combinaties van calcipotriol (Daivonex) 
en lokale corticosteroïden en de effecten van corticosteroïd-monotherapie (met of 
zonder hydrocolloïd-occlusie) op epidermale groei, keratinisatie en inflammatie. De 
antipsoriatische werking van vitamine D3-derivaten berust met name op een inhibitie 
166 Hoofdstuk 6 
van epidermale groei. Lokale corticosteroïden, daarentegen, bezitten bij zowel mono-
als combinatietherapie een uitgesproken anti-inflammatoir effect. Dit wordt klinisch tot 
uiting gebracht in de erythema-score. De combinatie van calcipotriol met 
corticosteroïden heeft een sterke antipsoriatische werking. Wat betreft relapse-
karakteristieken is het gebruik van corticosteroïden onder hydrocolloïd-occlusie geheel 
vergelijkbaar met klassiek corticosteroïdgebruik. 
In Hoofdstuk 5 worden de resultaten van de verschillende studies van deze thesis 
samengevat en besproken. Met betrekking tot de doelstellingen kunnen de volgende 
conclusies geformuleerd worden: 
(1) Multiparameter fiowcytometrie is een accurate and attractieve methode 
om psoriatische ziekteactiviteit te vervolgen. Er bestaat een sterke 
correlatie tussen klinische en flowcytometrische parameters, met name 
tussen de induratie-score en de proliferatieve activiteit van het basale 
compartiment. 
(2) Multiparameter fiowcytometrie bewerkstelligt een quantitatieve 
karakterisatie en evaluatie van in v/vo-modellen voor psoriasis. De 
éénmalige applicatie van leukotriène B4 op normale huid en de relapse 
van psoriatische huid na lokale behandeling met corticosteroïden zijn 
geschikte modellen voor vroege vormen van psoriasis. 
(3) Nieuwe ontwikkelingen in de lokale behandeling van psoriasis zijn 
veelbelovend. Multiparameter fiowcytometrie is een zeer geschikt 
instrument om de celbiologische effecten van nieuwe antipsoriatische 
strategieën te quantificeren en te vergelijken. 
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STELLINGEN 
behorende bij het proefschrift 
MULTIPARAMETER FLOW CYTOMETRY 
AS A TOOL TO STUDY PSORIASIS 
Conrad P. Glade, Nijmegen, 9 juni 1997 
Het fluorochroom TO-PRO-3 jodide is een uitstekend alternatief voor 
propidiumjodide bij de bepaling van relatieve DNA hoeveelheid en is 
gezien de geringe spectrale overlap met phycoerythrine uitermate 
geschikt voor multiparameter flowcytometrie. 
-dit proefschrifi-
Het enzym thermolysine bewerkstelligt een betrouwbare dermo-
epidermale separatie. 
-dit proefschrift-
Leukotriëne B4 speelt geen grote rol bij de instandhouding van de 
chronische psoriatische plaque. 
-dit proefschrift-
De relapse na clearance van psoriatische huid is een geschikt in vivo-
model ter bestudering van vroege processen in de psoriatische laesie. 
-dit proefschrift-
In vivo oefenen de vitamine D3 derivaten calcipotriol en 1 a,24-
dihydroxyvitamine D3 hun antipsoriatische werking met name uit door 
remming van epidermale groei. 
-dit proefschrift-
Bij de evaluatie van antipsoriatische therapieën is de multiparameter 
flowcytometrie een waardevolle aanvulling op de "Psoriasis Area and 
Severity Index (PASI). 
-dit proefschrift-
A 51 μηι particle clogs a 50 μιτι orifice. 
-Shapiro's first law of flow cytometry-
Een instrument kun je niet dwingen, maar moetje laten spelen. Dit 
geldt niet alleen voor mijn cello. 
No data analysis technique can make good data out of bad data. 
-Shapiro's seventh law of flow cytometry-
Binnen de dermatologische deelgebieden begint in Nijmegen de 
dermatopatisserie steeds vastere vorm aan te nemen. 
Alleen al de irritatie over het verstrekken van taxibriefjes betekent een 
grote belasting voor de gezondheid. 

